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ABSTRACT 
 The T cell receptor (TCR) is an αβ heterodimer that binds to a short peptide 
bound to a product of the major histocompatibility complex (MHC). The αβ chains each 
contain variable (V) and constant (C) region domains, followed by a transmembrane 
region. Each V domain contains three loops, called complementarity-determining 
regions (CDR1, CDR2, and CDR3), which interact with the peptide (pep)MHC antigen. 
The conserved docking angle of the six CDRs over the pepMHC antigens is thought to 
confer maximal signaling capabilities and it places the two most hypervariable loops 
(CDR3s) over the most diverse portion of the antigen (the peptide). Recent adoptive T 
cell trials have shown promising results using TCRs directed towards pepMHC 
complexes expressed in various types of malignancies. The process of immunological 
tolerance leads to the deletion of T cells with TCRs against possible cancer peptide self-
antigens. Those TCRs that remain typically do not have the required affinity to mediate 
a sufficient T cell response. To overcome this, TCRs can be engineered for higher-
affinity ex vivo and reintroduced into patient’s peripheral T cells.  
 In chapter two, a TCR with a switch in peptide specificity was characterized. In 
previous studies, a TCR called RD1-MART1HIGH was engineered to bind to the cancer 
peptide MART1/HLA-A2, using libraries of mutants form the parental TCR, which is 
specific for a viral peptide, Tax/HLA-A2. The switch in peptide specificity was achieved 
by a limited number of CDR substitutions. To understand which residues contributed to 
the new peptide specificity and TCR binding, single codon libraries were created at 
every CDR residue. Libraries were pooled and sorted for binding to MART1/HLA-A2 to 
produce a sequence fitness landscape, which measured the effect that each individual 
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substitution had on pepMHC binding. The sequence fitness landscape of RD1-
MART1HIGH was compared to a sequence fitness landscape of its parent TCR A6 to 
identify the key residues involved with peptide specificity. Our collaborators (Professor 
Brian Baker at Notre Dame) solved the structure of the RD1-MART1HIGH 
TCR/MART1/HLA-A2 complex and this structure showed that the switch in specificity 
was accomplished by the reorientation of the TCR over the pep/HLA-A2 and the 
distributed action of many CDR residues.  Despite the reorientation of the TCR, RD1-
MART1HIGH TCR was able to mediate MART1/HLA-A2-specific activity when introduced 
into T cells. 
 In chapter three, I analyzed the enriched mutants from the sequence fitness 
landscape. Mutants were characterized as individual mutants and combined as double 
and triple mutants. When combined, the enriched mutations from the sequence fitness 
landscape were able to increase the affinity of RD1-MART1HIGH by nearly 100-fold. 
Additionally, the surface expression level on yeast was substantially increased. The 
enriched mutants were compared to a high-affinity clone of RD1-MART1HIGH isolated 
from a directed evolution approach.  
 Chapter four is an analysis of the activity and specificity of two different high-
affinity TCRs in T cells. A high-affinity TCR for the cancer antigen WT1/HLA-A2 and 
another TCR called T1 that is specific for the melanoma antigen MART1/HLA-A2 were 
characterized. These TCRs were analyzed both as traditional full-length TCRs 
consisting of variable and constant domains as well as single chain signaling (SCS) 
constructs, which consist of TCR variable domains linked to intracellular signaling 
domains. These constructs were analogous to the chimeric antigen receptors (CARs) 
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currently in adoptive T cell clinical trials.  Despite being expressed at lower surface 
levels than their SCS counter parts, the full-length TCRs exhibited greater peptide 
sensitivity to pepMHC.  The results of these studies provided insight into the differences 
in sensitivities of the CAR compared to the TCR formats for adoptive T cell therapies. In 
addition, they provided information about the specificity of the two high-affinity TCRs in 
an adoptive T cell form. 
 Chapter five, as a prelude to studying a different human TCR, describes the 
engineering of a TCR for high-affinity against the survivin/HLA-A2 complex. Survivin is 
an anti-apoptotic protein overexpressed in a variety of cancers. A TCR isolated from 
peripheral lymphocytes was stabilized as a single-chain TCR (consisting of variable 
domains linked by a flexible linker) on the surface of yeast. Libraries were created in the 
CDR3α and CDR3β domains of the TCR and sorted for binding to survivin/HLA-A2. Two 
high-affinity clones were isolated that bind to survivin/HLA-A2 with nanomolar affinity.  
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CHAPTER ONE 
 
 
INTRODUCTION1 
 
 
Background: Immunology 
 The human body is in constant contact with potentially deadly pathogens. Fortunately, 
the immune system destroys the majority of these pathogens before they establish a virulent 
infection. The observation that humans have an internal system for keeping foreign pathogens 
at bay was first described by the ancient Greeks in the 5th century B.C (1). The Greeks 
observed that particular individuals were excluded from contracting plagues. However, it was 
not until the 18th century that humans began to manipulate the immune system to attack select 
pathogens. In 1796, Edward Jenner used the cowpox virus to vaccinate a young boy against 
smallpox. Jenner observed that this young patient became immune from contracting the much 
deadlier smallpox virus (2).   
For centuries, illness was rooted in superstitious beliefs, such as the idea that angered 
gods had the ability to cause disease.  The development of the microscope in the 17th century 
by Anton van Leeuwenhoek allowed scientists to observe microorganisms for the first time. 
Later in the 18th century Louis Pasteur performed fundamental experiments that demonstrated 
disease was caused by microorganisms, leading to the germ theory of disease (3). 
Simultaneously, while working with the bacterium bacillus anthracis, Robert Koch developed 
Koch’s postulates, which set criteria for identifying a microorganism responsible for causing a 
particular disease (4). 
																																																													
1	Based in part on: Harris, D.T and Kranz, D.M (2016) Trends in Pharmacological Sciences 37(3):220-330 
PMID: 26705086	
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 While Pasteur and Koch were identifying microorganisms responsible for diseases, 
others were observing that humans had an intrinsic system that provided protection against 
pathogens. Early in the study of immunology there were two theories for the responsible agent 
that provided protection. Elie Metchnikoff in the 1880’s made the keen observation that special 
cells in the blood had the capacity to phagocytize foreign bodies (5). Metchnikoff proposed the 
cellular centric hypothesis, which stated that phagocytic cells were the main mediators of 
immunity. Another hypothesis, held by Von Behring and others, proposed that soluble 
components of the serum were responsible for immunity. As it turns out, the cellular and 
humoral theories were not competing but rather complementary. Both humoral and cellular 
components are responsible for immune protection, often with humoral components directing 
immune cells to the proper foreign pathogen to phagocytize. The understanding of immunology 
has increased significantly since these early studies because of scientific advances in many 
disciplines, including cellular immunology, microbiology, and molecular biology. Due to these 
advances, nearly two hundred years after Jenner’s initial smallpox vaccination, the World Health 
Organization declared the complete eradication of smallpox in 1979 (6).   
 Unlike bacteria and viruses, cancer is a pathogenic invader that develops from an 
individual’s own cells (“self”). Usually, the immune system is tolerant of self-tissue, such that 
autoimmune diseases are considered the exception. However, the same processes that 
promote this tolerant state can also allow malignancies to go unrecognized by the immune 
system. Recent advances in cancer immunology have led to the development of drugs that can 
reveal cancerous tissue as foreign to the immune system, allowing a powerful cytotoxic 
response to cancer cells, and in some cases eradication of the malignancy (7).  
The ability to use the immune system to treat cancer was first recognized by William 
Coley in the 1890’s. Coley injected bacterial toxins into patients diagnosed with inoperable 
osteosarcomas. This treatment led to dramatic reductions in tumor size for some patients (8).  
Unfortunately, not every patient responded to this treatment (some were likely killed by the 
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treatment), and due to a lack of knowledge in molecular immunology along with the 
development of other treatments, such as radiotherapy, much of Coley’s work was dismissed. 
Decades later, scientists at the National Cancer Institute and other institutions began revisiting 
the idea of using the immune system to treat cancer, this time with a greater understanding of 
molecular biology and immunology (9).  
Based on decades of scientific work, there are now several FDA-approved 
immunotherapy drugs for the treatment of cancer. These drugs have led to unprecedented 
reductions in tumor size, particularly in melanoma malignancies (10). Greater understanding of 
the immune system will only further these exciting developments, and allow the treatment, and 
in some cases cures, of tumors previously classified as untreatable.  
Overview of the Immune System 
Innate Immunity 
 The innate immune system is the body’s first line of defense against pathogens and 
consists of both soluble and cellular components. One of the main soluble components is the 
complement system, which is comprised of proteins in the serum that opsonize and mark the 
pathogens for destruction by phagocytic cells. Defensins are another set of innate anti-microbial 
proteins present within the mucosa of the gastrointestinal, respiratory and urinary tracts. When 
active, these peptides disrupt pathogens’ basically physiology such that they are incapable of 
replicating and establishing an infection.   
 The cells that are responsible for providing innate immunity are macrophages, natural-
killer cells, and granulocytes. These cells use special receptors, such as toll-like receptors 
(TLRs), for recognition and elimination of pathogens. TLRs were initially discovered in 
drosophila for the role they played in preventing infection (11). For this discovery, Jules 
Hoffmann along with Bruce Beutler were awarded the 2011 Nobel Prize in Medicine. TLRs 
recognize and bind to pathogen-associated molecular patterns (PAMPs), which are structural 
domains shared by groups of pathogens (12). Some common PAMPs that are recognized by 
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TLRs include lipopolysaccharide (LPS), double-stranded RNA and leucine rich repeats (LRR). 
Upon activation of innate immune cells, an inflammatory response follows, which leads to the 
recruitment of more immune cells and the start of an adaptive immune response.  
 Another important component of the innate system is called stimulator of interferon 
genes (STING), which recognizes various ligands including DNA derived from cancer cells (13). 
This intracellular recognition appears to be critical for inducing an inflammatory reaction, 
especially Type I interferons, at the site of tumors. Hence they promote the activity of antigen 
presenting cells, and subsequently T cells. 
Adaptive Immunity 
The adaptive immune response is controlled by B and T cells. These cells recognize 
foreign antigens either by an antibody on B cells or T cell receptor on T cells. Once a pathogen 
is identified, B and T cells rapidly expand and eliminate the foreign pathogen. B cells contribute 
to the adaptive immune response by secreting large quantities of soluble antibodies, which can 
opsonize a pathogen and mark it for destruction by phagocytic cells. Cytolytic T lymphocytes 
(CTLs) maintain the ability to take on a cytotoxic role and destroy infected cells, or cancerous 
cells, directly. Also, upon activation, both CTLs and T helper cells can secrete chemokines and 
cytokines, which recruit other immune cells to the site of infection. After the immune response is 
complete, many of the B and T cells undergo apoptosis, but a select few differentiate into 
memory cells. These cells remain inactive in the body but upon repeat exposure to the particular 
pathogen they are specific for, memory cells rapidly expand and eliminate the pathogen, in most 
cases before an infection can be established.  
B and T Cell Development 
The success of the adaptive immune response is dependent on a vast repertoire of 
receptors that can recognize a variety of foreign antigens. However, within this vast repertoire of 
antibodies and T cell receptors (TCRs), it is vital that these proteins do not recognize normal 
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self-proteins. To prevent autoimmunity, B and T cells have a complex system for development, 
which removes cells that would react with self-tissue, a process called tolerance.  
The development of B and T cells begins in the bone marrow. Shortly after they are 
derived from stem cells, T cell precursors migrate to the thymus to complete their development, 
while B cell precursors differentiate in the bone marrow. Both B and T cells begin development 
with gene rearrangement. The genes that encode antibodies and T cell receptors (TCRs) are 
composed of V, D (antibody heavy chains and TCR beta chains) and J regions. During both B 
and T cell development antibody and TCR gene fragments, respectively, are joined to achieve 
extensive diversity of the encoded protein (14). During this process, nucleotides can be deleted 
by exonuclease or added by deoxy terminal transferase at the junctions of the V and J gene 
segments, which generates even greater diversity of receptors than can be derived from gene 
rearrangement alone. The discovery of how antibodies rearrange their genes to achieve 
extensive diversity led to the 1987 Nobel Prize in Medicine awarded to Susumu Tonegawa.   
Following successful gene rearrangement, B cells continue a selection process in the 
bone marrow to ensure that the cell-surface antibody does not react with self-tissue. Once they 
are validated as not being self-reactive, B cells migrate to peripheral components of the body 
where they can begin performing their duties.  
 In the thymus, T cell precursors begin development with the rearrangement of the β 
chain genes encoding the αβ TCR heterodimer. If successful rearrangement occurs with the β 
chain genes, α chain genes begin their process of rearrangement. When a complete αβ TCR is 
expressed on the T cell surface, T cells undergo two selection processes. The first ensures that 
the TCR can bind MHC (positive selection). The second process ensures that the selected 
TCRs, do not bind too tightly to self-peptides (negative selection). To test these TCRs against a 
wide variety of self-peptides, a transcription factor called autoimmune regulator (AIRE) is 
expressed in the thymus. This transcription factor permits the expression of a wide variety of 
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tissue specific proteins to minimize the chance that TCRs will not react with tissues in the 
periphery and thus cause autoimmunity. Once a T cell passes both selection processes, it 
migrates from the thymus to the periphery where it is available to survey foreign peptide 
antigens.  
Antibody Structure 
Antibodies can serve both as soluble proteins and as receptors for B cells. The structure 
of an antibody is composed of two variable domains (VHeavy and VLight) each of which is 
associated with constant domains. The two chains of an antibody are linked through disulfide 
bonds. The antigenic binding site of an antibody is formed by the variable domains and consists 
of six complementarity determining regions (CDRs), three CDR domains are present in VH and 
the other three are in VL. The CDRs, particularly CDR3, are the hypervariable in sequence due 
to multiple germline gene segments used in gene rearrangement and junctional diversity. Linked 
to each variable domain are constant domains (CL or CH1-CH2-CH3). When an antibody acts 
as a B cell receptor, the constant domains associate with other cell surface proteins to permit 
intracellular signaling. Upon activation, B cells differentiate into plasma cells that secrete large 
quantities of soluble antibody. In soluble form, antibody constant domains (CH2-CH3) interact 
with Fc receptors expressed on phagocytic cells, to direct them to destroy pathogens or to 
secrete cytokines. The constant domains of antibody heavy chains can undergo further gene 
rearrangement to produce different isotypes (i.e IgG, IgM, IgD, IgA, and IgE), which are 
associated with different types of immune responses. 
Major Histocompatibility Complex  
Zinkernagel and Doherty were the first to observe that T cells recognize their antigens 
together with a protein encoded by the major histocompatibility complex (MHC), a process 
called MHC-restriction (15). For their work, Zinkernagel and Doherty were both awarded the 
Nobel Prize in 1996. MHC proteins are present on nearly all cells in the body and consist of two 
broad categories, MHC class I and II. MHC class I is present on nearly every cell in the body 
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and presents short peptide fragments from proteins that are being expressed intracellularly. The 
first structure of MHC class I was solved by the Wiley lab in 1987 (16). The intracellular peptide 
is presented between two alpha helices of the MHC protein. T cells via their TCRs are thus 
capable of sampling proteins that are expressed intracellularly allowing them to identify and 
destroy virus-infected cells or other abnormal cells. Class I MHC has two chains, three domains 
in the heavy chain called α (α1, α2, α3) that associate with a single-domain protein called β2-
microglobulin; together with the intracellular peptide these form the peptide-MHC ternary 
complex (pepMHC) (Figure 1.1). To load peptide into the MHC molecule, a cytoplasmic 
proteasome cleaves intracellular proteins to produce short peptide fragments (8-10 A.A.), which 
are transported to the endoplasmic reticulum and loaded into MHC class I with the assistance of 
chaperone proteins. After the peptide is loaded, the pepMHC complex is transported to the cell 
membrane for recognition by a subset of T cells that express the CD8 co-receptor. The CD8 co-
receptor interacts with the invariant α3 domain of MHC (Fig 1.1). If the TCR recognizes the 
peptide as foreign, the TCR/CD3 complex initiates signals that activate the T cell so that it can 
destroy the infected cell.  
MHC class II is an αβ heterodimer that is present only on a particular subset of cells 
called antigen presenting cells (APCs). The primary APCs presenting MHC class II are B cells, 
macrophages and dendritic cells. The role of these cells is to sample proteins that are 
expressed extracellularly, and present proteolytically processed peptide fragments in complex 
with MHC class II. To accomplish this, APCs engulf extracellular proteins and cleave the 
proteins into peptide fragments. The endocytic vesicle carrying these peptides then fuses with a 
vesicle containing MHC class II and chaperones. The peptides bind to class II and the complex 
moves to the APC surface. Similar to CD8, the CD4 co-receptor aids in TCR binding by 
interacting with the β2 domain of MHC class II. When activated, CD4 T cells secrete a milieu of 
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cytokines and chemokines that leads to the recruitment and expansion of innate and adaptive 
immune cells.  
Structure and Signaling of the T Cell Receptor 
The TCR is an αβ heterodimer that binds to a short peptide bound to a product of the 
major histocompatibility complex (MHC). Each αβ subunit contains variable (V) and constant (C) 
region domains, and the latter is followed by a transmembrane region (Figure 1.1). Like 
antibodies, each V domain contains three loops, called complementarity determining regions 
(CDR1, CDR2, CDR3), that interact with the pepMHC antigen. The TCR exhibits a conserved 
docking angle of the six CDRs over the pepMHC antigen that is thought to confer maximal 
signaling capabilities and it places the two most hypervariable loops, CDR3s, over the most 
diverse portion of the antigen, the peptide (Figure 1.2) (17).  
T cell activation upon TCR binding to the pepMHC antigen involves multiple other cell 
surface molecules (Figure 1.3) that collectively initiate and amplify the signal (18). In fact, the αβ 
heterodimer lacks its own intracellular signaling domains and thus must associate with a six-
subunit complex called CD3, composed of three dimers: CD3εγ, CD3εδ and CD3ζζ  (19). The 
cytoplasmic domains of CD3γ, δ, and ε each contain one ITAM (immunoreceptor tyrosine-rich 
activation motifs) and each CD3ζ contains three ITAMs (20).  Accordingly, the TCR/CD3 
complex contains a total of 10 ITAMs, and 20 possible tyrosine-phosphorylation sites (Figure 
1.4), which serve as substrates for the Src-family kinase Lck.  
The ability of a T cell to be triggered by TCR binding to as few as one pepMHC molecule 
(21-23) is accomplished in part by the action of co-receptors CD4 and CD8. As indicated, CD4 
is associated with TH cells (and Tregs) and recognition of class II MHC. CD8 is associated with 
cytotoxic T lymphocytes (CTLs) and recognition of class I MHC. The synergy of these co-
receptors, with the TCR, is thought to be driven both by their ability to bind to invariant regions 
of MHC molecules (CD8 especially), and the fact that Lck associates with the cytoplasmic 
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domains of CD4 and CD8, and can thus bring this kinase to the TCR/CD3 complex (24, 25) 
(Figure 1.3).  Lck can be either free in the cytosol (26), anchored to the plasma membrane via 
myristoylation or palmitoylation, or associated with CD4 or CD8 co-receptors (27). Recently, 
Gascoigne and colleagues presented evidence that phosphorylation of CD3 ITAMs occurs in a 
two-step process, first with co-receptor independent Lck kinase, followed by co-receptor-
associated Lck (28). 
The exact biophysical mechanism through which TCR binding triggers intracellular 
signaling and T cell activation is not fully understood. Current theories are centered on several 
mechanisms: aggregation (clustering), conformational change, and segregation/redistribution 
(29). Aggregation/clustering of the TCR, driven by binding to pepMHC, leads to a local increase 
in TCR complexes, which causes T cell signaling via the recruitment of Lck. While T cell 
triggering has been shown to occur with a single pepMHC (21-23), it is possible that TCRs 
interacting with non-agonist pepMHC could facilitate sufficient signaling to initiate activation (30-
32). A conformational model suggests that ITAMs are normally in an inactivated state via 
association with membrane lipids (33) and upon TCR binding of pepMHC, a conformational 
change in CD3 subunits makes ITAMs more accessible for phosphorylation (34). TCR:pepMHC 
interactions appear to induce a torque-like force on CD3 molecules, which could also expose 
intracellular ITAMs (35, 36). The segregation/redistribution model is based on the premise that 
cell surface CD45 molecules are constitutively involved in dephosphorylating ITAMs but upon 
TCR engagement of pepMHC, CD45 molecules are redistributed and excluded from the 
immunological synapse, allowing stable ITAM-phosphorylation and signaling (37). Indeed, 
studies using a reconstituted non-immune cell system showed that exclusion of CD45 from the 
immunological synapse following TCR pepMHC engagement was sufficient to permit sustained 
ITAM phosphorylation (38). None of these models for T cell triggering are mutually exclusive 
and potentially all three may be involved (29).  
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 Signaling mediated by the TCR/CD3/co-receptor complex is considered necessary but 
not sufficient for the full array of T cell functions (e.g. cytokine release, proliferation, 
persistence). Additional co-stimulatory signals enhance the sensitivity of T cells, and drive them 
along a path that yields optimal proliferative and functional capacity (39). The most well studied 
co-stimulatory receptor, CD28, binds to the ligand B7 on antigen presenting cells (APCs) (40). 
Upon CD28:B7 engagement, the intracellular cytoplasmic domain of CD28 recruits PI3K, protein 
kinase Cθ, and RAS guanyl-nucleotide-releasing protein (RASGRP) (41). Another co-
stimulatory molecule, 4-1BB, promotes T cell survival upon binding ligand on the APC surface, 
in part through the upregulation of anti-apoptotic factors such as BCL-2, BCL-XL and BFL1 (42). 
Thus, these intermediates promote T cell activation and survival through various signaling 
pathways. Following T cell activation, co-stimulatory molecules such as CD28 and 4-1BB 
appear to be dominated by co-inhibitory molecules including CTLA-4 and PD1 (43). Upon 
binding to B7 or PD-L1, respectively, CTLA-4 and PD1 recruit phosphatases that 
dephosphorylate CD3ζ, ZAP70, and LAT and thereby extinguish T cell signaling.  
The orchestrated assembly of these receptor systems, mediated by both extracelluar 
binding to appropriate ligands and intracellular interactions among cytoplasmic domains, 
provides a complex but exquisitely sensitive mechanism for optimal T cell activity. The 
ultrasensitivity of the TCR system underlies the potential for targeting intracellular cancer 
antigens that might be at low levels, whether they be derived from upregulated self-proteins or 
mutated proteins (44). 
Cancer Immunotherapy 
The tumor-killing properties of T cells provide tremendous opportunities to treat cancer. 
One form of immunotherapy that has shown promising clinical results is checkpoint blockade 
(45). These therapies use monoclonal antibodies that bind to inhibitory receptors on cancer and 
T cells. This prevents cancer cells from inhibiting an immune response so that T cells can now 
recognize and destroy malignant cells.  
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Another more personalized immunotherapy is adoptive T cell therapies, which harness 
the potential of the immune system by endowing a functionally diverse repertoire of T cells with 
genetically-modified, tumor-specific recognition receptors.  Normally this antigen recognition 
function is mediated by an αβ T cell receptor (TCR), but the dominant therapeutic forms 
currently in development are synthetic constructs called chimeric antigen receptors (CARs) (46). 
While CAR-based adoptive cell therapies are already showing great promise, their basic 
mechanistic properties have been studied in less detail than αβ TCRs. 
Chimeric Antigen Receptor (CAR): Structure and Signaling  
CARs represent a class of synthetic constructs typically comprised of a single-chain 
antibody fragment (scFv, VH-linker-VL or VL-linker-VH), an extracellular stalk (hinge) domain, a 
transmembrane domain, and one or more intracellular signaling domains (47) (Figure 1.3). The 
scFv endows T cells with the ability to respond to cell surface antigens independent of MHC. 
The CAR format provides an opportunity to potentially exploit (or repurpose) many of the scFv 
against cancer antigens that have been developed over the past 30 years. Notably, some of 
these scFv may not have been amenable to expression as full-length antibodies, or the targets 
for these scFv may have been at too low a level to mediate activity in conventional antibody 
formats.  
The exact mechanism by which CAR binding to antigen leads to signaling is not clear. It 
has been shown that reorganizion of the CAR and CD45 into a synapse, as with the TCR/CD3 
system, occured with a CD19-specific CAR (38). Presumably, full signaling must be driven by 
engagement of multiple CAR molecules by multiple antigens on the opposing cell, but how 
these signals integrate with other endogenous pathways (e.g. TCR/CD3 complexes, co-
stimulatory or inhibitory molecules) remains to be determined. Recent studies have shown that 
some scFv fragments used in CARs stimulate T cells constitutively, in an antigen-independent 
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mechanism (48). This constitutive effect appears to lead to more rapid loss of the transferred T 
cells, and reduced effectiveness.  
The possible mechanism associated with the constitutive signaling appears to be 
associated with the propensity of some scFv to aggregate in the membrane of T cells, although 
the extent of the constitutive signaling was mitigated by the use of 4-1BB rather than CD28 
signaling domains (49). It remains to be seen if this is in part due to an overall reduced 
“sensitivity” associated with 4-1BB compared to CD28. Nevertheless, these findings indicate 
that not all scFv will be suitable for use as CARs, and that scFv screening for appropriate VL/VH 
pairs will be required to avoid undesirable antigen-independent signaling.  
The hinge region of a CAR typically consists of either immunoglobulin-like CH2-CH3 (Fc) 
domains from the constant region of IgG or the spacer domain from either CD4 or CD8 (50). 
Reports have shown that lengthening or shortening the extracellular domain can optimize 
activity of an individual CAR (51, 52). The optimal length of the hinge for each CAR may differ, 
depending on the dimensions of the cell-surface antigen that is targeted by the scFv. 
Various transmembrane regions have also been incorporated into CARs, including 
domains from CD3ζ, CD4, CD8, OX40 and H2-Kb  (53). Incorporation of the CD28 
transmembrane region was correlated with higher CAR expression levels than transmembrane 
regions from CD3ζ, OX40 or CD8 (54, 55). However, CARs with the CD3ζ transmembrane 
domain produced more robust signaling perhaps due to potential trans-signaling with 
endogenous CD3ζ (56).  
The intracellular signaling domains of CARs (Figure 1.3) have received the most 
attention in terms of their impact on T cell activity, T cell persistence, and efficacy. First-
generation CARs, containing only the intracellular domain of CD3ζ exhibited in vitro activity, but 
mediated minimal in vivo efficacy and T cell persistence (57). Second generation CARs added 
co-stimulatory signaling components (primarily CD28 or 4-1BB) in tandem with CD3ζ (58-61). 
These CARs have shown improved clinical efficacy and persistence (62, 63). Although 4-1BB+ 
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CARs mediate lower levels of cytokine release than CD28+ CARs, 4-1BB+ CARs appear to 
show greater in vivo persistence (64, 65).  
Given the variability in scFv fragments, hinge, and transmembrane domains, it can be 
difficult to compare results from different studies (e.g. to determine whether CD28 or 4-1BB is 
optimal for CAR based therapies). Third-generation CARs, containing two co-stimulatory 
domains along with the CD3ζ signaling sequence, have demonstrated promising early results 
and are likely to be further developed for clinical use (55, 66). The mechanism by which scFv 
binding to antigen leads to effects on the intracellular domains of CD3ζ, CD28, and 4-1BB, in 
terms of recruitment of adaptors and kinases, remains to be seen.  
Another emerging area is the use of multiple scFv fragments, each fused to different 
signaling domains. This combinatorial approach could provide enhanced safety and/or 
therapeutic efficacy by targeting two or more different cancer antigens. It also raises the 
possibility for enhanced sensitivities due to synergistic signaling (67, 68).  Further safety might 
also be achieved through the use of inhibitory CARs (iCARs), in which a separate CAR contains 
a scFv specific for an antigen on normal tissue, fused to an inhibitory cytoplasmic domain such 
as PD-1 (68, 69). This system could hold the potential to reduce on-target, off-tumor toxicities in 
either TCR or CAR-mediated adoptive T cell therapies. 
Sensitivity of TCRs and CARs  
As emphasized above, based simply on their design, the mechanism by which CAR 
binding to its cognate antigen leads to T cell activation differs in substantial ways from the 
mechanism by which TCR binding leads to T cell activation. Even without consideration of co-
stimulatory molecules (CD28, 4-1BB), TCRs mediate activity through a complex of 10 subunits 
that are poised to be triggered by very low numbers of pepMHC antigens and through the action 
of the co-receptors CD4 or CD8 (21, 22, 70) (Figure 2).  This single “fixed” mechanism 
associated with conventional TCR/CD3 complexes contrasts with the distinct and varied 
signaling properties that are likely associated with the array of diverse CAR structures. 
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Paradoxically, the ability of T cells to be stimulated by as few as one antigen molecule 
per target cell is accomplished not by high-affinity TCR:pepMHC interactions, but by low affinity. 
Thus, the physiological affinity range of TCRs is 104 to 106 M-1 (an equilibrium binding affinity of 
1 micromolar is considered a “high” affinity TCR in this context). It has been suggested that the 
ability of a single pepMHC molecule to activate a T cell is in part due to the ability of that 
pepMHC molecule to bind serially to many TCRs (serial triggering) (71, 72), which is consistent 
with a fast off-rate (i.e. lower affinity).  In contrast to TCRs, the affinity of most monoclonal 
antibodies that have been engineered as scFv fragments for CARs are in the range of 107 to 109 
M-1 (an equilibrium binding affinity of 1 nanomolar is considered a “high” affinity antibody in this 
context). T cells have evolved an exquisite system of multiple receptor subunits in order to 
achieve this high level of sensitivity and yet retain a high degree of specificity. Engineering a 
TCR’s affinity (micromolar) to the high end of the antibody affinity range (nanomolar) can in fact 
yield functional self-peptide cross-reactivities because of the very low-affinity threshold of the 
TCR system (73) (i.e. even 300 micromolar affinity for such a reaction can result in CD8-
dependent activity (74). CD8 acts to lower the TCR affinity required by about 100-fold (75), and 
it reduces the amount of pepMHC required from over 30 molecules per target cell to just one 
molecule (21-23). 
While the targets for TCR-based therapies are intracellular peptides bound by MHC, 
potential targets for CAR-based therapies are cell-surface antigens expressed at higher 
densities on cancer cells, and these densities typically vary from one target to another. A recent 
study investigated the density of CD20 required to activate T cells expressing a CD20-specific 
CAR (76). Using cell lines that expressed CD20 at various densities (very low to high, about 200 
molecules/cell to 200,000 molecules/cell), the CAR-CD20 T cells mediated lysis of cells 
expressing the lowest detectable level of CD20 (about 200 molecules/cell), similar to an earlier 
study with a carbohydrate-specific CAR (77). Cytokine release required higher densities of 
CD20, between 200 and 5,000 molecules/cell. The results with the CD20-CAR system are also 
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consistent with observations about the need for 30 or more pepMHC ligands on the surface of a 
target cell in the absence of co-receptor (21, 22). 
To increase the sensitivity of a CAR towards an antigen expressed at low levels, the 
scFv binding affinity could be increased (78). Conversely, recent studies have suggested that 
the therapeutic index for CAR targeting of antigens with significant expression on normal tissues 
could be improved by using lower affinity scFv fragments (79-81). (Note: to our knowledge, 
affinities cited for a particular CAR, i.e. of the scFv domains, are from binding measurements 
performed with the soluble scFv or the full antibody; thus, the actual affinity may differ to some 
extent in the context of the membrane-bound form). For example, the scFv from Nimotuzumab 
(KD of about 10-8M) mediated tumor cell activity (about 340,000 molecules/tumor cell) while 
ignoring normal fibroblasts with lower EGFR levels (about 15,000 molecules/cell). In the ErbB2 
system, an antibody with a KD value of about 1 µM was found to discriminate between 
enhanced levels on some ErbB2 tumors and levels found in normal tissues. While the optimal 
affinity for a scFv in the CAR format varies depending on the antigen density, other parameters 
such as the expression levels of the CAR and the propensity of the scFv to aggregate and 
cause cis-signaling (49) will also impact activity.  
Further work on CAR signaling will be needed to better determine whether the 
intersecting pathways and thresholds initiated in conventional T cells (82), by binding of multiple 
ligands to TCRs, co-receptors and co-stimulatory molecules, are quantitatively capable of 
driving the same polyfunctional responses. The potency and persistence of cytolytic CD8+ T 
cells has been demonstrated in many studies, but the ability to mediate activity, persistence, 
and localization of CD4+ T cells may be critically important (83, 84). Within T cell subsets, the T 
cell lineages that might be preferred in the adoptive T cell setting, whether using TCRs or CARs, 
is also an area of active study (85). 
While the many parameters that differ between TCRs and CARs (affinity, ligand 
structure, ligand density) have made it difficult to compare directly, we have developed a system 
16 
	
that allows comparisons by using the analog of a scFv, a single-chain TCR (Vβ-linker-Vα) as a 
CAR-like receptor (86, 87). This allows the same V regions to be used in a conventional full-
length αβ TCR for comparison with the CAR, where the affinity of the cell-associated forms, the 
ligand (pepMHC), and ligand density are identical. This system also allowed the direct 
measurement of CAR affinity using typical monomeric pepMHC antigens, and it allows rapid 
analysis of the effects of antigen density by simply “loading” different concentrations of peptides 
onto MHC-positive target cells.  Using a high-affinity variant of the 2C TCR called m33 (Kd of the 
TCR and CAR on T cells was identical), we observed in primary CD4+ T cells that the full-length 
TCR had greater sensitivity to pepMHC than the CAR format (with either CD28 or 4-1BB, and 
CD3ζ), even though the CAR format was expressed at higher densities on the surface of T cells 
(87). Thus, even in the absence of the CD8 co-receptor, the TCR machinery has greater 
sensitivity.  
Clinical Outcomes of Adoptive T Cell Therapies 
Early clinical data from adoptive T cell trials using TCRs and CARs have demonstrated 
the tremendous potential of redirected T cells in the control of tumors. Some of the most exciting 
results have come from trials using CAR T cells against hematological cancers. As described in 
recent reviews (88-90) the variability in scFv fragments, co-stimulatory domains and methods of 
gene transfer (such as retrovirus, lentivirus or other newly developed techniques), have made it 
difficult to compare results. Other parameters such as pre-existing tumor burden, conditioning 
chemotherapy, ex vivo expansion techniques, and T cell dosage have further complicated 
comparisons. To date, the most successful CARs have been those specific for CD19 on B-cell 
malignancies. Treatment with these second generation CARs have resulted in complete 
remissions in some patients who previously had been unresponsive to more traditional 
chemotherapy regiments (46, 91-93). Because the CD19 antigen is also expressed on non-
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malignant B cells, CD19-CAR therapy results in B cell aplasia, which has been treated with 
exogenous immunoglobulin administration.  
 While CD19-CAR therapies for hematological cancers have shown promising results, 
CAR therapy of solid tumors has so far not been as effective (94). Antigens from various types 
of solid tumors have been targeted with limited anti-tumor response (95, 96). CAR therapies 
against solid tumors could be less effective due to the local immunosuppressive environment 
seen with many solid tumors (97) and might also be due to the use of suboptimal signaling 
domain(s) within the CAR construct. Targeting solid tumors is also restricted by the number of 
cancer-associated antigens that are expressed at sufficient levels for effective responses 
without on-target/off-tumor toxicities. A trial using a scFv specific for ErbB2 led to an unexpected 
toxicity and ultimately death in one patient as a consequence of lung tissue expressing low 
levels of ErbB2 (98), but it is possible that affinity-tuning of scFv fragments could minimize these 
toxicities (79, 80). As described above, recent studies have suggested that some scFv 
fragments used as CARs (e.g. against mesothelin and GD2) may have problems associated 
with constitutive signaling, and it is possible as these issues are sorted out more effective 
treatments for solid tumors may be achieved (48, 49). 
 Clinical trials using TCRs for adoptive T cell therapy have had some successes in 
eradicating both solid and hematological tumors (99-103). As most of the targets for TCR-based 
therapies are self-peptide/MHC antigens, endogenous peripheral T cells against these targets 
exhibit low affinity due to negative selection in the thymus (104). These T cells have reduced 
effectiveness at promoting anti-tumor responses. To overcome this problem, affinity-enhanced 
TCRs have been developed from such techniques as yeast and phage display (105, 106).  
However, since these TCRs have not undergone negative selection, they carry with them the 
potential risk of off-target reactivity (73). 
Two different affinity-enhanced TCRs against a peptide from the MAGE-A3 protein were 
recently used in clinical trials, and both resulted in fatalities caused by TCR recognition of 
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structurally similar pepMHC complexes present in non-cancerous tissues (‘off-target/off-tumor’) 
(107, 108). While these results highlight the risks associated with affinity enhanced TCRs, the 
choice of target also plays a significant role in off-tumor toxicities. A TCR with nanomolar affinity 
(Kd= 730 nM) has been successfully used to target cancer testis antigen NY-ESO-1 without 
reports of ‘off-target/off-tumor’ toxicities (102, 103). To better identify potential target antigens, in 
silico proteome searches have been conducted that analyze target peptides for structural 
uniqueness (107, 109). This type of analysis could identify potential off-target/off-tumor toxicities 
associated with self-peptide/MHC antigens that could pose problems with cross-reactivity.  
Overview of Thesis 
This thesis studies the engineering of high-affinity human TCRs, the interactions of high-
affinity TCRs with their respective pepMHC complexes, and the activity of high-affinity TCRs 
when transduced into T cells. High-affinity TCRs have the potential to be used as therapeutics 
in both soluble and adoptive T cell formats. Given the exquisite sensitivity that T cells have 
towards low numbers of pepMHC complexes, the specificity of engineered TCRs is vitally 
important. Recent clinical trials, using affinity enhanced TCRs in adoptive T cell formats, have 
demonstrated the devastating effects that non-specific TCRs can have (107, 108). I have 
studied the specificity of high-affinity TCRs using basic biochemistry approaches as well as in 
vitro and in vivo methods utilizing transduced T cells. 
Previous work in the Kranz lab used yeast surface display to change the peptide 
specificity of the well-studied A6 TCR specific to the viral peptide Tax (LLFGYPVYV) to the 
MART1 (ELAGIGILTV) peptide expressed in melanoma (110). Tax is a nine amino acid peptide 
derived from the human T-cell leukemia virus type 1 (HTLV-1). MART1 is a ten amino acid 
peptide expressed normally in melanocytes and often in melanoma tissue. A five codon library 
of A6 distributed between CDR1α, CDR3α and CDR3β residues was created and sorted for 
binding to MART1/HLA-A2. A new TCR, called RD1-MART1, was isolated that bound to 
MART1/HLA-A2, but showed no detectable binding to Tax/HLA-A2. RD1-MART1 was further 
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affinity-enhanced by selection from a five codon CDR3β library to yield the RD1-MART1HIGH 
TCR. This new TCR binds to MART1/HLA-A2 with an affinity of approximately 50 nM and shows 
no detectable binding to Tax/HLA-A2. A comparable affinity enhanced version of A6, called A6-
c134, binds to Tax/HLA-A2 with an affinity of 50 nM. Since both of these TCRs share many 
similar residues, however, bind to structurally different peptides, we studied the interactions 
governing the peptide switch to gain a better understanding of the chemistry involved with TCR 
specificity.   
In chapter 2, the switch in peptide specificity from Tax to MART1 of the RD1-MART1 
TCR was studied by structural and mutational analysis of the RD1-MART1HIGH and A6-134 
TCRs. Our collaborators at the University of Notre Dame (Brian Baker and Nishant Singh) 
solved the crystal structure of RD1-MART1HIGH in complex with MART1/HLA-A2. To compare 
the two TCRs, we used the crystal structure of A6-c134, which had been solved previously 
(111). Interestingly, the RD1-MART1HIGH TCR made significantly less contacts with pepMHC 
than its A6-c134 counterpart. Additionally, the RD1-MART1HIGH TCR engaged MART1/HLA-A2 
at an incident angle that has yet to be observed in other TCR/pepMHC structures. To determine 
whether this new incident angle permitted TCR signaling by CD3, I transduced T cells with the 
RD1-MART1HIGH TCR and tested for activity. The TCR sustained activity when presented with 
MART1/HLA-A2 and did not show any cross-reactivity activity against Tax/HLA-A2.  
To study the contributions of each CDR residue to peptide specificity, I created single 
codon libraries at every TCR CDR residue of RD1-MART1HIGH. I then pooled these libraries and 
sorted via fluorescence activated cell sorting (FACS) for binding to MART1/HLA-A2. The sorted 
library was subsequently sequenced and enrichment values of every substitution (relative to the 
unsorted library) were calculated to produce a sequence fitness landscape. To compare the 
specificity to RD1-MART1HIGH to A6-c134, Qi Cai (a postdoctoral researcher in the Kranz lab) 
performed a similar analysis of A6-c134. Comparing structural data and the large mutational 
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analysis between the two TCRs allowed us to determine which residues were necessary in 
conferring peptide specificity.  
To develop more rapid methods for engineering high-affinity protein-protein interactions, 
in chapter 3, I analyzed the enriched residues of RD1-MART1HIGH from the sequence fitness 
landscape. I created mutants of RD1-MART1HIGH that contained single-site mutations of 
enriched substitutions from the sequence fitness landscape. These mutations modestly 
enhanced the affinity for MART1/HLA-A2 by approximately 10-fold. When I combined the three 
highest enriched mutations, the affinity of RD1-MART1HIGH for MART1/HLA-A2 was enhanced 
by nearly 100-fold. Additionally, the expression level on the surface of yeast was enhanced by 
approximately 3-fold, presumably due to enhanced stability of the TCR (112). To compare the 
single codon approach to other protein engineering methods, Ningyan Wang (a postdoctoral 
researcher in the Kranz lab) created a combinatorial library at the highest enriched residues 
from the sequence fitness landscape and sorted that library for binding to MART1/HLA-A2. We 
were able to compare mutations from high-affinity clones isolated from the combinatorial library 
to those identified in the single-codon analysis. Finally, Timothy Reilly (a graduate student in the 
Baker lab) developed a computational algorithm to predict high-affinity TCR mutations. The 
mutations identified from this algorithm were compared to enriched mutations from the 
sequence fitness landscape. It was concluded that directed evolution approaches (sequence 
fitness landscapes and combinatorial libraries) were superior at identifying affinity enhancing 
mutations than the computational approach.  
In chapter 4, I tested the activity of high-affinity TCRs in T cells. Using a set of TCRs with 
different affinities for the WT1/HLA-A2 complex, I tested the activity of these constructs in CD8 
and CD4 T cells. I then performed mutational analysis of the WT1 peptide to determine the 
peptide residues that contribute to TCR specificity. Finally, I tested the highest affinity WT1 TCR 
for cross-reactivity by injecting AAD transgenic mice with CD8 and CD4 T cells expressing the 
high-affinity TCR. No toxicities were observed in the treated mice. 
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Additionally, in chapter 4, I used the high-affinity WT1 TCR to compare sensitivity of 
TCRs to CARs. Currently, there is little known about the mechanistic properties of CARs and 
their sensitivity compared to TCRs. To gain a better understanding of CAR signaling properties, 
a TCR-CAR construct was created that consists of the TCR variable domains from the high-
affinity WT1 TCR expressed as a single-chain, tethered to the intracellular signaling domains 
commonly used in CARs (86, 87). I tested the high-affinity WT1 variable domains in the CAR 
format and compared it to activity as a traditional full-length TCR. The WT1 CAR had higher 
surface levels when expressed as CAR construct compared to its full-length counterpart. 
However, the full-length TCR construct was more sensitive to lower levels of pepMHC. These 
results are similar to data obtained using the M33 murine system as both a full-length TCR and 
CAR construct (87). We believe full-length TCRs to be more sensitive due to their robust 
signaling machinery as compared to CARs (Figure 1.3).   
In the final chapter, I describe the engineering of a high-affinity TCR against a peptide 
from the survivin protein. Survivin is an anti-apoptotic protein that is overexpressed in a variety 
of hematological and solid tumors (113, 114). The Kranz lab received a clone from our German 
collaborators (Wolfgang Ukert and Dolores Schendel) which bound with low-affinity to 
survivin/HLA-A2. An error-prone library of the TCR was created to identify mutations that 
stabilize the TCR in the single-chain format used in yeast display. From that library, I identified a 
stabilized clone and created CDR3α and CDR3β libraries. I pooled and sorted the libraries with 
survivin/HLA-A2 to identify two clones which bind with high-affinity (K2.4.1 and K2.4.6). I tested 
the K2.4.1 TCR in CD8 and CD4 T cells and showed that it was capable of mediating 
survivin/HLA-A2 specific activity. To identify mutations which could further enhance the affinity 
of the TCR, I advised an undergraduate student (Scott Anderson) in creating a sequence fitness 
landscape of the K2.4.1 TCR. The sequence fitness landscape of K2.4.1 is now guiding efforts 
by our collaborators to further develop the TCR as a therapeutic.  
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Figures 
 
Figure 1.1- Schematic diagramming interactions of CD8 T cells with MHC class I.  CD8 TCRs use 
their Vα and Vβ domains to interact with peptide presented by MHC class I. MHC class I consists of α
1
, 
α
2
, α
3
 domains (gray) that associated with β
2
 microglobulin (black). The CD8 co-receptor aids in TCR 
binding by interacting with the invariant α
3
 domain of MHC class I.  
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Figure 1.2- TCRs use CDR domains to bind with pepMHC. The MART1/HLA-A2 complex is shown 
with the CDR loops of the RD1-MART1
HIGH
 highlighted. The CDR loops of TCRs dock over pepMHC in a 
conserved orientation which places the CDR3 loops (red) predominately over the peptide. The CDR1 
loops (green) normally can interact with both peptide and MHC. The CDR2 loops (blue) are 
predominately involved with binding to MHC.  
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Figure 1.3- Structural Components of T Cell Receptor (TCR) and Chimeric Antigen Receptor 
(CAR) Signaling. (A) TCRs comprise an αβ heterodimer that binds to peptide major histocompatibility 
complex (pepMHC). (B) CARs are single-chain molecules that contain a single-chain variable fragment 
(scFv) recognition domain capable of binding to cell surface antigens. In complex with each TCR are 
CD3 subunits and a co-receptor (CD4 or CD8) associated with Lymphocyte-specific protein tyrosine 
kinase (Lck). CARs contain intracellular signaling domains from CD3ζ and a co-stimulatory molecule 
(typically CD28 or 4-1BB). Signaling is initiated by Lck-mediated phosphorylation of immuno-tyrosine 
activation motifs (ITAMs) within the cytoplasmic domains of CD3. 
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Table 1.1- Comparison of TCR and CAR Signaling Machinery. TCRs associate with endogenous 
signaling molecules and co-receptor, which provides TCRs with more ITAMs and tyrosine 
phosphorylation sites compared with CARs. TCRs typically have affinities in the micromolar range for 
pepMHC, while CARs typically have higher affinities for their ligands normally in the nanomolar range. 
Despite having lower affinity and expression levels, TCRs are more sensitive than CARs.  
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CHAPTER TWO 
 
 
 
 
AN ENGINEERED SWITCH IN T CELL RECEPTOR SPECIFICITY LEADS TO AN 
UNUSUAL BUT FUNCTIONAL BINDING GEOMETRY2 
 
 
 
 
Abstract 
Utilizing a diverse binding site, T cell receptors (TCRs) specifically recognize a 
composite ligand comprised of a foreign peptide and a major histocompatibility complex 
protein (MHC). To help understand the determinants of TCR specificity, we studied a 
parental and engineered receptor whose peptide specificity had been switched via 
molecular evolution. Altered specificity was associated with a significant change in TCR 
binding geometry, but this did not impact the ability of the TCR to signal in an antigen-
specific manner. The determinants of binding and specificity were distributed among 
contact and non-contact residues in germline and hypervariable loops, and included 
disruption of key TCR-MHC interactions that bias αβ TCRs towards particular binding 
modes. Sequence-fitness landscapes identified additional mutations that further 
enhanced specificity. Our results demonstrate that TCR specificity arises from the 
distributed action of numerous sites throughout the interface, with significant 
implications for engineering therapeutic TCRs with novel and functional recognition 
properties. 
																																																													
2 Harris D.T., Singh N.K., Cai Q., Smith S.N., Kooi C.V., Procko E., Kranz D.M., Baker B.M. (2016) An 
engineered switch in T cell receptor specificity leads to an unusual but functional binding geometry. 
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Introduction 
Antigen specificity is a hallmark of T cell immunity. Specificity is dictated by the T cell 
receptor (TCR), which recognizes peptide antigens bound and presented by self MHC 
proteins using six complementarity determining region loops (CDRs) with varying 
degrees of diversity. Crystallographic structures have illustrated how TCRs utilize their 
CDRs to engage peptide/MHC complexes (pMHC). Often, although not exclusively, the 
most diverse hypervariable CDRs are aligned alongside the antigenic peptide, and the 
germline-encoded alongside the self MHC (115). Although early studies emphasized the 
role of the hypervariable CDR3α and CDR3β loops in determining antigen specificity, 
more recent work has emphasized the capacity for specificity to arise from both 
germline-encoded and hypervariable loops and the composite peptide-MHC surface 
(116, 117). Further, although cross-reactivity is often discussed as a necessary feature 
of TCRs dichotomous to specificity, recent findings show that many cross-reactive 
ligands share key structural and/or chemical properties, such that even cross-reactivity 
reflects the specific nature of TCR binding (118).  
 Within this backdrop are ongoing efforts to more deeply understand and control 
TCR specificity. This is particularly important for emerging immunotherapeutic 
approaches that utilize exogenous TCRs, such as TCR-engineered T cells and soluble 
agents. The specificity of these TCRs and the impact of affinity-enhancing modifications 
remains a significant concern, as illustrated by adverse events in recent immunotherapy 
clinical trials that resulted from off-target TCR recognition (e.g. (107)). 
 To better understand TCR specificity and as a step towards productively 
manipulating it, we recently engineered a switch in the peptide specificity of a TCR by 
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operating on a limited set of CDR residues. Using in vitro directed evolution, we 
engineered the A6 TCR, which recognizes the viral Tax nonamer (LLFGYPVYV) 
presented by HLA-A*0201 (HLA-A2), to specifically recognize the anchor-modified 
cancer MART1 decamer (ELAGIGILTV), also presented by HLA-A2 (110). We further 
engineered a high affinity variant of the RD1-MART1 TCR, termed RD1-MART1HIGH that 
bound to MART1 complexes with nanomolar affinity and showed no recognition of Tax 
or unrelated peptides.  
 Here, we studied this specificity switch by solving the crystallographic structure of 
RD1-MART1HIGH bound to MART1/HLA-A2. This was followed by deep mutational 
scanning to test the impact of substituting all 20 naturally occurring amino acids in every 
CDR position of A6 and RD1-MART1HIGH on binding. The combined structural and 
mutational scanning results allowed us to concretely establish the determinants of 
binding and specificity in both interfaces. We found that a limited number of residue 
changes resulted in a striking change in the TCR binding mode, leading to altered 
interactions throughout the TCR-pMHC interface. These involved germline and 
hypervariable loops, and interactions with both peptide and MHC, the latter of which 
were of surprising importance for the switch in receptor specificity. Indeed, a key driver 
of the change was the disruption of interactions between the TCR and MHC that in 
humans biases αβ TCRs towards particular binding modes over HLA-A2 (119). 
Specificity and affinity in both TCRs were also strongly influenced by ‘second-shell’ 
CDR residues that do not contact peptide or MHC, allowing the identification of even 
higher affinity variants of RD1-MART1 and A6.  
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Despite the change in binding orientation of the RD1-MART1HIGH TCR, when 
transduced into T cells the TCR/CD3 complex was fully capable of initiating responses 
toward the MART1/HLA-A2 complex and not the Tax/HLA-A2 complex. Our findings 
provide an unprecedented level of insight into how TCR specificity is encoded, and 
demonstrate new strategies for generating TCRs with novel and fully functional 
recognition properties. 
Materials and Methods 
Reagents and flow cytometry 
Reagents used to induce and detect yeast surface expression of single-chain 
TCRs have been described previously (110). Peptides used in complex with HLA-A2 
were synthesized by the Macromolecular Core Facility at Penn State University College 
of Medicine. An ultraviolet-cleavable peptide, KILGFVFJV, was synthesized by 
GenScript. HLA-A2 heavy chain was expressed as inclusion bodies in Escherichia coli 
and refolded in vitro with an ultraviolet-cleavable HLA-A2 binding peptide and human 
β2microglobulin as described previously (120). The HLA-A2 heavy chain contained a 
biotinylation substrate sequence for in vitro biotinylation (Avidity, BirA enzyme). Peptide 
exchange with complexes containing the UV-cleavable peptide was achieved by 
exposure to UV light in the presence of 100-fold excess peptide.  
Single-codon library design and selection 
Single-codon libraries of the A6-c134 and RD1-MART1HIGH TCRs were cloned as 
single chains (Vβ-linker-Vα) for yeast display (121). Primers were synthesized by 
Integrated DNA technologies and PCR products containing degenerate NNK codons 
were generated via overlap extension PCR. Pooled single-codon PCR products for 
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each TCR were introduced along with digested pCT302 vector into yeast and libraries of 
independent transformants generated by homologous recombination. The A6-c134 and 
RD1-MART1HIGH libraries contained 3 million and 1 million independent clones, 
respectively, which exceeded by several orders of magnitude the potential diversity of 
the libraries (e.g., 40 positions x 32 codons, or 1280 for the RD1-MARTHIGH library). 
Libraries were stained using pMHC monomer and sorted by FACS.  
Transduction and activation of T cells 
The RD1-MART1HIGH full-length TCR construct (VαCα/VβCβ with mouse 
constant region genes) was cloned into the pMP71 retroviral vector and transfected in 
the platinum-E retroviral packaging cell line. Retroviral supernatants were harvested 
after 48 h and 58-/- cells were transduced as described previously (87). After cells were 
transduced they were sorted via FACS for binding to MART1/HLA-A2 tetramer to obtain 
a positive staining population. To measure IL-2 release, 7.5x105 cells were incubated in 
wells coated with MART1 or Tax tetramer (50 nM), anti-CD3 antibody (10 μg/mL) or with 
7.5 x 105 T2 cells pulsed with various concentrations of peptide. After 24 h at 37°C, 
supernatants were collected and analyzed for IL-2 via ELISA (87).  
Deep sequencing analysis 
Unsorted and sorted yeast libraries (4x107 cells) were lysed and DNA was 
isolated according to manufacturer’s protocol (Zymo Research). Genomic DNA was 
subsequently removed by incubation with 2000 U/mL Exonuclease I and 250 U/mL 
Lambda Exonuclease for 90 minutes, and plasmid DNA was purified using a PCR 
cleanup kit. Deep sequencing analysis was performed as described (122). Single-chain 
TCRs were amplified in two fragments (Vβ and Vα) through two sequential rounds; the 
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first round added overhangs for annealing to Illumina sequencing primers, and the 
second round added adaptamers for annealing to the MiSeq chip. PCR products were 
gel purified and sequenced (MiSeq sequencer) using 250 nt paired-end sequencing 
runs. The naïve libraries had 1.2x106 (RD1-MART1HIGH) and 2.4x106 (A6-c134) reads, 
and targeted single amino acid mutations ranged from 15–3.4x104 (RD1-MART1HIGH; 
median 798) and 38–4.7x105 (A6-c134; median 1016) reads. All mutations were 
therefore well sampled in the libraries. Sorted libraries had 4.2x105 – 1.9x106 reads. 
Enrichment ratios, Exi = log2 (fxi[sorted] / fxi[naïve]) where x is the amino acid identity, i is 
the position and f is the sequence frequency, were calculated using modified scripts 
from Enrich software (123). 
Crystallization, data collection, structure refinement, and analysis 
Single chain, soluble RD1-MART1HIGH, HLA-A2 heavy chain, and β2m for 
crystallization were generated from bacterially produced inclusion bodies as previously 
described (110). For producing the TCR-pMHC complex for crystallization, pMHC was 
first generated in a standard 1L refolding reaction, then inclusion bodies for the TCR 
were added (TCR:pMHC molar ratio of 1:3). The refolding buffer was 50 mM Tris (pH 
8), 2 mM EDTA, 2.5 M urea, 400 mM L-arginine, 9.6 mM cysteamine, 5.5 mM 
cystamine, 0.2 mM PMSF. The TCR was allowed to refold in the presence of pMHC 
overnight. The reaction was then desalted by dialysis at 4°C and the complex purified 
by anion exchange followed by size-exclusion chromatography. 
Crystals of the RD1-MART1HIGH-MART1/ HLA-A2 complex were grown in 15% 
PEG4000, 0.1 M sodium citrate (pH 5.6), 5% 2-propanol, and 2mM zinc acetate at 
25°C. Crystallization was performed using hanging drop/vapor diffusion. For 
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cryoprotection crystals were transferred into 20% glycerol/80% for 30 seconds and 
immediately frozen in liquid nitrogen. Diffraction data were collected at SER-CAT (22-
ID) at APS, Argonne National Labs. Data reduction was performed with HKL2000. The 
structure was solved by molecular replacement using MOLREP, using PDB entry 1QRN 
and the HLA-A2 heavy chain and TCR variable domains as a search model. Rigid body 
refinement followed by NCS torsion angle restraints, translation/libration/screw 
refinement, and multiple steps of restrained refinement were performed using Phenix. 
Anisotropic and bulk solvent corrections were taken into account throughout. Post 
refinement, it was possible to unambiguously trace the peptides and TCR CDR loops 
against σA-weighted 2Fo-Fc maps. Evaluation of models and fitting to maps were 
performed using COOT. MolProbity was used to evaluate the structure during and after 
refinement. Iterative build OMIT maps were calculated in Phenix. Analysis of hydrogen 
bonds used a donor-acceptor maximum distance of 3.6 Å. Contacts were calculated 
with a 4 Å cutoff. Surface areas were calculated using a 1.4 Å radius probe. TCR 
crossing angles were calculated as described by (17), using a line between the 
centroids of the Vα/Vβ disulphide bonds relative to a line through the α carbons of the 
MHC α helices. Incident angles were calculated as described by (124), using the MHC 
helix α carbons to define the plane of the binding groove and the TCR Vα/Vβ symmetry 
axis determined using the FAST structure alignment algorithm. The supplemental movie 
was generated with Chimera using corkscrew interpolation between the A6-c134 and 
RD1-MART1HIGH structures with a sinusoidal interpolation rate. 
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Results 
 
The RD1-MART1HIGH TCR binds with a docking mode distinct from other TCR-
peptide/HLA-A2 complexes 
We previously changed the specificity of the well-studied human TCR A6 from 
Tax/HLA-A2 to MART1/HLA-A2 by screening a library mutated at five amino acid 
positions: one in CDR1α, two in CDR3β, and two in CDR3β (Fig 2.1). To examine the 
structural basis for this switch in specificity, we determined the crystallographic structure 
of the high-affinity variant of this TCR, called RD1-MART1HIGH, bound to MART1/HLA-
A2. The structure was solved at a resolution of 2.5 Å, with two TCR-pMHC complexes in 
the asymmetric unit (Table 2.1). The two complexes were nearly identical, with all atoms 
of the complex superimposing with a root mean square deviation of 0.7 Å (Fig. 2.2). 
Clear electron density was observed throughout the structure, with density lacking for 
only the Vα/Vβ linker and a few side chains (Fig 2.3). 
Surprisingly, we found that RD1-MART1HIGH TCR adopted a different binding 
mode over pMHC compared to the wild-type A6 TCR or the A6-c134 high affinity 
variant, which incorporates some of the same mutations as RD1-MART1HIGH in the 
CDR3β loop (111, 125). Unlike the A6 and A6-c134 TCRs, RD1-MART1HIGH is tilted 
back and away from the peptide N-terminus (Fig. 2.2; left). This binding mode is also 
distinct from the MART1/HLA-A2-specific TCRs DMF5 and Mel5 (116, 126), a striking 
observation as the A6, RD1-MART1HIGH, DMF5, and Mel5 TCRs all utilize the same 
TRAV12-2 gene segment (Fig. 2.2B; right) (127). A broader comparison showed that 
the altered binding mode is facilitated by an unusual incident angle, quantified as the tilt 
of the Vα/Vβ pseudo-symmetry axis with respect to the plane of the pMHC binding 
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groove (124). While the crossing angle is within the range observed for other TCRs, the 
incident angle of RD1- MART1HIGH is distinct from all other TCRs bound to peptide/HLA-
A2 complexes (Fig. 2.2C). We note that the unusual binding mode of RD1-MART1HIGH 
is not associated with a lack of specificity, as we previously demonstrated that RD1-
MART1HIGH does not recognize Tax or other non-cognate peptides tested (110).  
Architectural changes in the RD1-MART1HIGH-MART1/HLA-A2 interface 
Compared to the complex with the A6-c134 TCR, the amino acid changes and 
the different binding mode of RD1-MART1HIGH substantially altered the footprint over 
pMHC and led to a reduced number of contacts across the interface (Fig. 2.4A). Using a 
4 Å cutoff, RD1-MART1HIGH forms only 75 interatomic contacts, compared to 171 with 
A6-c134. The reduction is greatest with the peptide, which is involved in 26 contacts 
with RD1-MART1HIGH and 80 with A6-c134. In comparison, there are 124 contacts in the 
complex of DMF5 with MART1/HLA-A2, of which 48 are to the peptide. The smaller 
number of contacts in the RD1-MART1HIGH interface translates into a smaller amount of 
buried solvent accessible surface area (1427 Å2 for RD1-MART1HIGH, 2124 Å2 for A6-
c134). As shown in Fig. 2.4B, differences in contacts are seen for every loop except for 
CDR2β, which does not contact pMHC in either complex.  
The conformation of the MART1 peptide in the RD1-MART1HIGH complex is 
essentially identical to the conformation in the DMF5 and Mel5 complexes and in the 
unligated MART1/HLA-A2 complex (Fig. 2.4C) (128). This conformation, however, 
differs substantially from that of Tax peptide, reflecting the different surface recognized 
by the TCR. Although some side chain rotamers are altered (e.g., Trp95α), only the 
CDR3β loop of RD1-MART1HIGH significantly alters its conformation relative to A6-c134 
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(Fig. 2.4D). This is a surprising observation given the amino acid substitutions and 
different molecular environments in the RD1-MART1HIGH and A6-c134 complexes (Fig. 
2.4E). The conformation of the CDR3β loop of the A6 TCR varies considerably in 
different structures, whereas the other loops remain static (127), perhaps reflecting a 
level of intrinsic flexibility or adaptability in the unbound TCR that is not altered by the 
various mutations. 
Structural drivers of the change in RD1-MART1HIGH specificity and binding mode  
A detailed examination of the RD1-MART1HIGH–MART1/HLA-A2 interface 
provided insight into how the amino acid substitutions in RD1-MART1HIGH work together 
to alter TCR binding and specificity. An important observation is the alteration of 
electrostatic interactions between the CDR3α loop and Arg65 on the HLA-A2 α1 helix 
(Fig. 2.5A). Accommodation of Arg65 via electrostatic interactions is a characteristic 
feature of TCR structures with HLA-A2, resulting from the need to offset the desolvation 
penalty associated with charge burial. This need is strong enough to have influenced 
the co-evolution of TCR alongside MHC genes (119). Thus, the mutations in RD1-
MART1HIGH broke an apparent “rule of engagement” between αβ TCRs and HLA-A2, 
with dramatic consequences. 
In every known structure of the A6 TCR and its variants, Arg65 is accommodated 
by a hydrogen bond and salt-bridge from Thr92α and Asp93α. Our previous analyses of 
these interactions by double mutant cycles revealed they are both very strong, each 
contributing in excess of -2.5 kcal/mol in binding free energy (117). In RD1-MART1HIGH, 
Thr92α is replaced with a lysine, and Asp93α with a tyrosine; thus the TCR is unable to 
form these same interactions with HLA-A2. In response, Arg65 on HLA-A2 swings 
36 
	
around away from its position with A6, likely due to charge repulsion from the new lysine 
at position 92α (Fig. 2.5A). In this altered position, Arg65 forms cation-π interactions 
with Trp95 of CDR3α, which adjusts its position to become sandwiched between Arg65 
and the backbone of Gly4 of the MART1 peptide. With the Tax peptide, Trp95α would 
be unable to assume this position due to clashes with the peptide backbone, illustrating 
how the altered TCR interactions with the MHC protein contributed to the new peptide 
specificity. The positioning of the new Lys92 in CDR3α, which as noted above 
contributes to the different position of Arg65 via charge repulsion, is stabilized by the 
formation of a new salt-bridge with Asp26 of CDR1α. This interpretation is supported by 
the loss of binding seen in both the K92Eα and K92Aα mutants of RD1-MART1HIGH 
when measured by yeast display titrations with monomeric MART1/HLA-A2 (Fig. 2.6).  
Another key change is the replacement of Gln30 of CDR1α with threonine (Fig. 
2.5A). With the A6 TCR, the side chain of Gln30α forms a hydrogen bond with Lys66 of 
HLA-A2, another important interfacial charge that must be accommodated (119). The 
shorter threonine in RD1-MART1HIGH is unable to form this interaction. Instead, the new 
tyrosine at position 93α interacts with Lys66. This interaction can only occur with the 
altered binding mode; otherwise atomic overlap would occur. The energetic importance 
of this tyrosine was also substantiated by mutational analysis, as the Y93Fα mutation 
resulted in about 10-fold weaker binding and the Y93Aα mutation showed no detectable 
binding in a yeast display titration (Fig. 2.6B).  
 In the structures of the TRAV12-2 TCRs DMF5 and Mel5 with MART1/HLA-A2, 
Gln30α interacts with the glutamate side chain at p1 of the peptide. Thr30α in RD1-
MART1HIGH is unable to form this interaction. Instead, the altered binding mode tips the 
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TCR back so pGlu1 is more exposed than in the DMF5 and Mel5 complexes (Fig. 2.7A). 
Rather than performing the functions of Gln30α, the side chain of the threonine at 
position 30α hydrogen bonds with the backbone of CDR3α, stabilizing the altered loop 
conformation. 
In all structures of A6 variants with Tax/HLA-A2, Glu30 of CDR1β hydrogen 
bonds with the side chain of the tyrosine at peptide position 8. This interaction is also 
very strong (117), and indeed, replacement of pTyr8 with alanine substantially weakens 
peptide potency in functional assays (125). As this tyrosine is replaced with a threonine 
in the MART1 peptide, MART1 would be unable to interact with Glu30β. However, the 
binding mode of RD1-MART1HIGH moves Glu30β away from the interface, allowing the 
backbone oxygen of Met98 of the remodeled CDR3β loop to hydrogen bond with the p9 
threonine, and the new tryptophan at position 97β to sandwich between Met98β and 
Trp95α (Fig. 2.5B). These observations further illustrate the connection between the 
new TCR binding mode and the switch in specificity. 
The central regions of the MART1 and Tax peptides differ significantly (Fig. 
2.4C), and are accommodated differently in the A6 and RD1-MART1HIGH interfaces. Tax 
has a central p5 tyrosine that points directly into a pocket between the CDR3α and 
CDR3β loops of the A6 TCR. The MART1 peptide has an isoleucine at p5. However, 
while modifications to p5 of Tax are accommodated by alterations in the size of the 
pocket via changes in CDR3β (126, 129), this does not occur with RD1-MART1HIGH. 
Instead, the CDR3β loop is repositioned away from the peptide center (Fig. 2.5B). This 
leaves the isoleucine at position 5 of MART1 relatively exposed, pointed towards the 
HLA-A2 α2 helix. It is partially “capped” by Tyr50 of CDR2α (Fig. 2.5C), mimicking 
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somewhat how p5 Ile is accommodated in the structure of the Mel5 TCR bound to 
MART1/HLA-A2 (116). The capping of the Ile side chain is important, as RD1-
MART1HIGH is unable to bind the MART1-I5A variant (Fig. 2.7B), and mutations that 
could improve capping lead to enhanced binding as discussed below. 
Lastly, in all A6, DMF5, and Mel5 complexes, the TRAV12-2 CDR2α loop is 
aligned alongside residues 154–158 of the HLA-A2 α2 helix, forming a similar pattern of 
interactions (127). The shift in the binding mode of RD1-MART1HIGH slightly alters this 
pattern, although Tyr50α is still aligned alongside Gln155, and Ser51α contacts Ala158 
(Fig. 2.5D). As discussed below, these subtle differences in a conserved interaction 
pattern create opportunities for introducing new mutations that allow improvements in 
receptor affinity and specificity.  
The unusual binding mode of the RD1-MART1HIGH TCR permits antigen-specific T cell 
signaling 
As noted above, the engineering process used to alter TCR specificity disrupted 
highly conserved interactions between the TCR and HLA-A2, ultimately leading to the 
altered orientation of RD1-MART1HIGH. An important question is whether these changes 
prevent competent signaling through the TCR/CD3 complex (130). To determine 
whether the RD1-MART1HIGH TCR could mediate activity, the full-length α and β genes 
(with the human V regions and mouse C regions) were transduced into the mouse T cell 
hybridoma 58-/- which lacks its own αβ TCR but contains the genes for the CD3 subunits 
(131). RD1-MART1HIGH TCR-transduced cells, but not mock-transduced cells, were 
positive for staining with MART1/HLA-A2 tetramer (Fig. 2.8A). The RD1-MART1HIGH 
TCR-positive cells were stimulated to release IL-2 by immobilized MART1/HLA-A2 
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tetramers but not Tax/HLA-A2 tetramers (Fig. 2.8B). When the RD1-MART1HIGH TCR-
positive cells were incubated with the HLA-A2+ T2 cells, the MART1 peptide was also 
stimulatory, whereas Tax was not (Fig. 2.8C). These results indicate that despite the 
altered orientation of RD1-MART1HIGH over pMHC, its ability to assemble with CD3 
subunits and signal efficiently in an antigen-specific manner was not impeded. 
Deep mutational scanning of the A6-c134 and RD1-MARTHIGH TCRs 
To obtain a comprehensive view of how the residues of the RD1-MART1HIGH and 
A6-c134 CDR individually contribute to ligand binding, we performed deep mutational 
scanning with both TCRs, using yeast displayed TCR mutants (Fig. 2.9A) (122). Yeast-
display TCR libraries were sorted with concentrations of monomeric peptide/HLA-A2 
ligand that ranged from 5-10 fold below to 5-10 fold above the KD of the parental TCR 
(Fig. 2.9B,C). After deep sequencing of naïve and sorted libraries, the change in 
frequency of each single amino acid variant was calculated. This calculated enrichment 
ratio is a proxy for sequence fitness: TCR variants that bind pMHC with high affinity are 
enriched, while deleterious mutations are depleted.  
The sequence-fitness landscapes determined from library selections at different 
pMHC concentrations yielded similar profiles (presented as heat maps; Fig. 2.10 and 
Fig. 2.11). As a validation of this approach, correlation plots between the enrichment 
values for each codon library selected at different concentrations showed excellent 
agreement for the positively enriched variants, and significant, although quantitatively 
more variable, agreement for negatively selected variants (Fig. 2.11C). For further 
analysis, we focused on selections conducted at the lowest ligand concentrations for 
each TCR (Fig. 2.10A,B). 
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To examine the impact of substitutions on overall protein stability and the 
inherent variability in the deep sequencing approach, the analysis of the A6-c134 TCR 
included a collection of residues that were present in exposed framework (FR) residues, 
many at the opposite end of the TCR (Fig. 2.12). As expected, these residues showed 
weaker selection (either positive or negative) compared to most of the CDR positions 
(Fig. 2.10A). However, there were some residues whose substitutions were depleted, 
likely due to protein destabilization (112). Substitutions of Gly40 in Vβ and Gly15 in Vα 
were nearly universally deleterious, as were substitutions of Asp77, Ser78 and Gln79 in 
Vα, suggesting stabilizing structural roles for these residues (Fig. 2.12). Two FR 
residues in RD1-MART1HIGH were examined and substitutions in each had minimal 
effects compared to those in CDR loop residues (Fig. 2.10B). 
Comparison of the impact of A6-c134 versus RD1-MARTHIGH CDR residues on binding 
As expected, the most significant effects on pMHC binding were in the CDR 
loops, especially the two CDR3 loops. When examining either the alanine substitution 
results alone (Fig. 2.13A,B) or the collective results of all 20 amino acids, many of the 
key residues were focused at the TCR-pMHC interface. The identity of these residues 
was in excellent agreement with the conclusions drawn from the crystallographic 
structures. For example, the structures suggested that Asp26α in RD1-MART1HIGH 
stabilizes the conformation of Lys92α, forcing the novel orientation of Arg65 in the α1 
helix of HLA-A2. Supporting this interpretation, only the conservative D26E substitution 
at position 26α permitted equivalent binding to the MART1 complex, based on similar 
enrichment ratios. Lys92α was required, as was the neighboring Tyr93α, which as 
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noted above offsets the charge of Lys66 of HLA-A2 via a cation-π interaction (Fig. 
2.10B and Fig. 2.11).  
Position 30 in CDR1α is another key position underlying the specificity switch. 
Threonine is required for high affinity pMHC binding by RD1-MART1HIGH, whereas the 
wild-type glutamine is required in A6-134 (Fig. 2.10). This is consistent with a role for 
Gln30α in “pinning down” the Vα domain of A6-c134, whereas the shorter threonine in 
RD1-MART1HIGH permits the TCR to tilt away from the peptide N-terminus, exposing 
pGlu1 as shown in Fig. 2.5A and Fig. 2.7A. 
In the case of CDR1β and CDR2β residues, a variety of substitutions permitted 
strong binding by RD1-MART1HIGH, reflecting the lack of involvement of these loops in 
direct ligand recognition as shown by the structure. Similar results were found with A6-
c134, with the exception of a requirement for Glu30 in CDR1β (Fig. 2.10A), consistent 
with the strong hydrogen bond it forms with the Tax pY8 side chain (117).  
In addition to contact positions, for both TCRs there were also significant effects 
in positions that do not directly contact ligand. These amino acids appear to be 
important for binding site architecture. This was particularly obvious in RD1-MART1HIGH 
(Fig. 2.13B), as mutations in several residues in CDR1β and CDR2β that are in 
proximity to the start of CDR3β showed significant effects on binding. These residues 
are likely critical in orienting key residues for their interactions with peptide and MHC. 
As noted with the scan of FR residues, some of these effects could also result from a 
reduction in TCR stability. We suspect that this is particularly true of the impacts seen 
with glycines or hydrophobic residues (e.g., I49α in A6-c134) that are packed in the 
center of a CDR loop. 
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Finally, it is worth noting the distributed nature of residues found to have the 
greatest impact on binding their pMHC ligands, for both RD1-MART1HIGH and A6-134 
(Fig. 2.13A,B). Some of these residues were shared between RD1-MART1HIGH and A6-
134, but many differences were observed even though they had not been mutated to 
yield the specificity switch. Thus, both binding and specificity are the product of multiple, 
distributed CDR residues and how they interact with both peptide and MHC. 
Distinct differences in the contribution of CDR residues in A6-c134 versus RD1-
MART1HIGH 
To examine the role of several key residues in more detail, we focused on four 
residues in A6-c134 and RD1-MART1HIGH that were of particular significance: position 
30 in CDR1α (Gln or Thr), position 50 in CDR2α 50 (Tyr), position 91 in CDR3α (Thr), 
and position 92 in CDR3α (Thr or Lys). The enrichment values for substitutions at these 
four positions were compared directly in A6-c134 and RD1-MART1HIGH (Fig. 2.14A). As 
indicated above, for position 30 in CDR1α, glutamine in A6-c134 and threonine in RD1-
MART1HIGH each were important, and neither amino acid could substitute for the other 
in their respective TCR context. To confirm this, the individual mutations were 
introduced into A6-c134 and RD1-MART1HIGH and titrations performed with monomeric 
pMHC (Fig. 2.14B). Consistent with the inferences from the mutational scanning and 
structural analysis, substitution of threonine into A6-c134 reduced binding to Tax/HLA-
A2 and substitution of glutamine into RD1-MART1HIGH eliminated binding to 
MART1/HLA-A2. These results confirm the differential contributions for the amino acid 
at this key CDR1α position to the specificity of both TCRs. 
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The enrichment data for position 50 in CDR2α also showed a significant negative 
impact with all substitutions, except that a tryptophan was well tolerated in RD1-
MART1HIGH (Fig. 2.14A). Separate alanine mutations in both A6-c134 and RD1-
MART1HIGH showed reduced binding of their respective ligands (Fig. 2.14C), but as 
predicted by deep mutational scanning, mutation of Y50α to tryptophan enhanced 
binding with RD1-MART1HIGH but weakened binding with A6-c134 (Fig. 2.14C). The 
need for a tyrosine at position 50α is consistent with a previously determined role for 
Tyr50α in TRAV12-2 TCRs in interacting with the HLA-A2 α2 helix (132). As discussed 
above, these interactions are altered in the RD1-MART1HIGH complex, with Tyr50α 
“capping” the isoleucine at peptide position 5 in addition to interacting with the α2 helix 
(Fig. 2.5C). The bulkier tryptophan likely buries additional isoleucine non-polar surface 
without disrupting the interactions with the helix, leading to improved binding. Thus 
Y50α makes key interactions with the MHC in both TCRs, but the altered binding mode 
of RD1-MART1HIGH provides an opportunity for enhancing binding that is absent with 
A6-c134.  
Although position 92 of CDR3α (threonine in A6-c134 and lysine in RD1-
MART1HIGH) contributed to peptide specificity as illustrated by the importance of these 
alternative residues in their respective TCRs (Fig. 2.14A), we noticed that the adjacent 
position threonine 91α could be substituted with amino acids that either improved or 
reduced binding. Two of the substitutions (glutamine and aspartic acid) had opposing 
effects with the two TCRs. To substantiate this and examine the magnitude of the 
effects, the two mutations were introduced into each TCR (Fig. 2.14D). The T91Q 
mutation nearly eliminated binding of Tax/HLA-A2 by A6c-134 but significantly 
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enhanced binding of MART1/HLA-A2 by RD1-MART1HIGH. Remarkably, the T91D 
mutation had exactly the opposite effect. In both structures, Thr91α is at the N-terminal 
start of the CDR3α loop. Beyond this though, the altered binding mode and loop 
structure leads to a local environment that is quite different between the TCRs, which 
can explain the opposing effects of the mutations in the two TCRs (Fig. 2.15). 
Second-shell positions that yielded improvements in binding to the peptide/HLA-A2 
complexes 
The sequence-fitness landscapes showed that a high fraction of substitutions 
(7.8% in A6-c134 and 8.3% in RD1-MART1HIGH) yielded improvements in binding or 
stability for RD1-MART1HIGH and A6-c134. In both TCRs, these improvements were 
distributed at various positions among the CDR loops, and thus did not indicate the 
existence of a sub-optimal sequence for any single loop.  
To gain a structural perspective in the ability of the substitutions to generate 
improvements, we highlighted the positions of the most improved residues (based on 
either enrichment of a single substitution or the ability of multiple substitutions at the 
same position to yield enrichment) (Fig. 2.13C,D). Two features were apparent from this 
analysis. First, in the cases of both A6-c134 and RD1-MART1HIGH, the positions that 
yielded enhancements were often in ‘second-shell’ residues, i.e., those that were not in 
contact with ligand. This reflects what was seen with Thr91α (Fig. 2.14A,D) and has 
been observed in other affinity maturation efforts (133). Many of these changes likely 
allow subtle reconfiguration or stabilization of the CDR loops for optimal binding. 
Second, the majority of positions that yielded improvements were not shared 
between the two TCRs, despite the high level of TCR sequence identity and their 
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common origin (i.e., the A6 TCR). Key examples of the opposite effects of a single 
position in the two TCRs were the T91D and T91Q mutations in CDR3α and the Y50W 
mutation in CDR2α, as described above. This finding is consistent with our general 
conclusion that multiple sites working collectively are required for achieving specificity. 
Discussion 
	 The RD1-MART1 variant of A6 represents the first example of a TCR custom 
engineered to possess a novel specificity. The structure of the complex combined with 
deep mutational scanning allowed us to ascertain the underlying mechanism of the 
specificity switch, and in turn to gain unprecedented insight into the determinants of 
TCR specificity and affinity and how they may be productively manipulated.  
A key observation is the unusual tilt or incident angle of RD1-MART1HIGH over 
MART1/HLA-A2, which substantially alters interactions throughout the TCR-pMHC 
interface. Importantly its formation is not simply due to introduction of new “attractive” 
interactions, but also mutations that destabilize the binding mode of the parental A6 
TCR. A prime example is the replacement of negative with a positive charge in a crucial 
region of the interface, catalyzing the rearrangement of Arg65 on the HLA-A2 α1 helix 
and the subsequent formation of several new stabilizing interactions. The 
consequences that follow from this substitution in CDR3β reinforce our recent finding 
that accommodation of Arg65 strongly influences how human TCRs bind class I MHC 
proteins, and HLA-A2 in particular (119). 
Another example of an altered interaction that involves the MHC protein is the 
“repurposing” of Trp95α to interact with Arg65 and pack between the peptide and the α1 
helix. Thus, the new position of the TCR over the pMHC and the resulting change in 
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specificity can be attributed to the interplay of mutated and non-mutated amino acids 
across multiple CDR loops and how they interact with the composite peptide/MHC 
surface. Our experiments thus reveal a more “distributed” view of TCR specificity than is 
usually considered. This point is reinforced by our finding through mutational scanning 
that multiple positions throughout the TCR binding site, and non-contact residues in 
particular, could be mutated to alter both the specificity and affinity of RD1-MART1HIGH 
and A6-c134. 
It is interesting that RD1-MART1HIGH maintains an alignment between CDR2α 
and HLA-A2 seen in structures with all other TRAV12-2 TCRs (127). The residues 
comprising this motif, and Tyr50α in particular, are important in the binding of A6-c134 
and RD1-MART1HIGH as indicated from the mutational scanning of this region. However, 
tryptophan at position 50α disrupts binding with A6c-134 but improves binding with 
RD1-MART1HIGH. This indicates that the structural differences in this motif between 
RD1-MART1HIGH and the other TRAV12-2 TCRs are sufficient to alter the energetics of 
these conserved interactions. This observation highlights the difficulty of identifying 
energetically significant interactions between TCRs and MHC proteins from structure 
alone. However, it also indicates how mutational scanning can be used to alter or even 
improve the specificity of TCRs by introducing substitutions that simultaneously weaken 
canonical interactions but enhance binding to a specific peptide/MHC complex (e.g., the 
opposite effects of the Y50Wα substitution in A6-c134 and RD1-MART1HIGH). 
Another important finding is the ability of many mutations in residues that do not 
contact pMHC to strengthen TCR binding. The presence of such ‘second shell’ 
mutations has been noted in other applications of affinity maturation (133), and indeed, 
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in many affinity-enhanced TCRs mutations are found in residues that do not contact 
ligand. In some high affinity TCRs, however, contact residues have been mutated (e.g., 
(105)), and efforts using structure-guided design to generate high affinity TCRs have 
almost exclusively emphasized contact residues (e.g., (134)). As mutating contact 
residues could potentially introduce new specificities by improving chemical 
complementarity with new peptides, these ‘second-shell’ sites are potentially superior 
candidates for mutation to improve binding. While more work is needed to understand 
how these mutations impart their effects, the combination of structure-guided 
engineering and comprehensive mutational analysis provides a new and powerful 
strategy to improve both TCR specificity and affinity.  
Lastly, the mechanisms of TCR triggering remain widely debated. One model of 
TCR triggering places fine constraints on TCR binding geometry, and indeed, unusual 
binding has been associated with a loss of signaling with the 42F3 TCR (130). We 
found here that despite the unusual binding mode of RD1-MART1HIGH compared to 
other HLA-A2 complexes, it was fully capable of mediating antigen-specific signaling in 
T cells. This could indicate that T cell signaling mechanisms are more tolerant to 
incident rather than crossing angles, as the signaling-incompetent 42F3 TCR has an 
altered TCR crossing angle, which is not observed here. Intriguingly through, two TCRs 
from regulatory T cells that bind pMHC with “reversed polarity” still signal (135). 
Although additional studies relating TCR binding geometries to signaling are obviously 
needed, our results nonetheless indicate that T cell signaling mechanisms are tolerant 
to engineering approaches that alter TCR binding modes. 
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Figure 2.1- Amino acid sequence alignments. The amino acid sequences of A6 (PDB, 1AO7), A6-
c134 (PDB, 4FTV) and RD1-MART1
HIGH
 are aligned. Residues that resulted in the switch in 
specificity from Tax/HLA-A2 to MART1/HLA-A2 are highlighted in blue (109). Residues that enhance 
affinity are highlighted in yellow.  Residues mutated in order to stabilize the A6 and RD1-MART1
HIGH
 
single-chain forms are underlined and in bold.  These Vβ mutations have been shown to allow the 
scTCRs to be displayed on the yeast surface display and to facilitate soluble protein expression, but 
they did not affect peptide specificity  (114). Numbering of residues is partially modified from Aggen 
et al to achieve consecutive numbering of amino acids in the polypeptide chains, and for 
correspondence to numbering in the RD1-MART1
HIGH
 PDB file.  
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Figure 2.2. The switch in specificity of RD1-MART1
HIGH
 is associated with an altered docking 
mode. (A) Overview of the RD1-MART1
HIGH
-MART1/HLA-A2 complex. The two complexes in the 
asymmetric unit (green and yellow) are essentially indistinguishable, as shown in the 
superimposition. (B) The binding mode of RD1-MART1
HIGH
 is distinct from the parental A6 TCR 
(left) as well as the MART1-specific TCRs DMF5 and Mel5 (right), despite all three sharing 
TRAV12-2. The vertical dashed lines show the incident angle of the various TCRs over pMHC. 
Horizontal lines show the crossing angles. (C) Comparison of the incident and crossing angles of 
RD1-MART1
HIGH
 with other HLA-A2 restricted TCRs reveals it is an outlier compared to A6, other 
MART1-specific TCRs, and HLA-A2-restricted TCRs in general. The graph on the left quantifies 
incident and crossing angles, while the image on the right compares the binding of RD1-
MART1
HIGH
 to A6 and three other MART1-specific TCRs. The spheres represent the centers of 
mass of the Vα/Vβ domains of the TCRs, with horizontal and dashed lines reflecting crossing and 
incident angles, respectively.  
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Figure 2.3- Electron densities of CDR domains and peptide. Electron density from a simulated 
annealing composite 2Fo-Fc omit map contoured at 1σ for the CDR loops (top) and the peptide 
(bottom) in the RD1-MART1
HIGH
-HLA-A2 structure. 
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Figure 2.4 The RD1-MART1
HIGH
 complex is architecturally distinct from the A6-c134 and DMF5 
complexes. (A) Comparison of TCR and pMHC contacted residues in the RD1-MART1
HIGH
, A6-c134, 
and DMF5 complexes. Complexes have been opened up “book” style and amino acids contacted on the 
pMHC (left) or TCR (right) colored. Red lines either outline peptide (left) or separate Vα and Vβ (right). 
The number of interatomic contacts and buried solvent accessible surface for each complex is indicated. 
The color scheme is used throughout the figure. (B) Schematic showing contacts between CDR loops 
and peptide in the three complexes. Line widths are proportional to the number of contacts between 
each loop and peptide residue. Only those CDR loops making contacts are listed. (C) The backbone of 
the MART1 peptide in the RD1-MART1
HIGH
 complex is essentially identical to that in the DMF5 complex 
and the free pMHC (left). However, this conformation differs from that of the Tax peptide (right). (D) 
Detailed view of the altered conformation and side chains of CDR3β. The conformations of the remaining 
CDR loops are largely unperturbed between the RD1-MART1
HIGH
 and A6-c134 complex. (E) Even 
though five of six CDR loops adopt the same conformation, the difference in binding mode between 
RD1-MART1
HIGH
 and A6-c134 places them in different molecular environments, as shown by 
superimposing the HLA-A2 peptide binding domains in the two structures and viewing the positions of 
the loops. 
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Figure 2.5 Structural drivers of the change in binding mode and switch in specificity. (A) Cross-
eyed stereo view comparing the A6-c134 and RD1-MART1
HIGH
 interfaces, viewed from the N-terminal 
ends of the peptides. The difference in the positions of Arg65 and various interacting side chains is 
apparent, as is the difference in position 30 of CDR1α, which when glutamine interacts strongly with the 
peptide in the A6-c134 TCR structure, but does not contact the peptide when threonine in RD1-
MART1
HIGH
. For this and panels B-C, green lines indicate hydrogen bonds, orange lines salt-bridges or 
cation-π interactions, cyan lines van der Waals contacts. B) As in panel A, but viewed from the C-
terminal ends of the peptides. The placement of important tryptophans in RD1-MART1
HIGH
 is apparent, 
as are the different mechanisms for engaging the C-terminal portion of the peptide (CDR3β in RD1-
MART1
HIGH
, CDR1β in A6-c134). (C) Cross-eyed stereo view showing how Y50 of CDR2α helps “cap” 
the p5 Ile side chain of the MART1 peptide in the RD1-MART1
HIGH
 interface. The p5 Ile side chain is still 
partially solvent exposed, as shown by the blue surface. (D) Comparison of how CDR2α is aligned 
alongside HLA-A2 α2 helix in the complexes with RD1-MART1
HIGH
, A6-c134, DMF5, and Mel5. Yellow 
lines show interatomic contacts (indiscriminate of contact type). 
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Figure 2.6- Binding of K92a and Y93a mutants of RD1-MART1
HIGH
. Mutants K92Aα and K92Eα 
(A) and Y93Aα and Y93Fα (B) were expressed on the yeast surface and stained with MART1/HLA-
A2 monomer at various concentrations. Mean fluorescence intensity (MFI) is plotted against 
peptide/HLA-A2 monomer concentration. Titrations are representative of two experiments with similar 
results. RD1-FL refers to the full length “wild type” RD1-MART1
HIGH
 protein. 
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Figure 2.7- Position of the p1Glu of the MART1 peptide and impact of the p5Ile  on the RD1-
MART1
HIGH 
interaction.  (A) pGlu1 of peptide MART1 is more solvent exposed in the RD1-
MART1
HIGH
 complex than in the complexes with Mel5 and DMF5. Red highlight shows the solvent 
accessible surface area of the oxygens of the pGlu1 side chains in the three TCR-pMHC structures, 
quantified as indicated. (B) Binding of the I5A variant of the MART1 peptide. Yeast cells expressing 
RD1-MART1
HIGH 
were stained with various concentrations of peptide/HLA-A2 monomer containing 
either MART1 peptide (ELAGIGILTV) or the MART1-I5A variant peptide (ELAGAGILTV). Grey filled 
histograms are yeast stained with secondary antibody only. Data are representative of two 
experiments with similar results.  
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Figure 2.8 RD1-MART1
HIGH
 TCR mediates activity of T cells in the presence of MART1/HLA-A2 
but not Tax/HLA-A2. (A) The coreceptor negative mouse 58
-/- 
T cell hybridoma cell line was 
transduced with the full-length RD1-MART1
HIGH
 TCR and stained with 50 nM MART1/HLA-A2 tetramer 
(black lined histogram). Mock-transduced cells were also stained with 50 nM MART1/HLA-A2 tetramer 
(gray filled histogram). (B) IL-2 release from RD1-MART1
HIGH
 (filled bars) and mock (open bars) T cells 
incubated in wells coated with Tax/HLA-A2 tetramer, MART1/HLA-A2 tetramer, or anti-CD3 antibody. 
(C) IL-2 release from RD1-MART1
HIGH
 T cells incubated with T2 antigen presenting cells and various 
concentrations of MART1 peptide (filled circles), Tax peptide (open circles) or no peptide (gray circles).  
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Figure 2.9-Deep mutational scanning of A6-c134 and RD1-MART1
HIGH
. (A) Diagram of work flow 
for generating single codon mutational fitness landscapes. (B) A6-c134 and RD1-MART1
HIGH
 were 
expressed on the surface of yeast as single chain TCRs and stained with indicated concentrations 
of Tax (LLFGYPVYV)/HLA-A2 and MART1(ELAGIGILTV)/HLA-A2 monomers (grey filled 
histograms, secondary antibody only). Mean fluorescence intensities (MFI) were plotted versus 
HLA-A2 monomer concentrations. KD values were calculated using nonlinear regression. (C) Single 
codon libraries (SCL) of A6-c134 and RD1-MART1
HIGH
 were stained with various concentrations of 
Tax/HLA-A2 and MART1/HLA-A2 monomer.  
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Figure 2.10 Deep Mutational Scanning of A6-c134 and RD1-MART1
HIGH
. All single amino 
acid substitutions were expressed in a yeast display library of A6-c134 (A) and RD1-MART1
HIGH
 
(B). Mutants that bound with the top 0.5% fluorescence signal for Tax/HLA-A2 at 5 nM (A) and 
top 1% fluorescence signal for MART1/HLA-A2 at 10 nM pMHC (B) were collected by FACS. 
Sequences were then analyzed using next generation sequencing. The sequence enrichment 
compared to the naïve library was calculated as a log2 ratio. Enrichment ratios are color-coded 
from ≤ 2
-3
 (orange) to ≥ 2
5 
(blue). Stop codons are denoted with an asterisk. See also Figs. S5-
S8. 
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Figure 2.11- Deep mutational scanning of A6-c134 and RD1-MART1
HIGH
. Single amino acid 
substitutions were expressed in yeast display libraries (single-codon libraries) of A6-c134 and RD1-
MART1
HIGH
. (A) A6-c134 mutants that bound with the top 0.5% fluorescence signal for Tax/HLA-A2 at 
50 nM were collected using FACS, and deep sequencing of selected population was conducted as 
described to determine the frequency of each single-amino acid mutant in the libraries.  (B) RD1-
MART1
HIGH 
mutants that bound with the top 1% fluorescence signal for MART1/HLA-A2 at 50 nM and 
250 nM were collected using FACS and deep sequencing of selected population was conducted as 
described to determine the frequency of each single-amino acid mutant in the libraries. Sequence 
enrichment was compared to the naïve library and was calculated as log2 ratio. The enrichment ratio 
was color-coded from 2
-3
 (orange) to 2
5 
(blue). Stop codons are denoted with an asterisk (*). (C)  
Comparison of enrichment values between different sorting conditions. Enrichment values for different 
sorting conditions of RD1-MART1
 HIGH
 and A6-c134 are plotted. R
2
 values for positively enriched 
substitutions ranged from 0.84 to 0.96 and R
2
 values for negatively enriched substitutions ranged from 
0.36-0.50.  
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Figure 2.11 (cont.)- Deep mutational scanning of A6-c134 and RD1-MART1
HIGH
.  
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Figure 2.12- Position of framework residues analyzed in deep mutational scan of A6-
c134. Framework residues that were included in the A6-c134 single codon analysis are 
highlighted in yellow or red. Residues that yielded predominately negative enrichments are 
highlighted in red. 
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Figure 2.13 CDR Residues critical in binding pMHC and those residues that can potentially 
enhance affinity. (A) CDR residues of A6-c134 shown to have the largest reduction in Tax/HLA-A2 
binding upon mutagenesis, based on the alanine results of the deep mutational screen. (B) CDR 
residues of RD1-MART1
HIGH
 shown to have the largest reduction in MART1/HLA-A2 binding upon 
mutagenesis, based on the alanine results of the deep mutational screen. (C) CDR residues of A6-
c134 where mutations were capable of increasing binding to Tax/HLA-A2. (D) CDR residues of RD1-
MART1
HIGH
 where mutations were capable of increasing binding to MART1/HLA-A2. For (A) and (B), 
alanine mutation enrichment values were averaged for all selection conditions (A6-c134 n=2, RD1-
MART1
HIGH 
n=3); residues with the ten lowest values are highlighted in yellow. Glycine residues were 
excluded from analysis due to their likely disruption of backbone conformation rather than specific 
side-chain contribution. For (C) and (D) residues are highlighted in yellow where at least one 
mutation in the single codon analysis showed an enrichment of 8-fold or greater than that of the wild-
type residue. 
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Figure 2.14 Enrichment and binding comparison of select mutants from A6-c134 and RD1-
MART1
HIGH
. (A) Enrichment ratios from single-codon library sorts of A6-c134 and RD1-MART1
HIGH
 were 
compared at residues Q30α (A6-c134) or T30α (RD1-MART1
HIGH
), Y50α (A6-c134 and RD1-MART1
HIGH
), 
T91α (A6-c134 and RD1-MART1
HIGH
), and T92α (A6-c134) or K92α (RD1-MART1
HIGH
). The data for 
several key mutations that were analyzed further using single-site mutations are indicated by the upward 
arrows. (B) Mutant Q30Tα of A6-c134 or mutant T30Qα of RD1-MART1
HIGH
. (C) Mutants Y50Wα and 
Y50Aα of both A6-c134 and RD1-MART1
HIGH
. (D) Mutants T91Dα and T91Qα of both A6-c134 and RD1-
MART1
HIGH
 . TCR mutants were expressed on the yeast surface, and cells were stained with Tax/HLA-A2 
and MART1/HLA-A2 monomer respectively. Mean fluorescence intensity (MFI) is plotted against 
peptide/HLA-A2 monomer concentration. Titrations are representative of two experiments with similar 
results.  
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Figure 2.15- View of Thr91 at the beginning of the CDR3α loop in the complexes with A6-
c134 and RD1-MART1
HIGH
. In the A6-c134 complex, Thr91α is tightly packed alongside Arg94 
of CDR3β and Tyr5 of the Tax peptide (yellow). In the RD1-MART1
HIGH
 complex, Thr91α is more 
exposed, and distant from the MART1 peptide (yellow) and Arg94 of CDR3β. 
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Indeed, a key driver of the change was the disruption of interac-
tions between the TCR andMHC that in humans biases ab TCRs
toward particular binding modes over HLA-A2 (Blevins et al.,
2016). Specificity and affinity in both TCRs were also strongly
influenced by second-shell CDR residues that do not contact
peptide or MHC, allowing the identification of even higher affinity
variants of RD1-MART1 and A6.
Despite the change in binding orientation of the RD1-
MART1HIGH TCR, when transduced into T cells the TCR complex
was fully capable of initiating responses toward the MART1/
HLA-A2 complex and not the Tax/HLA-A2 complex. Our findings
provide an unprecedented level of insight into how TCR speci-
ficity is encoded, and demonstrate new strategies for generating
TCRs with novel and fully functional recognition properties.
RESULTS
The RD1-MART1HIGH TCR Binds with a Docking Mode
Distinct from Other TCR-Peptide/HLA-A2 Complexes
We previously changed the specificity of the well-studied human
TCR A6 from Tax/HLA-A2 to MART1/HLA-A2 by screening a li-
brary mutated at five amino acid positions: one in CDR1a, two
in CDR3a, and two in CDR3b (Figure S1). To examine the struc-
tural basis for this switch in specificity, we determined the crys-
tallographic structure of the high-affinity variant of this TCR,
called RD1-MART1HIGH, bound to MART1/HLA-A2. The struc-
ture was solved at a resolution of 2.5 A˚, with two TCR-pMHC
complexes in the asymmetric unit (Table 1). The two complexes
were nearly identical, with all atoms of the complex superimpos-
ingwith a root-mean-square deviation (rmsd) of 1.7 A˚ (Figure 1A).
Clear electron density was observed throughout the interface,
with density lacking for only the Va/Vb linker and a few side
chains (Figure S2).
Surprisingly, we found that RD1-MART1HIGH TCR adopted a
different binding mode over pMHC compared with the wild-
type A6 TCR or the A6-c134 high-affinity variant, which incorpo-
rates some of the same mutations as RD1-MART1HIGH in the
CDR3b loop (Cole et al., 2013; Ding et al., 1999). Unlike the A6
and A6-c134 TCRs, RD1-MART1HIGH is tilted back and away
from the peptide N terminus (Figure 1B; left). This binding
mode is also distinct from the MART1/HLA-A2-specific TCRs,
DMF5 and Mel5 (Borbulevych et al., 2011; Cole et al., 2009), a
striking observation as the A6, RD1-MART1HIGH, DMF5, and
Mel5 TCRs all utilize the same TRAV12-2 gene segment (Fig-
ure 1B; right) (Baker et al., 2012). A broader comparison showed
that the altered bindingmode is facilitated by an unusual incident
angle, quantified as the tilt of the Va/Vb pseudo-symmetry axis
with respect to the plane of the pMHC binding groove (Pierce
and Weng, 2013). While the crossing angle is within the range
observed for other TCRs, the incident angle of RD1-MART1HIGH
is distinct from all other TCRs bound to peptide/HLA-A2 com-
plexes (Figure 1C; an interpolated animation illustrating the
change in binding mode is available as Movie S1). We note
that the unusual binding mode of RD1-MART1HIGH is not associ-
ated with a lack of specificity, as we previously demonstrated
that RD1-MART1HIGH does not recognize Tax or other non-
cognate peptides tested (Smith et al., 2014).
Architectural Changes in the RD1-MART1HIGH-MART1/
HLA-A2 Interface
Compared with the complex with the A6-c134 TCR, the amino
acid changes and the different bindingmode of RD1-MART1HIGH
substantially altered the footprint over pMHC and led to a
reduced number of contacts across the interface (Figure 2A).
Using a 4 A˚ cutoff, RD1-MART1HIGH forms only 75 interatomic
contacts, compared with 171 with A6-c134. The reduction is
greatest with the peptide, which is involved in 26 contacts with
RD1-MART1HIGH and 80 with A6-c134. In comparison, there
are 124 contacts in the complex of DMF5 with MART1/HLA-
A2, of which 48 are to the peptide. The smaller number of con-
tacts in the RD1-MART1HIGH interface translates into a smaller
amount of buried solvent-accessible surface area (1,427 A˚2 for
RD1-MART1HIGH, 2,124 A˚2 for A6-c134). As shown in Figure 2B,
differences in contacts are seen for every loop except for
CDR2b, which does not contact pMHC in either complex.
The conformation of the MART1 peptide in the RD1-
MART1HIGH complex is essentially identical to the conformation
in the DMF5 and Mel5 complexes and in the unligated MART1/
HLA-A2 complex (Figure 2C) (Sliz et al., 2001). This conforma-
tion, however, differs substantially from that of Tax peptide,
Table 1. X-Ray Data Collection and Refinement Statistics for the
RD1-MART1HIGH Complex
Data Collection
Resolution range (A˚) 20.0–2.5 (2.6–2.5)a
Space group P21
Cell dimensions
a, b, c (A˚) 50.4, 164.5, 95.2
a, b, g (!) 90.0, 100.6, 90.0
Unique reflections 47,848 (3,596)a
Rmerge 0.13 (0.55)
a
<I/s(I)> 10.6 (2.1)a
% Data completeness 92.4 (74.3)
Temperature (K) 100
Wavelength (A˚) 1.0
Refinement
Resolution range (A˚) 20.0–2.5
Rwork/Rfree 0.19/0.24
No. of protein atoms 9,745
No. of water molecules 76
Rmsd from ideality
Bond lengths (A˚) 0.004
Bond angles (!) 0.97
Ramachandran statistics (%)
Most favored 97
Allowed 3
Disallowed 0
Average B factor
TCR 53.0
Peptide 46.0
Heavy chain/b2m 69.7
Database code PDB: 5E9D
aValues in parentheses refer to highest-resolution shell.
2 Structure 24, 1–13, July 6, 2016
Please cite this article in press as: Harris et al., An Engineered Switch in T Cell Receptor Specificity Leads to an Unusual but Functional Binding Ge-
ometry, Structure (2016), http://dx.doi.org/10.1016/j.str.2016.04.011
Table 2.1- X-Ray data collected and refinement statistics for the RD1-MART1
HIGH
complex 
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CHAPTER THREE 
 
 
 
 
SEQEUNCE FITNESS LANDSCAPES AS A GUIDE TO ENGINEERING HIGHER AFFINITY 
PROTEIN-PROTEIN INTERACTIONS3 
 
 
 
 
Abstract 
 Proteins are often engineered to have higher affinity for their ligands in order to 
achieve therapeutic benefit.  For example, many studies have used phage- or yeast-
display libraries of mutants within complementary determining regions (CDRs) to affinity 
mature antibodies and T cell receptors (TCRs). However, these approaches do not 
allow rapid assessment or evolution across the entire interface. With the advent of deep 
sequencing it is now possible to generate sequence fitness landscapes that survey the 
impact of every amino acid substitution across the entire protein-protein interface.  Here 
we used the sequence fitness landscape of a TCR:peptide-major histocompatibility 
complex (pepMHC) interaction to guide mutational strategies. The approach yielded 
stable TCRs with affinity increases of over 200-fold. The substitutions with the greatest 
enrichments based on the deep sequencing were validated to have higher affinity, and 
could be combined to yield additional improvements.  
 
 
																																																													
3Based on: Harris D.T., Riley T., Wang N., Anderson S., Baker B.M., Kranz D.M. Sequence fitness 
landscapes as a guide to engineering higher affinity protein-protein interactions. (In preparation) 
    
Author’s contribution statement: Ningyan Wang created and isolated high-affinity clones from the 
combinatorial library of RD1-MART1HIGH. Scott Anderson assisted with flow cytometry and creating single-
site mutants. All other experiments were completed by Daniel Harris under the guidance of David Kranz.		
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Introduction 
The process of increasing the affinity of a protein occurs naturally with 
antibodies, where somatic mutation within the variable region genes is followed by 
antigen-driven selection of B cells that express membrane-bound antibodies. In 
contrast, T cell receptors (TCRs) do not undergo somatic mutations and bind to their 
antigen, a peptide:MHC complex (pepMHC), with low (micromolar) affinities. However, 
improvements in TCR affinity to the same levels of antibodies can be achieved by in 
vitro approaches involving the generation of mutant TCR libraries followed by antigen 
selection (105, 106).    
For therapeutic purposes, the affinity of a variety of protein-protein interactions, 
and especially antibody:antigen interactions, have been enhanced using in vitro directed 
evolution approaches including phage, yeast, ribosomal, and mammalian display (136-
139). These methods rely on the generation of large libraries of mutants at residues 
within the protein-protein interface, followed by several rounds of selection for desired 
parameters (such as affinity, stability and expression levels) (140, 141).  
While directed evolution using larger degenerate libraries has been successful, 
the most recent techniques involving deep sequencing of single-codon libraries have 
the potential to provide both mechanistic structural information about a binding site and 
at the same time provide leads for affinity improvements. Sequence fitness landscapes 
have successfully been utilized to map protein-DNA interactions (142), protein-peptide 
interactions (143) and protein-protein interactions (122). Furthermore, using a PDZ 
protein domain as a model system, McLaughlin and colleagues were able to manipulate 
ligand-binding specificity through key mutations identified using sequence fitness 
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landscapes (144). Additionally, a sequence fitness landscape of an influenza-binding 
antibody was used to enhance affinity and redirect specificity of the antibody to a single 
H1 hemagglutinin subtype (145). 
In the present study, we focused on TCRs because they have evolved to bind to 
a diverse repertoire of clinically relevant targets and they represent a class of molecules 
with significant therapeutic potential. In addition, because of their naturally low affinities 
they represent protein-engineering targets for both stability and affinity.  Previously, we 
reported successful affinity engineering of TCRs by directed evolution using yeast 
display (105, 121, 132, 146) and mammalian cell display (139, 147).  
More recently, we reported the use of single-codon libraries with two different 
TCRs to generate sequence fitness landscapes that allowed analysis of the impact of 
each residue on binding to their cognate pep-HLA-A2 complexes (148). Sequence 
fitness landscapes offer a powerful perspective of protein-protein interactions not 
available from structural data alone by experimentally determining, on a residue by 
residue basis, which amino acids contribute to binding as well as the most optimal 
amino acids at each position (143, 149). Accordingly, the two higher affinity TCRs, A6-
c134 and RD1-MART1HIGH, that are specific for Tax/HLA-A2 and MART1/HLA-A2 
respectively, were examined both structurally and by deep scanning mutagenesis to 
determine the basis of specificity and binding.  
Here we further studied the mutations that were highly enriched in the sequence 
fitness landscape of the cancer antigen-specific TCR, RD1-MART1HIGH. We 
demonstrate that the mutations that exhibited the highest levels of enrichment acted 
both individually and in synergy to significantly increase the affinity and yeast surface 
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levels of the RD1-MART1HIGH TCR.  We also compared strategies that involved 
individual combinations of mutations versus construction and selection of multi-codon 
libraries, both based on sequence fitness landscapes.  
Materials and Methods 
Reagents and Flow Cytometry 
 Procedure for induction of yeast to express single-chain TCRs has been 
described previously (110). HLA-A2 heavy chain and β2 microglobulin were expressed 
as inclusion bodies in Escherichia coli and refolded with a UV-cleavable peptide 
(KILGFVFJV) (120). At the C-terminus of HLA-A2 heavy chain a biotinylation site was 
included for addition of biotin with BirA enzyme (Avidity). To exchange peptide, refolded 
HLA-A2 with UV-cleavable peptide was incubated with 100-fold excess MART1 10mer 
peptide (ELAGIGILTV) during 45 min of UV-exposure. Yeast stained with HLA-A2 
monomer were incubated with a minimum of 2-fold excess monomer relative to total 
number of TCRs (50,000 receptors/cell). Cells were washed and stained with 
streptavidin-PE (1:300) and subsequently read by flow cytometry.  Yeast were 
additionally stained with anti-HA (1:50) and anti-c-myc (1:100) followed by secondary 
goat anti-mouse Alexafluor 647 (1:100) and goat anti-chicken Alexfluo 647 (1:100) 
respectively. For tetramer stains, yeast were stained with 50 nM MART1/HLA-A2 
tetramer for 1.5 h, washed and analyzed by flow cytometry.  
Single-Site Mutants and Combinatorial Library Design 
 Single-site mutants of the RD1-MART1HIGH TCR in the pCT302 yeast-display 
vector were created using the QuikChange II Site-Directed Mutagenesis Kit (Agilent 
Technologies).  Identity of mutants was confirmed by sequencing. EBY100 yeast were 
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subsequently transformed using a lithium acetate heat shock protocol (150). A 4-codon 
combinatorial library of RD1-MART1HIGH spanning 4 CDR domains was created by 
splice overlap extension (SOE) PCR. Pre-SOE products were created using the 
following primers: Splice4/L: 5'- GGC AGC CCC ATA AAC ACA CAG TAT -3'; T7 rev: 
5'- TAA TAC GAC TCA CTA TAG GG -3'; V50b-fwd: 5'-TGG GCT TAA GAT TGA TTC 
ACT ATT CAN NKG GTG TTG GCA TCA CTG ATC A-3'; V50b-rev: 5'-TGA ATA GTG 
AAT CAA TCT TAA GCC CA-3'; A99b-fwd: 5'-TCC CGT CCG GGT TGG ATG NNK 
GGG GGG GTG GAA CTG T-3'; A99b-rev: 5'-CAT CCA ACC CGG ACG GGA-3'; 
G28a-fwd: 5'-GCG TCT TTA AAC TGT ACA TAT TCA GAT AGA NNK AGC ACG TCT 
TTC TTT TGG TAT C-3'; G28a-rev: 5'-TCT ATC TGA ATA TGT ACA GTT TAA AGA 
CGC-3'; T91a-fwd: 5'-CAC ATA CTT GTG CGC GGT TNN KAA GTA CTC GTG GGG 
TAA ACT G-3'; T91a-rev: 5'-AAC CGC GCA CAA GTA TGT G-3'. Pre-SOE products 
were combined by SOE PCR using the T7 and Splice 4L primers. Libraries were 
created using homologous recombination in EBY100 yeast as described previously 
(151). The estimated size of the combinatorial library was: 2 x 107. The library was 
sorted 3 times with MART1/HLA-A2 monomer at 50nM, 0.5nM, 0.1nM respectively. 
After the third sort, 8 high-affinity clones were sequenced of which 3 unique sequences 
were identified. 	
Results 
Approaches to engineering a TCR/MHC interaction for higher affinity 
The A6 TCR was previously used as a template for directed evolution of a novel 
peptide specificity, whereby the specificity was switched from Tax/HLA-A2 to the 
completely distinct cancer peptide, MART1/HLA-A2 (110). The resulting TCR, called 
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RD1-MART1, was further affinity-matured to yield the RD1-MART1HIGH TCR, with a KD 
value of about 100 nM. Recently, we generated a sequence fitness landscape of RD1-
MART1HIGH by deep sequencing analysis of antigen-selected, single-codon libraries 
(148). For the sequence fitness landscape study and the studies conducted in the 
present study, RD1-MART1HIGH and various mutants were displayed on the surface of 
yeast as single-chain TCRs containing the Vβ and Vα domains linked by a flexible linker 
(Fig. 3.1A). Hemagglutinin (HA) and c-myc tags were attached at the N-terminus and C-
terminus, respectively. In order to understand the most expeditious strategy to generate 
higher affinity binding leads from a protein, here we explored two approaches. These 
methods were based on the substitutions from the single-codon libraries that yielded 
increases in the number of antigen-selected TCR, characterized as enrichment values 
(Fig. 3.1B).  
The individual enrichment values for the top substitutions of the RD1-MART1HIGH 
TCR are plotted in Fig. 3.1C.  To explore the robustness of these results from the 
sequence fitness landscape, we tested individual mutants within this range of 
enrichment values, from 10- to 51-fold (T91Qα, A99Yβ, V50Dβ, G28Eα, S51Gα, 
Y50Wα, N28Gβ, K97Qα). The top binders among this group were then tested in 
combination to determine if there was binding additivity (Fig. 3.1B, left).  
It is possible that the individual mutation approach, followed by combination of 
improved mutations, will not identify those collections of mutations that act cooperatively 
to yield the highest affinity TCRs.  Furthermore, positions where there were multiple 
enriched substitutions (e.g. positions 91α and 99β) would not be fully sampled by the 
individual mutation route.  Accordingly, we took an alternative approach in which a 
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combinatorial library at four residues with the highest enrichment values was generated. 
This combinatorial library was sorted with MART1/HLA-A2 by fluorescence activated 
cell sorting (FACS) (Fig. 3.1B, right) to yield clones that bound with higher affinity.  
Site-specific mutants act individually and in combination to enhance affinity and 
expression 
Based on the sequence fitness landscape of RD1-MART1HIGH, 8.3% of the 
mutations showed enrichment above the wild-type TCR (148). Eight mutations with 
enrichment values ranging from 10- to 51-fold (Fig. 3.1C, arrows) were expressed 
individually on the surface of yeast and tested for binding to the MART1/HLA-A2 ligand.  
Interestingly, the four residues with the highest enrichment values were each in different 
CDR loops (Fig. 3.2A), raising the possibility that the combined mutations could yield 
additive effects. Mutants on yeast were stained with various concentrations of 
MART1/HLA-A2 monomer to determine affinities (Fig. 3.3A and Table 3.1). In some 
cases we also stained yeast with an excess of MART1/HLA-A2 tetramer to compare 
relative surface levels of the mutants (Table 3.1) because surface levels of TCRs in the 
yeast display system are known to be influenced by stability of the proteins (112). This 
would allow us to address the possibility that the enrichment of TCRs with mutations in 
the single-codon libraries were due to enhanced affinity or higher surface levels or both.  
Of the eight mutations, five showed significant improvements in affinity compared 
to the RD1-MART1HIGH TCR (Figure 3.3B and Table 3.1). The five mutants exhibited 3-
fold (Y50Wα) to 11-fold (A99Yβ) increases in affinity above the wild-type protein. While 
the other three mutants did not exhibit affinity increases, they did appear to be 
72 
	
expressed at higher surface levels which likely accounts for the enhancement values 
observed in the deep mutational scan. 
To test whether the mutations could be combined to yield further improvements, 
four double mutants and a triple mutant were generated (Fig. 3.4, Fig. 3.3, and Table 
3.1). The double mutants yielded increases of 10- to 20-fold, while the triple mutant 
yielded an increase of almost 100-fold, to an estimated KD value of 2 nM.  Furthermore, 
combination of these mutations also led to increased TCR surface levels (Table 3.1), 
indicating that the mutations also may operate by stabilizing the TCR domains. A plot of 
KD value versus enrichment value (Fig. 3.3C) supports the view that the highest 
enhancement values in a deep mutational scan can be used to reliably generate higher 
affinity variants of a protein.  
Selection of a combinatorial library yields further improvements and correlates with the 
sequence fitness landscape  
To compare with individual site-specific mutagenesis, we generated a 
combinatorial library at the four residues (28α, 91α, 50β, 99β) with the most highly 
enriched mutations in the deep mutational scan. Selection of this library could yield 
improved combinations that were not identified in the one-by-one mutational approach. 
The combinatorial library was sorted three times with MART1/HLA-A2 monomer at 
concentrations ranging from 1 μM to 1 nM (Fig. 3.5A). After the third sort, ten clones 
were sequenced and there were three unique sequences identified (represented by 
clones S3-2, S3-7, and S3-8) (Table 3.2). Titrations of these three clones were 
performed and compared to the triple mutant described above (Fig. 3.4B,C). Mutants 
S3-7 and S3-8 were similar in affinity to the triple mutant, but clone S3-2 had about a 
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three-fold higher affinity and a two-fold higher surface level (Table 3.1). Based on this 
result, the combinatorial library/selection approach can yield modest but significant 
improvements above the single mutation approach (e.g. when there are positions where 
multiple substitutions yield high enrichment values). 
The sequences of the mutants were interesting when considered in regards to 
the sequence fitness landscape, and the triple mutant. For example, the T91Qα 
mutation had one of the highest affinities and expression levels among individual 
mutants (Table 3.1), and this mutation was present in all three clones from the 
combinatorial library. Position 50β had either an aspartic or glutamic acid in all three 
clones isolated, consistent with the nearly four-fold improvement of V50Dβ (Table 3.1) 
and the deep mutational scan results (Fig. 3.1C).  While all three clones identified in the 
combinatorial library did not contain the A99Yβ mutation that showed the highest affinity 
individually (Table 3.1), each had a different highly enriched mutation (A99Dβ, A99Eβ, 
A99Vβ) (Fig. 3.1C). Interestingly, in clones S3-2 and S3-8, the G28α position was 
mutated to arginine despite this residue having a strong preference for glutamic acid in 
the deep mutational scan (Fig. 3.1C) and the improvement in affinity of the G28Eα 
mutant. In fact, the G28Rα mutation was not enriched compared to wild-type in the 
deep mutational scan, suggesting that this mutation may have operated only in the 
context of one or more of the other three CDR mutations. In conclusion, the 
combinatorial approach yielded the greatest improvement as shown by the S3-2 mutant 
which exhibited an increase in affinity of 250-fold and an improved surface-level 
expression of 6-fold.  
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Discussion 
Proteins often require affinity and stability enhancements for therapeutic 
purposes. To achieve the desired characteristics, various protein-engineering 
techniques that use in vitro directed evolution have been employed. These include 
ribosomal, phage, bacterial, yeast, and mammalian display of degenerate mutational 
libraries, followed by various selection schemes. More recently, it has been possible to 
conduct deep mutational scans of every residue in a protein’s binding site to construct a 
sequence fitness landscape.  Among the substitutions assessed in these scans are 
those that appear to be favored over the wild-type residues.  Here we used information 
from the sequence fitness landscape of a TCR (RD1-MART1HIGH) specific for the cancer 
antigen MART1/HLA-A2 as a guide to compare various approaches to engineer 
improvements in the affinity and/or stability.  We were able to identify specific mutants 
that enhanced the affinity over 200-fold and increased the yeast surface level 
expression by 6-fold.  
To determine the robustness of identifying higher affinity mutations strictly from 
the results of the sequence fitness landscape, we generated single site-specific 
mutations with enrichment values ranging from 10- to 51-fold. These mutations were 
tested as individual and combined mutants. Site-specific mutagenesis was able to 
increase the TCR affinity by 100-fold when three of the highest-affinity mutants were 
combined. A previous study that aimed to improve the affinity of an influenza inhibitor, 
reported a maximum affinity improvement of 28-fold using a combination of eight 
mutations identified from a sequence fitness landscape (145). In our study, when 
enrichment values were >12 we observed a direct correlation with enrichment value and 
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affinity enhancement. In addition to affinity increases, the yeast display approach also 
selects for TCRs that are expressed at higher levels due to the increased 
thermostability of the mutant (112, 152-155). Accordingly, the present study identified 
mutations that increased surface levels up to about 6-fold. Similar observations have 
been made about the role of residues in the thermal stability of antibody scFv fragments 
(156). 
While the individual mutations with the highest enhancement values in the 
sequence fitness landscape yielded higher affinity, and their combinations provided 
even higher affinity (100-fold), we were interested in determining if a directed evolution 
approach based on the same data could yield combined mutations with even higher 
affinity or stability. This combinatorial approach would include variants with multiple 
mutations that have additivity or positive cooperativity in binding. To test this, we 
generated a combinatorial library at the four highest enriched residues (G28α, T91α, 
V50β, A99β). Three successive selections of this library yielded multiple clones that 
bound with higher affinity than RD1-MART1HIGH to the MART1/HLA-A2 ligand. One of 
these clones (S3-2) had the highest affinity (700 pM) and greatest surface level (6-fold 
above RD1-MART1HIGH) among all of the mutants examined in the present study.  The 
sequences of this and the other two unique clones revealed that three of the four 
positions in the library had mutations that were highly enriched in the sequence fitness 
landscape. Unexpectedly, the G28α position had two clones, including S3-2, with an 
arginine substitution, whereas the G28Rα substitution was not enriched in the sequence 
fitness landscape. Accordingly, the use of sequence fitness landscapes to generate 
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higher affinity mutants can benefit by subsequent selections of combinatorial libraries in 
the codons of enriched amino acid positions. 
The single-codon approach used with sequence fitness landscapes also 
improves upon the many early studies using directed evolution and error-prone PCR 
techniques. While the latter can sample the entire protein interface, it is limited to single-
site mutations that are generated by a single base substitution. This is because the 
probability of having two substitutions in the same codon or in two codons with 
beneficial substitutions is quite low and often beyond the size of the libraries (or 
detrimental mutations at a higher error-rate would obscure these mutations).  As an 
example, the A99Yα mutant was one of the highest enriched mutations of RD1-
MART1HIGH but it would require two nucleotide substitutions to mutate from alanine to 
tyrosine.  
In conclusion, deep mutational scans of the entire protein-protein interface 
provide physical insights into binding. Sequence fitness landscapes also serve as a 
robust guide for conducting site-specific mutagenesis to enhance affinity. In the future 
one might be able to simply combine all of the top enriched mutations into a single 
mutant and thus bypass the need for any selections. This might be especially true 
where the residues are located at different locations in the interface. However, the 
combinatorial library/selection approach, based on the results of the sequence fitness 
landscape, yielded an improved mutant compared to the single-site mutant strategy. 
Thus, there may still be advantages to using a directed evolution, selection-based 
strategy for optimizing improvements.  
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Methods for identifying affinity-enhancing mutations of RD1-MART1
HIGH
. (A) 
Schematic of the single-chain TCR (scTCR) of RD1-MART1
HIGH
 with HA and c-myc tags at N-
terminus and C-terminus respectively. (B) Diagram of steps used in different methods for identifying 
affinity-enhancing mutations of RD1-MART1
HIGH
. The sequence fitness landscape is used for both 
single site and combinatorial methods, the computational method uses structural guided algorithms. 
(C) Rank-ordered mutations from the RD1-MART1
HIGH
 sequence fitness landscape with enrichment 
scores ≥ 10 are shown with their respective enrichment value. Mutations tested for binding by 
yeast-display are indicated with a red arrow.  
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G28α 
Figure 3.2 Structure of RD1-MART1
HIGH
 TCR:MART1/HLA-A2 complex and models for affinity-
enhancing mutations. The four CDR residues with mutations that had the highest enrichments 
values (V50Dβ, A99Yβ, G28Eα and T91Qα) are highlighted in yellow.  
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Figure 3.3 Titrations of RD1-MART1
HIGH
 mutants identified from sequence fitness 
landscape. (A) The RD1-MART1
HIGH 
TCR, four single mutants (G28Eα, T91Qα, V50Dβ, 
A99Yβ), and one triple mutant (G28Eα/T91Qα/A99Yβ) were titrated with MART1/HLA-A2 
monomer at concentrations ranging from 1 μM to 8 nM. (B) Mean fluorescence intensity (MFI) 
of the indicated mutants is plotted against concentration of MART1/HLA-A2 monomer. (C) The 
enrichment value of the indicated mutants from the sequence fitness landscape of RD1-
MART1
HIGH
 is plotted against the calculated binding disassociation constant (KD).  
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Figure 3.4- Titrations from double mutants of RD1-MART1
HIGH
 identified from the 
sequence fitness landscape. (A) Double mutants of RD1-MART1
HIGH
 (G28Eα/T91Qα, 
G28Eα/V50Dβ, G28Eα/A99Yβ, and T91Qα/A99Yβ) were stained with various concentrations of 
MART1/HLA-A2 monomer (from 250 nM to .2 nM). (B) Mean fluorescence units (MFI) of RD1-
MART1
HIGH
 double mutants were plotted against concentration of MART1/HLA-A2 monomer.   
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Figure 3.5 Titrations of RD1-MART1
HIGH
 high-affinity clones isolated from a combinatorial 
library. (A) The combinatorial library of RD1-MART1
HIGH
 and the subsequent sorted libraries were 
stained with MART1/HLA-A2 monomer at concentrations ranging from 1 μM to 1 nM. (B) The 
G28Eα/T91Qα/A99Yβ mutant identified from the sequence fitness landscape and the three clones 
isolated from a combinatorial library were titrated with MART1/HLA-A2 monomer at concentrations 
ranging from 167 nM to 25 pM. (C) The mean fluorescence intensity (MFI) of the indicated mutants 
is plotted against concentration of MART1/HLA-A2 monomer.   
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Table 3.1- Affinity and MFIMAX ratios of RD1-MART1
HIGH
 mutations identified from sequence 
fitness landscape. The calculated affinities of RD1-MART1
HIGH
 and its mutants are indicated. 
Affinities were based on titrations of MART1/HLA-A2 with yeast displaying the indicated scTv. 
MFI
MAX
 Ratio is the ratio of MFI from staining with 50 nM MART1/HLA-A2 tetramer to MFI from 
RD1-MART1
HIGH
 stained with 50 nM MART1/HLA-A2 tetramer.  
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TCR 28α 91α 50β 99β
RD1-MART1HIGH G T V A
G28Eα E T V A
T91Qα G Q V A
V50Dβ G T D A
A99Yβ G T V Y
G28Eα /T91Qα E Q V A
G28Eα /V50Dβ E T D A
G28Eα /A99Yβ E T V Y
T91Qα /A99Yβ G Q V Y
G28Eα /T91Qα /A99Yβ E Q V Y
S3-2 R Q E D
S3-7 E Q D E
S3-8 R Q E V
TCR Position
Table 3.2 Identity of RD1-MART1
HIGH
 TCR mutants examined in this study. The wild-
type RD1-MART1
HIGH
 sequence at the 28α, 91α, 50β and 99β CDR residues is indicated. 
Mutants created based on the sequence fitness landscape and mutations of clones isolated 
from the combinatorial library are shown. Residues that differ from wild-type are bolded.  
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CHAPTER FOUR 
 
 
 
 
CHARACTERIZING A HIGH-AFFINITY T CELL RECEPTOR AGAINST WT1/HLA-A2 
FOR USE IN ADOPTIVE T CELL THERAPY4 
 
 
 
 
Abstract 
 Chapter four is an analysis of the activity and specificity of a high-affinity TCR in 
T cells. A high-affinity TCR for the cancer antigen WT1/HLA-A2 was characterized. This 
TCR was analyzed both as conventional full-length TCRs consisting of variable and 
constant domains as well as chimeric antigen receptor (CAR) constructs, which consist 
of TCR variable domains linked to intracellular signaling domains. These constructs 
were analogous to the chimeric antigen receptors (CARs) currently in adoptive T cell 
clinical trials.  Despite being expressed at lower surface levels than the CAR 
counterpart, the full-length TCR exhibited greater peptide sensitivity to pepMHC.  The 
results of these studies provided insight into the differences in sensitivities of the CAR 
compared to the TCR formats for adoptive T cell therapies. In addition, they provided 
information about the specificity of the two high-affinity TCRs in an adoptive T cell form. 
 
 
 
 
																																																													
4 Author’s contribution statement: An initial TCR clone that bound to WT1/HLA-A2 was provided by Phil 
Greenberg’s lab at the Fred Hutchinson Cancer Center. The high-affinity WT1 TCR (D13.1.1) was 
engineered by Sheena Smith (Kranz lab). All in vitro and in vivo T cell data was conducted by Daniel 
Harris under the guidance of David Kranz.  
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Introduction 
 Many tumors are eliminated due to the immune system’s ability to detect and kill 
cancer cells early in their growth. However, when a tumor does develop, the immune 
system has failed to prevent unwanted growth due to a variety of mechanisms evolved 
by cancer cells. Some of these mechanisms include the secretion of 
immunosuppressive cytokines within the tumor microenvironment and the expression of 
receptors on the tumor cell surface that prevent destruction by immune killer cells. For 
over a century, scientists have been attempting to develop methods that promote the 
recognition of cancer cells by the immune system. With the recent development and 
clinical responses of checkpoint blockade inhibitors and adoptive T cell therapies, 
immunotherapies now have an established role in the treatment of many cancers. 
Cancers previously deemed untreatable are now having long term survivors due to 
immunotherapies.  
One exciting new class of immunotherapies are checkpoint blockade inhibitors. 
These antibodies work by binding to immunosuppressive receptors on T cells, or their 
ligands expressed on cancer cells, thereby preventing the interaction that leads to 
inhibitory signaling in the T cells (reviewed in:(43)). Once the cancer cells are 
recognized by T cells, the later are able to be activated and can subsequently destroy 
the malignancy. While checkpoint blockade inhibitors have been successful in treating 
many malignancies (particularly melanoma), they can also lead to autoimmune side-
effects. Additionally, checkpoint blockade treatments have not been as successful in 
treating tumors that are non-immunogenic (i.e. that have fewer mutations) such as 
pancreatic tumors. 
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A more direct, and personalized, approach for cancer cell recognition is adoptive 
T cell therapy (ACT). ACT allows an exogenous receptor that binds to specific antigens 
expressed on the surface of cancer cells to be introduced ex vivo into a patient’s T cells, 
and the engineered T cells are then reintroduced into the patient (reviewed in: (157)). 
There are a variety of antigens that can be targeted using this approach. Ideally, an 
antigen is expressed at high enough levels on the cancer cell to be recognized and 
destroyed by the T cell, but at low enough levels on normal tissue so as not to cause 
off-tumor toxicity.  
Recently NCI compiled a list of over 75 potential cancer peptide antigens that 
can be presented by MHC, and ranked them on a variety of criteria (i.e. specificity, 
expression level, immunogenicity) (113). Wilms tumor antigen (WT1) was ranked 
number 1 on this list and is a target now being pursued by many labs using a variety of 
approaches, including vaccination and adoptive T cell therapies.   
The WT1 protein is a 62 kDa zinc finger transcription factor (158). WT1 was 
initially shown to have a role in the development of a pediatric kidney tumor, known as 
Wilm’s tumor (159). Further investigation of WT1 revealed that it is a transcription factor 
critical in the development of the urogenital tract. Using WT1-/- knock-out mice, it was 
shown that WT1 is necessary for the proper formation of the ureter. After fetal 
development, WT1 is expressed at low levels in podocyte cells present within the 
kidneys’ glomeruli (160). Additionally, WT1 is expressed at low levels in developing 
hematopoietic stem cells but it does not appear to be required for progression of 
hematopoiesis (161, 162).  Mutations of the WT1 gene have led to clinical 
manifestations of mental retardation and genitourinary malformation (163).  
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The role that the WT1 transcription factor plays in oncogenesis has been difficult 
to discern due to the protein having the ability to be both a tumor suppressor and an 
oncogene (reviewed in: (164)). The WT1 protein has tumor suppressor properties by 
activating anti-apoptotic proteins (such as BAK) and inhibiting pro-growth genes such as 
EGFR (165, 166). However, WT1 was initially identified as an oncogene due to its 
overexpression in a variety of leukemias, including acute myeloid leukemia (AML) (167) 
and myeloid dysplastic syndrome (MDS) (168). The mechanism through which WT1 
acts as an oncogene has not been fully determined, however, some studies suggest 
that WT1 overexpression may contribute to maintaining cancer cells in a non-
differentiated state (169, 170). A high level of WT1 expression has been correlated with 
poor clinical prognosis of many forms of leukemia (171). Besides being expressed in 
hematological cancers, WT1 has been shown to be overexpressed in a variety of solid 
tumors including ovarian and lung cancers (172). 
Given the expression of WT1 in a wide array of tumors, it has been a target for 
many different therapies. Clinical trials using dendritic cell vaccines with an HLA-A2 
binding peptide from the WT1 protein have been conducted for patients with non-small 
cell lung cancer, malignant glioma and a variety of other tumors (173, 174). These trials 
have been successful in increasing a population of T cells that activate in the presence 
of WT1/HLA-A2 and they have suggested the safety of WT1 as a target because of the 
minimal toxicity associated with the trials.  
To target WT1/HLA-A2 more directly, a TCR-like antibody has been developed 
that binds the WT1/HLA-A2 complex with high-affinity (KD approximately 200 pM) (175). 
For clinical application, this antibody was formatted as a bispecific T-cell engager (BiTE) 
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consisting of variable domains of the WT1 antibody linked to antibody domains specific 
for the CD3 signaling molecule present on T cells (176). The WT1 BiTE was 
administered as a soluble therapeutic with the goal of directing and activating T cells 
against tumor cells expressing WT1/HLA-A2. The WT1 BiTE has demonstrated early 
promising results with in vitro and in vivo mouse experiments. For use as an adoptive T 
cell therapy, this antibody was developed as a chimeric antigen receptor (CAR) (177). 
However, recent structural findings have shown that the antibody contacts only the N-
terminal portion of the peptide and thus has limited peptide specificity (178). Given the 
likelihood that this antibody is not specific for WT1/HLA-A2 and the finding that it could 
bind to other pepMHC complexes, raises a question about the safety of using this 
antibody as a soluble form or in adoptive therapies. 
A more conventional approach to recognizing the WT1/HLA-A2 complexes with 
high-affinity is to use a T cell receptor (TCR), which has coevolved with pepMHC to bind 
and activate T cells. In fact, this co-evolution has generated TCRs that dock in a 
conserved diagonal orientation over the pepMHC, such that the CDR3 loops are 
optimally positioned to contact the exposed regions of the peptide, thereby maximizing 
specificity.  Phase I clinical trials have been conducted with tumor infiltrating 
lymphocytes (TILs) expressing TCRs that activate in the presence of WT1/HLA-A2 
(101). These trials have demonstrated the ability to control tumor growth when using T 
cells specific for WT1. Also, a WT1/HLA-A2 TCR is currently being tested by Greenberg 
and colleagues in an adoptive T cell format with promising, but early, results (Juno 
Therapeutics, unpublished).  
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TCRs isolated from peripheral lymphocytes do not have the affinity required to 
efficiently direct CD4 T cells to class I pepMHC complexes. CD4 T cell responses are 
advantageous in promoting immune cell recruitment and has been shown to be capable 
of controlling tumor growth (83, 179). When the affinity of a TCR is engineered below 
about 1 µM, it can recognize class I MHC independent of the CD8 co-receptor, and thus 
it can mediate a CD4 T cell response (180-182). To enhance TCR affinity, several 
protein engineering methods have been employed, such as yeast and phage display 
(105, 106, 183).  
 A potential disadvantage of using affinity enhanced TCRs is toxicity from 
recognition of structurally similar non-tumor pepMHC complexes. Off-tumor toxicities 
can be due to either recognition of the targeted pepMHC complex in non-cancerous 
tissue (on-target/off-tumor) or due to TCR recognition of structural similar pepMHC 
complexes present in non-cancerous tissue (off-target/off-tumor). Two recent clinical 
trials resulted in fatalities due to off-target/off-tumor toxicities mediated by affinity-
enhanced TCRs against MAGE antigens (107, 108). To address whether WT1 could 
safely be targeted by affinity enhanced TCRs without potential off-tumor toxicities, our 
lab, in collaboration with the Greenberg lab, engineered a high-affinity TCR against the 
murine WT1/Db complex and the Greenberg lab tested it in vivo (147). This TCR was 
transduced into primary T cells, which were then injected into immune competent mice. 
After extensive histological analysis, no overt toxicity was observed, suggesting that 
WT1/MHC complexes can be safely targeted using affinity enhanced TCRs.   
For development of a human TCR that is capable of driving CD4 T cell 
responses, the Greenberg lab provided us with a WT1/HLA-A2 TCR clone to engineer 
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for high-affinity using yeast display. Sheena Smith, a former graduate student in the lab, 
engineered the D13.1.1 TCR, which binds with high-affinity to WT1/HLA-A2 (binding KD 
approximately 100 nM). D13.1.1 was engineered with mutations in the CDR1α and 
CDR3β domains. To understand the properties that D13.1.1 endows to T cells, I 
transduced the D13.1.1 TCR into T cells and tested for activity and specificity.  
My initial studies were focused on determining the activity of D13.1.1 and 
whether it was capable of driving both CD8 and CD4 T cells against WT1/HLA-A2 
complexes. Further work focused on the specificity of D13.1.1 and whether the high-
affinity TCR was safe to use for adoptive T cell therapies. To examine the fine specificity 
of D13.1.1, I performed an alanine scan of the WT1 peptide to identify which peptide 
residues were critical for driving T cell activity. To determine if D13.1.1 was cross-
reactive against self-peptides, Jennifer Stone conducted a proteome search for 
structurally similar peptides and I tested the D13.1.1 TCR against a panel of identified 
peptides. None of the tested peptides were capable of activating T cells expressing the 
D13.1.1 TCR. To test D13.1.1 in vivo, I transduced CD8 and CD4 T cells with the TCR 
and then injected the T cells into AAD transgenic mice. I monitored mice receiving 
transduced T cells for graft vs. host disease and persistence of transduced T cells. 
Signs of graft vs. host disease were not observed and D13.1.1 expressing T cells 
appeared to persist, at levels above mock T cell controls.  
While TCRs have been successful at redirecting T cells against cancer pepMHC 
complexes, the predominant therapeutic currently used for adoptive T cell therapies is 
the chimeric antigen receptor (CAR) (46, 47, 90) CARs consist of antibody variable 
domains (scFv) linked to intracellular signaling domains (primarily CD28, CD3ζ, and 4-
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1BB). Unfortunately, there is less known about sensitivity and signaling properties of 
CARs compared to conventional TCRs.  
To gain a better understanding of the mechanistic differences between TCRs and 
CARs, the D13.1.1 TCR was tested for activity as a CAR construct (single-chain TCR 
linked to intracellular signaling domains) and compared to a conventional full-length 
TCR. Previous high-affinity TCRs have been tested in a CAR format and have shown 
that they do not mis-pair with endogenous TCR chains and that they can control tumor 
growth (86, 87). Using D13.1.1 as a CAR allowed us to effectively compare a human 
TCR to a CAR that shared the same affinity and specificity for WT1/HLA-A2. The 
D13.1.1 CAR was capable of mediating WT1/HLA-A2 specific activity in CD8 and CD4 
T cells. When the TCR and CAR constructs were tested for activity, the CAR was nearly 
100-fold less sensitive to WT1/HLA-A2 than the conventional full-length TCR despite 
the CAR being expressed at significantly higher levels on the surface of T cells. These 
results are consistent with previous studies with the murine m33 system (87) and they 
provide a fundamental framework for future studies with CARs.  
Materials and Methods 
Peptides, MHC and staining reagents 
 WT1 peptide (RMFPNAPYL), alanine peptide mutants, and conserved peptide 
mutants were synthesized by Genscript (Piscataway, NJ, USA). MART1 peptide 
(ELAGIGILTV) was synthesized by standard F-moc chemistry at the Macromolecular 
Core Facility at Penn State University College of Medicine (Hershey, PA, USA). T cells 
were stained with various concentrations of refolded monomers or tetramers of HLA-A2-
biotin and AAD-biotin. Both HLA-A2-biotin and AAD-biotin were refolded in complex with 
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a UV-cleavable peptide, which was exchanged with the desired peptide in excess by 
exposure to UV light for >30 minutes (120). To generate HLA-A2 tetramer, HLA-A2-
biotin monomer was incubated at a 4:1 ratio with SA-PE (BD Biosciences). Antibodies 
used to detect expression of TCRs on surface of T cells included: anti-TCR Vβ3.1 
(Thermo Fisher), PE streptavidin (BD Pharmingen), Alex Fluor 647 F(ab’)2 fragment of 
goat anti-mouse IgG (H+L) (life technologies). 
T cell transduction and activation 
 The D13.1.1 and T1 full-length TCR genes (human variable domains, murine 
constant domains) and D13.1.1-CAR and T1-CAR genes (human variable domains 
linked to murine CD28 and CD3ζ) were synthesized by GenScript. The D13.1.1 and T1 
full-length genes were cloned into the pMP71 vector using NotI and EcoRI restriction 
sites. The D13.1.1-CAR and T1-CAR genes were cloned into the pMP71 vector using 
NotI and SalI restriction sites. Plat-E cells were plated at a concentration of 1 x 106 
cell/well (6 well plate) in DMEM media with added puromycin and blasticidin. After 24 h, 
approximately 30 µg of DNA was transfected into Plat-E cells and retroviral particles 
were harvested 48 h post-transfection. CD8 and CD4 T cells were harvested from AAD 
transgenic mice using CD4 and CD8 mouse untouched T cells dynabead kit 
(ThermoFisher). T cells were activated with anti-CD28 and anti-CD3 beads 
(ThermoFisher) and 30 U/mL of recombinant mouse IL-2 (Roche) for 24 h. 1 x 106 T 
cells were then added to 1 mL of filtered (.45 µm) retroviral supernatant with 50 µL of 
Lipofectamine 2000 (Life Technologies) per 6 mL of retroviral supernatant and an 
additional 30 U/ mL of recombinant IL-2. The cells were spinfected by spinning cells at 
2000 rpm for 1 h in the presence of IL-2. Cells were then incubated at 37°C for 72 h. 
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After 48 h, T cells were split 1:2 in IMDM media. For activation assays, 7.5 x 104 T cells 
were incubated with 7.5 x 104 T2 cells (HLA-A2+) and various concentrations of peptide 
in a final volume of 200 µL (96 well plate) for 24 h. 50 µL of supernatants were assayed 
for IFN-γ using Mouse IFN gamma ELISA Ready-SET-Go kit (eBioscience). For IL-2 
detection from transduced 58-/- cells, 2HB 96-flat bottom plates were coated with 50 µL 
of 2.5 mg/mL anti-murine IL-2 (BD Pharmingen) in 0.1M Na2HPO4 (pH=9) overnight at 
4°C. 50 µL of supernatants were incubated in coated plates, followed by diluted (1:200) 
biotinylated anti-murine IL-2 (BD Pharmingen), followed by streptavidin-HRP (BD 
Pharmingen) diluted 1:10,000. Finally, TMB substrate (KPL) was added to well until a 
color change occurred. The reaction stopped by adding 1N H2SO4 and the absorbance 
was read at 450 nm.   
Adoptive T cell transfer in AAD mice 
 Total T cells (CD8 and CD4) from AAD transgenic mice were isolated using 
Dynabead kit (ThermoFisher) and transduced with the D13.1.1 and T1 full-length TCRs 
as described above. Mice were treated with cyclophosphamide (100 mg/kg) 24 h prior 
to T cell transfer. Cyclophosphamide was administered by intra-pleural (I.P.) injection. 
Prior to T cell injection, T cells were washed in Hank’s balanced salted solution (HBSS) 
buffer 2X. 5-10 x 106 cells were injected intravenously into AAD mice (via tail vein). After 
injection the weight of treated mice was monitored. At select time-points after injection, 
mice were sacrificed and total T cells were isolated from splenocytes using mouse 
untouched T cells Dynabeads kit (ThermoFisher). Isolated T cells were co-stained with 
WT1/AAD tetramer and either anti-CD4 AlexaFluor 647 or anti-CD8α AlexaFluor 647 
(BD Pharmingen). Isolated T cells were also used for IFN-γ activation ELISA as 
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described above. Lung, spleen and kidney tissues were isolated from mice and placed 
in 10% formaldehyde solution. Tissues were given to the University of Illinois veterinary 
pathologists (Vincent Hsiao, DVM, PhD) to perform histology and analyze tissues for T 
cell mediated damage.  
Results 
Activity of WT1 specific TCRs in CD4 and CD8 T cells 
 AAD transgenic mice were used rather than conventional C57 Bl/6 mice in order 
to test the human TCRs that are restricted by HLA-A2 in a “humanized” murine system. 
The AAD transgene expresses a chimeric class I MHC containing the α1 and α2 
domains from the human HLA-A2 heavy-chain and the α3 domain from the mouse Db 
heavy-chain (Figure 4.1) (184). The AAD system allows for murine CD8 molecules to 
associate with the α3 domains of this chimeric MHC molecule. It is well known that CD8 
binding to class I MHC significantly enhances sensitivity of T cells (131). Accordingly, 
the AAD mice allows for enhanced sensitivity when testing human TCRs in a murine 
system for potential cross-reactive peptides, which will likely require CD8 co-association 
to show activity in T cells. To test our human TCRs in this system, a human/murine TCR 
chimera was also created, using human variable domains and murine constant domains 
(Figure 4.1).  This system allows for association of murine TCR constant domains with 
murine CD3 molecules to permit T cell activation, while the variable domains interact 
with the α1 and α2 domains of the AAD molecule. For expression of TCRs in AAD T 
cells, constructs were cloned into the pMP71 retrovirus vector for transductions.  
 Four different WT1 TCR constructs were transduced into AAD CD8 and CD4 T 
cells. These TCRs consisted of wild-type (WT), CDR1α high-affinity mutations (D13.1), 
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CDR3β high-affinity mutations (D13.0.1), and combined CDR1α and CDR3β high-
affinity mutations (D13.1.1) (Figure 4.2). The two mutations identified in a stability 
selection of the original single-chain TCR were reverted to wild-type in the full-length 
constructs. 
Transduced CD8 and CD4 T cells from AAD mice were stained with anti-human 
Vβ3 antibody and WT1/AAD tetramer (Figure 4.3A). All cells stained positive for Vβ3 
expression. In CD8 T cells, the D13.0.1 and D13.1.1 transduced cells were positive for 
WT1/AAD tetramer staining. The D13.1.1 TCR had a higher surface level (e.g. as 
measured by MFI) than D13.0.1, which may be due to enhanced stability provided by 
the CDR1α mutations in the D13.1.1 TCR. In CD4 T cells, only D13.1.1 transduced cells 
stained positive for WT1/AAD tetramer. Therefore, presumably the D13.0.1 TCR’s 
affinity is below the threshold required for co-receptor independent binding (<1 µM) (75, 
182). The CDR1α mutations alone appeared not to provide binding enhancement over 
wild-type in either CD8 or CD4 T cells, at least that was detectable by flow cytometry.  
 The four different TCR constructs were tested for activity by incubating 
transduced T cells with T2 cells (HLA-A2+) and various concentrations of WT1 peptide 
(Figure 4.3B). Supernatants were assayed for IFN-γ as a measure of T cell activity. 
Consistent with binding data, the D13.0.1 and D13.1.1 TCRs were most active in CD8 T 
cells. The additional CDR1α mutations in the D13.1.1 did not appear to provide any 
additional sensitivity for T cell activity in CD8 T cells compared to D13.0.1. In CD8 T 
cells, the D13.1 TCR mediated an increase in activity compared to the wild-type TCR, 
which showed weak activity at the highest concentration of peptide.  
96 
	
In CD4 T cells, only the D13.1.1 TCR was capable of mediating activity against 
WT1/HLA-A2, confirming that D13.0.1 requires CD8 co-association with pepMHC to 
mediate binding and activity (Figure 4.3B, right). The sensitivity of D13.1.1 in CD4 T 
cells was comparable to CD8 T cells with both CD8 and CD4 T cells having an EC50 
value of approximately 10-7 M peptide.  
Fine specificity of D13.0.1 and D13.1.1 in CD8 and CD4 T cells 
 To understand the fine specificity of the D13.1.1 and D13.0.1 TCRs, single-site 
alanine mutants of the WT1 peptide were incubated with transduced AAD T cells and 
T2 target cells, and 24 hours later assayed for IFN-γ release. The D13.0.1 TCR was 
tested only in CD8 T cells since D13.0.1 did not mediate activity in CD4 T cells (Figure 
4.4A, left). The D13.1.1 TCR was tested in both CD4 and CD8 T cells (Figure 4.4A, 
right). For the D13.0.1 TCR, R1A and L9A mutant peptides maintained the same activity 
as the WT1 peptide. The activity of the L9A peptide was unexpected given that it is an 
anchor residue and a mutation to alanine likely would decrease affinity of the peptide to 
MHC. The greatest lost in activity for the D13.0.1 TCR was seen with the F3A, N5A, 
A6G and Y8A peptides, while the M2A, P4A and P7A peptides showed modest 
decreases in activity. These centric residues of the WT1 peptide are pointed towards 
the TCR’s CDR residues (Figure 4.4B) and potentially are necessary interactions with 
the CDR3 loops (including the CDR3β mutations) for enhanced activity. However, 
without a structure of the entire TCR pepMHC complex it is difficult to determine which 
CDR mutations are contributing to enhanced affinity of the TCR.   
For the D13.1.1 TCR in CD8 T cells, the F3A and P7A peptide mutants reduced 
activity by approximately 5-fold (Figure 4.4A, right). The remaining alanine peptide 
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mutants of WT1 had similar activity as the wild-type peptide. The D13.1.1 TCR in CD4 T 
cells were more sensitive to peptide alanine mutants than CD8 T cells, presumably due 
to a required affinity <1 µM for CD8-independent activity. The R1A, F3A and Y8A 
peptide mutants showed the greatest reduction in activity.  
The difference in sensitivity of R1A between D13.0.1 and D13.1.1 is quite 
dramatic.  It is possible that the arginine has no interactions with the wild type CDR1α 
found in D13.0.1 but that the mutations in CDR1α present in D13.1.1 result in 
substantial interactions with this arginine. In fact, the CDR1a mutations of D13.1.1 
(DLG, see Figure 4.2) contain a negative-charged aspartic acid that could form 
electrostatic interactions with the positive-charged arginine of the WT1 peptide.  
Unlike D13.0.1, the M2A peptide mutant maintained activity in both CD4 and 
CD8 T cells transduced with D13.1.1. Similar to D13.0.1, in CD4 T cells the D13.1.1 
TCR showed a reduction in activity with the A6G and P7A peptide mutants compared to 
wild-type peptide (approx. 5-10-fold). These differences could either be due to the 
differences in affinity thresholds required for CD4 and CD8 activity, or to unique 
interactions caused by the CDR1α loop, or both. 
 Given the activity observed with each of the alanine variants when testing the 
highest affinity TCR D13.1.1 in CD8 T cells, it is possible that structurally similar self-
peptides might stimulate these T cells. To identify structurally similar peptides that the 
D13.1.1 TCR may cross-react with, a proteome scan was performed. Jennifer Stone (a 
post-doctoral researcher in the Kranz lab) created an in silco search string based on 
conservative substitutions of the residues within WT1 peptide (Figure 4.4C). The 
allowed conservative substitutions were based on size, charge and hydrophobicity. This 
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string identified 13 peptides in the human proteome, of which 11 of the 9mer peptides 
were predicted to bind to HLA-A2 above a threshold level, using HLA peptide binding 
algorithms. To identify whether the D13.1.1 TCR would be cross-reactive, 10 of these 
structurally similar peptides were tested for activity (Figure 4.4D). None of these 
peptides stimulated activity with the D13.1.1 TCR in CD8 T cells from AAD mice.  
High-affinity WT1-TCR in AAD transgenic mice 
 Although the D13.1.1 TCR did not mediate activity against the 10 other self-
peptides in vitro, it is possible other self-peptides would lead to auto-reactivity in vivo.  
To test the D13.1.1 TCR in vivo, combined CD4 and CD8 T cells were transduced with 
the D13.1.1 TCR and injected into AAD mice. To confirm expression of the D13.1.1 
TCR prior to injection, T cells were stained with anti-Vβ3 antibody and WT1/AAD 
tetramer (Figure 4.5A). Approximately 50% of the T cells were transduced with the TCR 
as indicated by staining with both reagents. 
To determine if the D13.1.1 transduced T cells persisted, approximately 20 days 
after injection, T cells were isolated from spleens of one mouse, and co-stained with 
WT1/AAD tetramer and either anti-CD4 or anti-CD8 antibodies (Figure 4.5B). Although 
the positive populations were small, there was a 20-fold higher number of CD4 T cells 
that stained positive for WT1/AAD tetramer than mock CD4 T cells and a 5-fold higher 
number of CD8 T cells that stained positive for WT1/AAD tetramer than mock CD8 T 
cells. This suggests that the D13.1.1 transduced T cells persisted at low levels in both 
CD8 and CD4 T cells. To determine whether these T cells could mediate WT1 specific 
activity, the isolated T cells were incubated with various concentrations of WT1 peptide 
and T2 cells.  The T cells had activity with WT1 peptide compared to a null peptide 
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(MART1) (Figure 4.5C), suggesting that the transduced T cells that persisted 
maintained functionality.  
Given that some studies have shown low levels of WT1 protein expression in the 
lung and kidney (185), and that mouse and human WT1 are identical in the region of 
this peptide, histology was performed on kidney and lung tissues from mice treated with 
transduced and mock T cells to investigate if on-target toxicity was mediated by D13.1.1 
T cells (Figure 4.5D). These tissues were analyzed by a veterinary pathologist (Vincent 
Hsaio DVM, PhD) and there was no evidence of significant T cell mediated damage to 
either tissue.  
Finally, to monitor for potential graft versus host disease, the weight of the mice 
was measured throughout the experiment (Figure 4.5E). All mice experienced an initial 
drop in weight (approx. 10%), most likely due to cyclophosphamide treatment prior to T 
cell injection, but both the mock and D13.1.1 T cell-treated mice recovered to their initial 
weights, suggesting that the transferred T cells did not causing significant graft versus 
host disease.  
High-affinity MART1-reactive-TCR in AAD transgenic mice 
To extend the studies with the WT1 high affinity TCR, and to further investigate 
whether AAD transgenic mice is a valid model for identifying toxicities with high-affinity 
TCRs, I also tested the T1 TCR, which binds with high-affinity to the MART1/HLA-A2 
complex (132). T cell trials conducted with TCRs specific for MART1/HLA-A2 have 
demonstrated on-target toxicities (99). Patients have developed vitiligo (skin 
depigmentation) (186) along with T cell mediated damage to eye and ear tissues when 
treated with MART1 specific TCRs. These toxicities became more severe when a higher 
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affinity MART1 TCR was used (100), despite the fact that this TCR has significantly 
lower affinity than our T1 TCR (187).  
Our collaborators previously transduced human CD8 T cells with the high-affinity 
T1 TCR and observed non-specific basal activity well above the level of non-transduced 
CD8 T cells (unpublished). To test the T1 TCR in AAD mice, I transduced a full-length 
construct similar to the WT1 TCR (human variable domains, murine constant domains) 
into CD8 and CD4 T cells. I then stained the transduced cells with MART1/AAD 
tetramer (Figure 4.6A). The construct was expressed in both CD8 and CD4 T cells, with 
a higher transduction efficiency observed in CD4 T cells (63% in CD4 compared to 33% 
in CD8). The difference in transduction efficiency could have been due to different 
states of activation at the time of transduction or “fratricide” mediated the CD8 T cells 
expressing the T1 TCR.  
To examine if the T1 T cells could recognize both human MART1 (ELAGIGILTV) 
and murine MART1 (EAAGIGILIV) peptides, the transduced T cells were stimulated with 
various concentrations of each peptide (Figure 4.6B). As observed with human T cells 
transduced with the T1 TCR, mouse CD8 T cells mediated a high level of basal activity 
compared to mock controls. Nevertheless, CD8 T cell activity was increased about 50% 
with MART1 peptide.  The CD8 T cells with the T1 TCR were approximately 50 to 100-
fold more sensitive to the human MART1 peptide, compared to the mouse peptide. 
Some of the enhanced activity with human MART1 could be due to the leucine 
substitution at p2, which has been shown to enhance affinity of the peptide for HLA-A2 
(188).  
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In CD4 T cells transduced with the T1 TCR, there was no observable basal 
activity compared to mock controls (Figure 4.6B, right). Therefore, CD8 co-association 
with MHC is likely required to mediate this non-MART1-specific basal activity. Also 
similar to CD8 T cells, the CD4 T cells were stimulated by both human and mouse 
MART1, but the human peptide was about 50- to 100-fold more sensitive. Nevertheless, 
given the reactivity with mouse MART1, and the clear self-reactivity exhibited by CD8 T 
cells expressing the T1 TCR, it was worth testing in vivo. 
To test the T1 TCR in vivo, AAD mice were injected with 5 x 106 transduced T 
cells and monitored for toxicity. Similar to mice treated with the D13.1.1 TCR there was 
an initial drop in weight of all mice, likely due to cyclophosphamide treatment (Figure 
4.6C), However, those mice that received T cells with the T1 TCR exhibited a slightly 
greater loss of weight, and they did not appear to recover to their initial weights as well 
as mock controls (Figure 4.6C). Given the limited number of mice used in this 
experiment, further studies will need to be done to confirm this observation.  
As with the WT1 TCR experiment, the T1 mice were sacrificed 20 days after 
administration of T cells and CD8 and CD4 T cells were isolated from spleens. There 
did not appear to be a positive CD8 population staining for MART1/HLA-A2, whereas 
CD4 T cells contained a significant population that stained positive above the mock 
control. Given the high basal activity of the T1 TCR in CD8 T cells, it is possible that 
these cells were rapidly eliminated after injection. Similar results have been observed 
with a high-affinity variant of the murine 2C TCR (83, 179). Finally, skin tissue from the 
mice receiving the T1 TCR was analyzed histologically. It was noted by the pathologist 
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that mice receiving the T1 TCR had signs of vitiligo, which is consistent with 
observations made in clinical trials of MART1 therapies (186).  
Comparison of TCR and CAR sensitivity in T cells 
 Given our efforts to engineer human single-chain TCRs with enhanced affinities 
against the WT1 and MART1 cancer antigen, I was in a unique position to compare 
features of the conventional TCR/CD3 machinery with the synthetic constructs known 
as chimeric antigen receptors (CARs). Specifically, to gain a better understanding of 
CAR sensitivity compared to full-length TCRs, I expressed both the D13.1.1 (WT1) and 
T1 (MART1) TCRs as CAR constructs consisting of a single-chain TCR (variable 
domains fused via a flexible linker) tethered to CD28 and CD3ζ intracellular signaling 
domains (Figure 4.7A).  
In initial studies, I transduced 58-/- cells (T cell hybridoma lacking an endogenous 
TCR and CD8/CD4 co-receptors (180) with both CAR and TCR constructs (Figure 
4.7B,C). For both D13.1.1 and T1, the CAR constructs were expressed at about 10-fold 
higher surface levels than their full-length TCR counterparts. To determine if these 
constructs bound to their respective ligands with similar affinity, I titrated cells with 
biotinylated pepMHC monomer and detected with SA-PE (Figure 4.7B,C right). The 
D13.1.1 and T1 CAR constructs bound with similar affinity as their full-length TCR 
counterparts. Accordingly, I was in a position to examine the issue of sensitivity with two 
different systems in which the TCR and CAR had identical antigen specificities and 
affinities, and any effects could be attributed to either surface levels or signaling 
components. 
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To test for activity in 58-/- cells, I incubated transduced cells with T2 cells (HLA-
A2-positive) and various concentrations of peptide. Supernatants were assayed for IL-2 
concentrations (Figure 4.7D). In the case of both systems, the TCR constructs were 
approximately 100-fold more sensitive than their respective CAR counterparts. To 
quantify this difference, and compare to the surface levels of each format, the mean 
fluorescence intensities (MFI) of CAR and TCR cells stained with tetramer were plotted 
along with EC50 values for IL-2 release (Figure 4.7E).  This presentation format showed 
quite clearly, and dramatically, that despite lower levels of the TCR, they exhibited 
significantly greater sensitivity to the antigen than the CAR format. 
 The above results were observed with a transformed T cell line (58-/-), and not 
primary T cells, the cells used in adoptive T cell therapies. Accordingly, the D13.1.1 
TCR and CAR constructs were transduced into primary CD8 and CD4 T cells from AAD 
mice to determine if primary cells had the same sensitivity differences observed in 58-/- 
cells. Transduced CD8 and CD4 T cells were stained with WT1/HLA-A2 tetramer and 
anti-Vβ3 antibody to confirm expression (Figure 4.8A). In both CD8 and CD4 T cells the 
full-length TCR had slightly greater transduction efficiencies than the CAR construct, 
which could be due to the quality of the DNA used for the transfection of the retroviral 
packaging cell line. Nevertheless, the D13.1.1 full-length TCR appeared to be 
expressed at a more homogenous surface level in CD8 and CD4 T cells (seen as a 
sharper peak in the flow histogram), while the CAR constructs were expressed at more 
heterogenous levels (seen as broader peaks in the flow histogram) with some cells 
expressing higher levels and others cells having lower levels than the TCR transduced 
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cells. While the average surface levels of the TCR were slightly greater than CAR 
(about two-fold), the difference was not as substantial as in the 58-/- cells. 
To compare binding affinities, the transduced CD4 T cells were stained with 
various concentrations of WT1/HLA-A2 monomer and tetramer (Figure 4.8B). Similar to 
58-/- cells, the CAR and TCR constructs bound with similar affinity to WT1/HLA-A2 
monomer. With WT1/HLA-A2 tetramer, the CAR construct bound with approximately 2-
fold higher affinity than the TCR construct, potentially due to its membrane mobility or its 
density, compared to the full-length TCR.  Activation of transduced CD8 and CD4 T 
cells was examined by incubating T cells with T2 cells and various concentrations of 
WT1 peptide. Supernatants were assayed for IFN-γ concentrations (Figure 4.8C). 
Similar to the results from 58-/- cells, the TCR construct was nearly 100-fold more 
sensitive in both CD8 and CD4 T cells. Activation profiles were similar between CD8 
and CD4 T cells, with no additional sensitivity provided by CD8 co-association with 
MHC.  
Comparison of specificity of TCRs to CARs in primary T cells 
 To compare the specificity of TCRs and CARs, primary CD8 T cells were 
transduced with the D13.1.1-FL and D13.1.1-CAR receptors and tested for activity (IFN-
γ release) against the single-site alanine (Figure 4.9A) or single-site conserved (Figure 
4.9B) mutants of the WT1 peptide. Overall, the CAR format was more sensitive to the 
various substituted peptide variants than the TCR format. This is likely due to the 
greater sensitivity, and inherent different activity threshold, for the TCR. Specifically, the 
D13.1.1-FL construct showed the greatest reduction in activity with the P7A mutant and 
diminished activity with the R1A, Y8A and L9A peptides (Figure 4.9A). The reduction 
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from the P7A peptide could be due to structural effects on the entire peptide. It is likely 
that the L9A peptide showed a reduction in activity, due to a decrease in binding affinity 
to HLA-A2.  
Unlike, the FL construct, the CAR only maintained full-activity with the M2A and 
P4A peptides, and showed significantly diminished activity with the R1A peptide. All 
other peptide mutants were not active with the CAR construct. For conservative 
mutants, similar to the alanine mutants, the P7V showed the greatest reduction in 
activity with the D13.1.1-FL construct. The F3Y and N5Q mutants also showed 
modestly reduced activity for the D13.1.1-FL construct. For the D13.1.1 CAR construct, 
the R1K mutant restored full activity compared to WT1 peptide, while the M2L, Y8F and 
L9I peptides had diminished activity.  
Discussion 
 WT1 is a promising target for cancer therapies. Due to WT1’s expression levels 
in malignant cells and its role in oncogenesis it has been listed as the top shared 
antigen target for cancer immunotherapies (113). Since mechanisms of immune 
tolerance normally eliminate T cells with TCRs that have higher affinity for self-
peptide/MHC, an endogenous response against WT1 is often limited. To overcome this 
obstacle, a former graduate student (Sheena Smith) in the Kranz lab engineered a TCR 
with higher affinity for the WT1/HLA-A2 complex, using yeast-display of a wild-type TCR 
isolated by our collaborator Phil Greenberg (University of Washington). This TCR had 
affinity enhancing mutations in the CDR3β and CDR1α domains.  
Using the sequences of this collection of TCRs against WT1, I generated several 
different TCR constructs containing these mutations and tested them for activity in T 
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cells. Using the AAD transgenic mouse system, I was able to show that the CDR3β 
high-affinity mutations (D13.0.1) could enhance activity in CD8 T cells over the wild-type 
affinity TCR, however, this construct was not active in CD4 T cells. Presumably the KD 
value of D13.0.1 for WT1/HLA-A2 is greater than the 1 µM required for CD8 
independent activity (75, 182, 189). When the CDR3β and CDR1α high-affinity 
mutations were combined (D13.1.1) they were able to drive both CD8 and CD4 activity. 
In CD8 T cells, the D13.1.1 construct did not provide any additional sensitivity to 
WT1/HLA-A2 compared to D13.0.1, likely because these two TCRs have affinities that 
exceed the threshold associated with optimal CD8 T cell activity (i.e. KD values that are 
below about 10 µM).  Based on the T cell activities and CD8-dependence of the four 
TCRs tested, I would predict that they exhibit the following affinities (KD values) for the 
WT1/HLA-A2 complex:  wild-type TCR, KD >100µM; D13.1 (CDR1α mutations), KD 
100µM; D13.0.1 (CDR3β  mutations), KD 10µM; and D13.1.1, KD 100 nM (CDR3β and 
CDR1α mutations). 
 When tested for peptide fine-specificity, the D13.0.1 TCR in CD8 T cells showed 
diminished activity with several alanine peptide mutants, while the D13.1.1 TCR had 
substantial activity for most of the alanine mutants in CD8 T cells. Therefore, I would 
suggest that the D13.0.1 TCR would be optimal for CD8 T cells because it had the 
same sensitivity for WT1/HLA-A2 as the D13.1.1, but maintained greater specificity with 
respect to alanine mutants of the peptide than the D13.1.1 TCR.  
In CD4 T cells, only the D13.1.1 TCR had activity, and it appeared to have a 
slightly altered fine-specificity compared to the D13.0.1 TCR in CD8 T cells. The most 
significant difference was at the N-terminal residue of the WT1 peptide, which is an 
107 
	
arginine (Figure 4.4B).  A model of the TCR docked over the WT1/HLA-A2 complex, 
based on many previous TCR/pep-HLA-A2 structures, actually positions the CDR1α 
loop directly over the N-terminus of the peptide, which would position Asp29α close to 
the P1-arginine of WT1. This electrostatic interaction may not only increase the affinity 
of the D13.1.1 TCR for WT1/HLA-A2, but it may actually improve its specificity by 
requiring an arginine (or lysine) at the N-terminus of the peptide. I propose that to 
reduce the affinity for optimal CD4 and CD8 activity, yet maintain this added specificity, 
it might be advantageous to mutate residues of the CDR2 loops that engage the HLA-
A2 helices. 
These results support the view that TCRs against class I antigens will require 
different affinities for optimal use in CD8 and CD4 T cells. The affinity required to 
efficiently direct CD4 T cells against a class I antigen is likely of too high-affinity for CD8 
T cells to maintain sufficient peptide specificity. Currently, most adoptive T cell clinical 
trials do not separate CD8 and CD4 T cells for transduction. However, in the future, 
separate transductions will be required if both CD8 and CD4 responses are desired. 
Additionally, further work in the lab is being conducted to solve the crystal structure of 
the D13.1.1 TCR with WT1/HLA-A2, which will allow us to structurally determine which 
CDR residues are contributing to binding and peptide specificity.  
 Given the recent adverse events of adoptive T cell trials with affinity-enhanced 
TCRs (107, 108), we wanted to test structurally similar peptides for activity with the 
D13.1.1 TCR. Proteome searches have now been successfully used to identify peptides 
for which affinity-enhanced TCRs cross-react (107). A proteome search using 
conservative substitutions at each residue of the WT1 peptide was conducted by 
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Jennifer Stone and structurally similar peptides were identified. Several of these 
peptides were tested with CD8 T cells transduced with the D13.1.1 TCR and did not 
show any activity in vitro. Further work is now being done using the alanine data to 
guide more specific proteome searches. Additionally, the PIGQ peptide (RMFPGEVAL) 
for which the WT1/HLA-A2 antibody cross-reacts (178) with is being tested for activity 
with D13.1.1 transduce CD8 T cells. Although the CDR1α mutations may enhance 
binding to this peptide due to its N-terminal similarity with WT1, the importance of the C-
terminal residues of the WT1 peptide (particularly pP7) observed with the alanine scan 
using the D13.1.1 TCR, may suggest that the TCR does not react with the PIGQ 
peptide.  
 While the WT1 structurally similar peptides identified by the in silco search did 
not show activity with the D13.1.1 TCR, not all structurally similar peptides were tested. 
Using AAD transgenic mice, we tested the D13.1.1 TCR in an in vivo model. For 
potential off-target structurally similar peptides, the murine proteome has nearly 50% 
identical similarity with the human proteome (109).  Also, we wanted to determine if a 
high-affinity TCR for WT1/HLA-A2 would mediate damage against tissues that have 
been proposed to express WT1 at low levels (classified as on-target/off-tumor toxicity) 
(185). Given that the murine and human WT1 proteins shared the same sequence for 
residues 126-134, AAD transgenic mice provided a useful model to test our high-affinity 
TCR for these on-target toxicities. CD8 and CD4 T cells transduced with the D13.1.1 
TCR did not mediate detectable toxicities when injected into AAD mice. Despite reports 
that WT1 is expressed at low levels in lung and kidney tissues, no toxicity was observed 
in mice receiving D13.1.1 T cells.  Previous work analyzed the safety of a high-affinity 
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TCR for the murine WT1/Db complex (147). Similar to our results, this study did not 
identify toxicities mediated by the T cells in lung or kidney tissue.   
 To further test the validity of using the AAD model for identifying toxicities, we 
used the T1 TCR, specific for MART1/HLA-A2. MART1 directed therapies have known 
on-target toxicities in eye, ear and skin tissues (99, 100). Additionally, the T1 TCR has 
been transduced into human CD8 T cells and has shown high levels of basal activity, 
suggesting non-specific activity (unpublished). When the T1 TCR was transduced into 
AAD CD8 T cells we observed a high level of basal activity, similar to results observed 
with human T cells, suggesting that T1-transduced AAD CD8 T cells maintained similar 
properties as the T1-transduced CD8 human T cells. Additionally, when injected into 
mice, the T1-transduced CD8 T cells disappeared. These results are consistent with the 
cross-reactive high-affinity m33 TCR, which led to rapid eliminated of transduced CD8 T 
cells when injected into mice (83, 87).  
Although it was not tested, the CD4 T cells that persisted could potentially be 
regulatory T cells (Tregs), which would be incapable of mediating a cytotoxic anti-tumor 
response. Mice that received the T1 TCR had histological signs of vitiligo, which has 
also been observed in patients receiving MART1 specific therapies (186). These 
symptoms may have become more serious if the T1 TCR was as sensitive for the 
murine MART1 peptide as it was for the anchor modified human MART1 peptide. 
Overall, the studies of the T1 TCR suggest that some on-target toxicities can be 
identified using the AAD model. The more similar the murine peptide is to the human 
peptide, the more likely on-target toxicities will manifest.  
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 While TCR therapies have had some successes in the clinic, the major receptors 
currently used in adoptive T cell trials are chimeric antigen receptors (CARs). Using the 
variable domains of T1 and D13.1.1, I generated CARs that bound to MART1/HLA-A2 
and WT1/HLA-A2 respectively. These CARs allowed me to effectively compare 
sensitivity and specificity of CARs to full-length TCRs. Both the CARs and the TCRs 
shared the same affinity and specificity for their respective ligands. When transduced in 
to T cells (both a T cell hybridoma and primary CD8 and CD4 T cells), the CARs were 
expressed at higher levels on the T cell surface. Despite this lower level of the TCR 
format, the full-length TCRs were 50- to 100-fold more sensitive.  
A likely explanation for these results is that full-length TCRs, unlike CARs, 
assemble with the CD3 subunits on the surface of T cells and the CD3 levels are known 
to limit the number of TCR/CD3 complexes on a T cell (190).  The enhanced sensitivity 
of TCRs despite their lower surface levels are probably due to their robust signaling 
machinery, including 10 ITAMs, compared to CARs (Figure 1.3). These results are 
similar to observations made using the high-affinity m33 TCR as both a CAR and a full-
length TCR (87). We are now currently comparing the activity of TCRs to CARs for a 
panel of cytokines (such as IL-6, IL-10 and MIP-1β), which will allow us to determine if 
the two formats trigger the same quantitative response in T cells.  
  Binding titrations with pepMHC monomer showed that the CAR and TCR 
constructs shared similar affinities for their respective pepMHC complexes. Titrations 
with tetramer on primary CD4 T cells, revealed that the CAR constructs bound slightly 
better than the full-length TCR. CARs do not require additional co-receptors or signaling 
molecules when present on the T cell surface, which may allow them to cluster more 
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efficiently than full-length TCRs and hence bind better to pepMHC tetramer. The lower 
sensitivity of the CARs than the TCRs, despite higher surface levels and greater avidity, 
suggests that more optimal signaling mechanisms for single-chain constructs could be 
pursued. Recent work has had promising results of increasing sensitivity of CARs by 
tethering three signaling domains to a single CAR construct (191). Also, two CAR 
constructs with different specificity and signaling domains have been examined by co-
transducing into T cells (67, 68). This system may allow for enhanced specificity and 
sensitivity due to synergistic signaling of the two CARs. Finally, further investigations of 
the effect that CAR affinity has on sensitivity need to be conducted to identify the 
optimal CAR affinity for mediating robust T cell signaling while maintaining antigen 
specificity.  
 When testing specificity of the FL and CAR constructs, the CAR construct had 
significantly diminished activity with WT1 peptide mutants compared to the FL construct. 
Full-length receptors require affinity enhancements to drive activity of CD4 T cells. 
However, affinity enhancements in CD8 T cells usually decrease peptide specificity and 
increase the risk for cross-reactivity. The D13.1.1 CAR is capable of driving both CD8 
and CD4 T cells, while maintaining a high level peptide specificity. For clinical trials with 
the conventional TCRs, CD8 and CD4 T cells may need to be separated and 
transduced with TCRs of different affinities. Since the D13.1.1 CAR construct is capable 
of driving activity in CD8 and CD4 T cells, it may have an advantage compared to 
conventional full-length receptors.  The same CAR construct with the same affinity could 
be used in both CD8 and CD4 T cells. However, given the reduced sensitivity of the 
CAR compared to the TCR, it still needs to be determined if the D13.1.1 CAR construct 
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can sufficiently recognize and mediate T cell activity against WT1+ tumors at their 
endogenous levels of the WT1/HLA-A2 complexes. Collectively, these results 
demonstrate that the TCR or CAR formats used for adoptive T cell therapies should be 
optimized depending on the densities of antigens targeted by either receptor.  
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Figures 
  
 
 
 
 
 
 
 
 
Figure 4.1- Schematic diagramming the AAD system with CD8-MHC interaction. A CD8 T cell 
expressing a TCR chimera consisting of human Vα and Vβ domains (gray, top) and murine Cα and Cβ 
domains (black, top) interacting with AAD MHC molecules consisting of α
1
 and α
2
 domains (gray) of 
HLA-A2 and the α
3
 domain (black) of mouse D
b
 MHC. The murine CD8 molecule interacts with the α
3
 
domains of AAD molecule. T cell signaling molecules, such as CD3 interact with Cα and Cβ domains of 
TCR.  
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WT D V K V T Q S S R Y L V K R T G E K V F L E C V Q D M D H E N M F W Y R Q D P G L G L R L I Y F S Y D V K M K E
Stability D V K V T Q S S R Y L V K R T G E K V F L E C V Q D M D H E N M F W Y R Q D P G L G L R L I Y S S Y G V K M K E
D13.1 D V K V T Q S S R Y L V K R T G E K V F L E C V Q D M D H E N M F W Y R Q D P G L G L R L I Y F S Y D V K M K E
D13.0.1 D V K V T Q S S R Y L V K R T G E K V F L E C V Q D M D H E N M F W Y R Q D P G L G L R L I Y F S Y D V K M K E
D13.1.1 D V K V T Q S S R Y L V K R T G E K V F L E C V Q D M D H E N M F W Y R Q D P G L G L R L I Y F S Y D V K M K E
Vβ (Continued) CDR 3
57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 10
0
10
1
10
2
10
3
10
4
10
5
10
6
10
7
10
8
10
9
11
0
11
1
11
2
11
3
11
4
11
5
WT K G D I P E G Y S V S R E K K E R F S L I L E S A S T N Q T S M Y L C A S S S I N E Q F F G P G T R L T V L E D L K N
Stability K G D I P E G Y S V S R E K K E R F S L I L E S A S T N Q T S M Y L C A S S S I N E Q F F G P G T R L T V L E D L K N
D13.1 K G D I P E G Y S V S R E K K E R F S L I L E S A S T N Q T S M Y L C A S S S I N E Q F F G P G T R L T V L E D L K N
D13.0.1 K G D I P E G Y S V S R E K K E R F S L I L E S A S T N Q T S M Y L C A T S N Y L E Q F F G P G T R L T V L E D L K N
D13.1.1 K G D I P E G Y S V S R E K K E R F S L I L E S A S T N Q T S M Y L C A T S N Y L E Q F F G P G T R L T V L E D L K N
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D13.1.1 Q K E V E Q N S G P L S V P E G A I A S L N C T Y S D R D L G S F F W Y R Q Y S G K S P E L I M S I Y S N G D K
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Figure 4.2- Sequences of different WT1/HLA-A2 TCRs. The sequences of the different TCRs 
tested for activity are shown along with necessary stability mutations to express the high-affinity 
TCR as a single-chain. The different TCRs consisted of D13.1 (CDR1α mutations), D13.0.1 
(CDR3β mutations) and D13.1.1 (CDR3β + CDR1α mutations).  
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Figure 4.3- Peptide specificity of high-affinity WT1/HLA-A2 TCRs. Alanine mutants of the WT1 peptide 
were tested for activity with the D13.0.1 TCR in AAD CD8 T cells and the D13.1.1 TCR in AAD CD8 
(black) and CD4 (gray) T cells. The –log(EC
50
) value for INF-γ activity is plotted (A). A view of the WT1 
peptide (blue) within the HLA-A2 molecule (orange) is shown (PDB 3HPJ) (B). A search string for WT1 
structurally similar peptides is shown. The number of peptides predicted to bind HLA-A2 and the 
percentage of those peptides present in mouse proteome are highlighted in yellow (C). A list of WT1 
structurally similar peptides tested (D, right side) and the activity of those peptides compared to WT1 
peptide when incubated with D13.1.1 CD8 T cells and T2 cells (1:1) is shown (D, left side) 
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Figure 4.4- Specificity and persistence of D13.1.1 T cells in AAD mice. Total AAD T cells were 
isolated from spleenocytes and transduced with the D13.1.1 TCR. Flow histograms with percentage of 
positive transduced and mock cells stained with Anti-Vβ3 and WT1/AAD tetramer are shown (A). 20 days 
after injection, T cells were isolated from mice receiving D13.1.1 or mock T cell treatment. T cells were 
stained with WT1/AAD tetramer and either anti-CD4 or anti-CD8 antibody. Percentage of positive cells is 
indicated (B). Isolated cells were incubated with T2 cells (1:1) and either WT1 or MART1 peptides at 
various concentrations. Measured IFN-γ concentrations from supernatants via ELISA is indicated (C). H&E 
stained histological samples of lung and kidney tissues from mice receiving transduced and mock T cells 
are shown (D). The percentage of D13.1.1 and mock treated initial weight is plotted against days post-
transfer of T cells (E).  
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Figure 4.5- Specificity and persistence of T1 cells in AAD mice. CD8 and CD4 AAD T cells were 
isolated from spleenocytes and transduced with the T1 TCR. Flow histograms with percentage of positive 
transduced and mock cells stained with MART1/AAD tetramer are shown (A). Transduced CD8 and CD4 
cells were incubated with T2 cells and various concentrations of human MART1 (ELAGIGILTV) or murine 
MART1 (ELAGIGILIV) peptides. IFN-γ concentrations from supernatants measured via ELSIA are 
indicated (B). AAD mice were injected with transduced T1 total T cells. The percentage of initial weight of 
mock and T1 treated mice was plotted against days after treatment (C). 20 days after injection, T cells 
were isolated from mice and stained with MART1/AAD tetramer and either anti-CD4 or anti-CD8 
antibody. Percentage of positive cells is indicated (D). H&E stained histological samples of skin tissue 
was prepared and analyzed (E).  
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Figure 4.6- Activity of D13.1.1 and T1 TCR and CAR constructs in 58
-/-
 cells. A diagram of the TCR and CAR 
constructs used for the D13.1.1 and T1 TCRs (A). 58
-/-
 cells transduced with the D13.1.1 TCR and CAR (B, left 
side) and T1 TCR and CAR (C, left side) were stained with 50 nM WT1/HLA-A2 and MART1/HLA-A2 tetramer 
respectively. Transduced cells were titrated with WT1/HLA-A2 and MART1/HLA-A2 monomer respectively and 
mean fluorescence intensity (MFI) was plotted against concentration of monomer (B,C right side). Transduced cells 
were incubated (1:1) with T2 cells and various concentrations of WT1 and MART1 peptide respectively. 
Supernatants were then assayed for IL-2 concentrations via ELISA (D). The log of mean fluorescence intensity 
(MFI) is plotted along with EC
50
 values from IL-2 activation (E).  
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Figure 4.7- Activity of D13.1.1 TCR and CAR constructs in primary CD8 and CD4 T cells. 
Primary CD8 and CD4 T cells were isolated from AAD mice and transduced with D13.1.1 TCR and 
CAR constructs (stability mutations added in both TCR and CAR). Transduced cells were stained 
with 50 nM WT1/HLA-A2 tetramer and anti-Vb3 antibody (A). Transduced CD4 cells were titrated 
with WT1/HLA-A2 monomer (left) and tetramer (right). % maximum binding (100% set at highest 
concentration stained) was plotted against concentration monomer and tetramer respectively (B). 
Transduced CD8 and CD4 T cells were incubated with T2 cells (1:1) and various concentrations of 
WT1 peptide. Supernatants were assayed for IFN-g concentrations via ELSIA (C).  
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Figure 4.8- Fine specificity of the D13.1.1-FL and D13.1.1-CAR constructs. Primary CD8 and 
CD4 T cells were isolated from AAD mice and transduced with D13.1.1 TCR and CAR constructs 
(stability mutations added in both TCR and CAR). Transduced D13.1.1-FL and D13.1.1-SCS cells 
were incubated with T2 cells and various concentrations of alanine mutants of the WT1 peptide (A) 
and conservative mutants of the WT1 peptide (B). EC
50 
values were calculated using non-linear 
regression models. The N5Q mutant was not included with the D13.1.1-CAR construct.   
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CHAPTER FIVE 
 
 
 
 
ENGINEERING AND CHARACTERIZING A HUMAN HIGH-AFFINITY T CELL 
RECEPTOR AGAINST SURVIVIN/HLA-A2 
 
 
 
 
Abstract 
 In chapter five, as a prelude to studying a different human TCR, I describe the 
engineering of a TCR for high-affinity against the survivin/HLA-A2 complex. Survivin is 
an anti-apoptotic protein overexpressed in a variety of cancers. A TCR isolated from 
peripheral lymphocytes was stabilized as a single-chain TCR (consisting of variable 
domains linked by a flexible linker) on the surface of yeast. Libraries were created in the 
CDR3α and CDR3β domains of the TCR and sorted for binding to survivin/HLA-A2. Two 
high-affinity clones were isolated that bind to survivin/HLA-A2 with nanomolar affinity. I 
then tested this TCR for activity in vitro by transducing it into primary CD8 and CD4 T 
cells. 
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Introduction  
 The survivin gene was originally identified due to expression in some cancers 
and in some fetal cells (114). To determine if survivin was involved with oncogenesis, 
the gene was targeted using antisense cDNA, which resulted in an increase in 
apoptosis and inhibition of cell proliferation (192). Later work demonstrated that survivin 
was stored in mitochondria and upon release into the cytoplasm it inhibited apoptotic 
signaling by binding caspases associated with apoptosis (193). Additional studies 
showed that survivin localized to the mitotic spindle during mitosis and could play a role 
in proper chromosomal segregation (194). Additionally, survivin has shown to be a 
prognostic factor in cancer progression, with cancers that express survivin having less 
favorable clinical outcomes (195-197).  
 A small molecule inhibitor of survivin, called YM155, has been developed and 
has shown early promising results. YM155 was tested in vitro on a large panel of both 
hematological and solid tumors and had the ability to inhibit cellular growth (198). A 
phase II clinical trial using YM155 in patients with non-small-cell lung cancer 
demonstrated that YM155 had a 43% disease control rate (199). However, a more 
recent phase II clinical trial with YM155 in patients with stage III and IV melanoma did 
not reach a primary efficacy endpoint (200). These results with a traditional small 
molecule chemotherapy-type drug suggest that alternative approaches are required.  
An immunotherapy that selectively targets survivin expressing cancer cells could 
potentially provide a better response rate with more tolerable side-effects than those 
associated with chemotherapy.  In this regard, several survivin-derived peptides have 
entered testing in clinical trials. Recently, a phase II clinical trial was started by 
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Immunovaccine using survivin derived peptides in a vaccine format. This trial has 
demonstrated early promising results, specifically in patients with ovarian cancer (201). 
However, given that this treatment is stimulating endogenous T cells against a self-
protein, survivin, it is possible that the response is not as robust as it would be against a 
foreign antigen.  
 T cell receptors (TCRs) bind to peptide/MHC (pepMHC) complexes present on 
the cell surface. Peptides presented with class I MHC are from intracellular proteins that 
have been digested into short fragments (8-10 A.A.) and placed in complex with MHC. 
TCRs can sample proteins that are being expressed intracellularly and identify foreign 
peptides, so that the cell can be destroyed to prevent further propagation of the 
pathogen. Due to thymic selection, endogenous TCRs normally do not bind to many of 
the self-proteins expressed in cancerous cells with sufficient affinity to activate T cells 
and destroy the cancer. This “tolerance” process represents one of the major problems 
associated with the use of peptides, such as those from survivin, as vaccines.  
To overcome tolerance that leads to loss of effective T cells, our lab and others 
have engineered TCRs for higher affinity. Various techniques have been employed such 
as yeast and phage display (105, 106). These techniques typically involve creating large 
libraries in the CDR domains of the TCR followed by several rounds of selection to 
identify high-affinity clones. The Kranz lab has used yeast display to engineer several 
human TCRs for higher-affinity (110, 121, 132). To engineer and analyze a TCR by 
yeast display, it has to be first stabilized on the surface of yeast as a single-chain TCR 
(scTv) consisting of variable domains fused via a flexible linker. Previous work by Aggen 
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et al. demonstrated that Vα2 containing TCRs are favorable for expression as single-
chain TCRs (121). 
 The Kranz lab received a Vα2 containing TCR clone from our collaborators in 
Germany (Wolfgang Uckert and Dolores Schendel) that likely binds to survivin/HLA-A2 
with low affinity (> 1 uM). This TCR was cloned as a single-chain TCR and 
subsequently stabilized for expression on the surface of yeast by Beth Marshall. To 
attempt to isolate a high-affinity clone, in this Chapter, I used the stabilized TCR 
template to generate CDR3α and CDR3β libraries and sorted for binding to 
survivin/HLA-A2. After several rounds of sorting, two high-affinity clones were isolated 
that bound to survivin/HLA-A2 with mid-nanomolar affinity. Previous work has 
demonstrated that high-affinity TCRs confer both CD4 and CD8 T cell activity against 
class I antigens, which can be beneficial for tumor control (83, 179). To determine the 
activity of the high-affinity survivin TCR, it was cloned into a retroviral vector as a full-
length TCR (variable and constant domains) and transduced into CD4 and CD8 T cells. 
When presented with survivin/HLA-A2, this TCR activated both CD4 and CD8 T cells.  
Material and Methods 
Peptides, MHC and staining reagents 
 Survivin (LTLGEFLKL) and anchor modified SurvT2M (LMLGEFLKL) were 
synthesized by standard F-moc chemistry at the Macromolecular Core Facility at Penn 
State University College of Medicine (Hershey, PA, USA). Yeast and T cells were 
stained at various concentrations with HLA-A2-Ig fusion dimer (BD Biosciences) and 
refolded HLA-A2-biotin. HLA-A2-biotin was initially in complex with a UV-cleavable 
peptide, which was exchanged with the desired peptide by exposure to UV light for >30 
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minutes. To generate HLA-A2 tetramer, HLA-A2-biotin monomer was incubated at a 4:1 
ratio with SA-PE (BD Biosciences). Antibodies used to detect expression of TCR on 
surface of yeast and T cells included: anti-TCR Vβ20-PE (Clone ELL1.4: BD Coulter), 
anti-Vα2 (generated in the Kranz lab), anti-HA (Covance), anti-c-myc chicken IgY 
fraction (life technologies), PE streptavidin (BD Pharmingen), Alexa Fluor 647 goat anti-
chicken IgG (H+L) (life technologies), Alex Fluor 647 F(ab’)2 fragment of goat anti-
mouse IgG (H+L) (life technologies). 
 To induce yeast to express the single-chain TCR (scTv), 2 x 107 cells were 
washed 2X in 1 mL of SG media. Cells were then suspended to 1 x 107 cells/mL in SG 
media and incubated at 20°C while shaking for 48 h. For staining, 50 uL of induced 
yeast were removed, washed 1X with 1 mL of PBS/BSA (1%) and suspended in 50 uL 
of primary stain. Cells were incubated for a minimum of 1 h in primary stain and then 
washed 1X with 1 mL of PBS/BSA (1%) and suspended in 50 uL of secondary stain. 
After 45 min incubation, cells were washed 2X with 1 mL of PBS/BSA (1%) and read on 
flow cytometer (Accuri).  
Generation and sorting of yeast libraries 
 The SURV71 scTv (Vβ-L-Vα) had been previously cloned into the pCT302 yeast-
display vector by Beth Marshall. Pre-SOE products for the CDR3β and CDR3α libraries 
were generated using the following primers: NEW CDR3b1 fwd scSurv: 5’- CTG ATT 
CAG GTT TTT ATC TGT GTG CCT GGN NSN NSN NSN NSN NSC AGT TTT TCG 
GTC CAG GTA CCC GCC TGA CTG -3’; NEW CDR3b2 fwd scSurv: 5’- GAT TCA GGT 
TTT TAT CTG TGT GCC TGG TCT NNS NNS NNS NNS NNS TTT TTC GGT CCA 
GGT ACC CGC CTG ACT GTG C -3’; scSurv CDR3b rev: 5’- CCA GGC ACA CAG 
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ATA AAA ACC -3’; NEW CDR3a fwd scSurv: 5’- CTG ATT CAG CTA CCT ATC TGT 
GCG CTG TGN NSN NSN NSN NSN NSA TGT TTG GCG ATG GTA CTC AGC TGG 
TTG TG -3’; scSurv CDR3a rev: 5’- CAC AGC GCA CAG ATA GGT AGC -3’; Splice 4L: 
5’- GGCAGCCCCATAAACACACAGTAT -3’; T7: 5’- TAATACGACTCACTATAGGG -3’. 
 Pre-SOE products were spliced together using T7 and Splice 4L primers. The 
pCT302 vector was digested with NheI and XhoI restriction enzymes and electroporated 
into EBY100 yeast with SOE products as described previously (151). The diversity of 
the libraries was as follows: CDR3β1= 3.94 x 106, CDR3β2= 7.21 x 106, and CDR3α= 
2.98 x 107. After the libraries were generated, they were grown separately in SD media 
for 48 h and then combined in equal ratios.  
 For sorting libraries, induced yeast were counted and approximately 4 x 108 
yeast cells (10X library size) were taken for sorting.  Cells were stained in a volume of 1 
mL of primary stain (either anti-Vb20 or survivin/HLA-A2 dimer) for 1 h on ice. Cells 
were washed 1X with 9 mL of PBS/BSA. For magnetic sorts, cells were suspended in 
200 uL of anti-mouse IgG magnetic beads or anti-biotin magnetic beads and incubated 
for 30 mins on ice while inverting every 10 mins. Cells were then washed 1X with 9 mL 
of PBSM buffer and resuspended in a volume of 7 mL PBSM buffer. Resuspended cells 
were then passed through magnetic assembly in a LS column (Miltenyi Biotec). Column 
was then washed with 5 mL of PBSM buffer after which cells were eluted by removing 
column from assembly and passing 7 mL of SD media through column with plunger. 
Residual cells were washed through with another 3 mL of SD media. 
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T cell transduction and activation 
 The K2.4.1 full-length TCR gene (human variable domains, murine constant 
domains) was synthesized by GenScript and cloned into the pMP71 vector using NotI 
and EcoRI restriction sites. The retroviral packaging cell line, Plat-E, cells were plated at 
a concentration of 1 x 106 cells/well (6 well plate) in DMEM media with added puromycin 
and blasticidin. After 24 h, approximately 30 µg of K2.4.1 TCR DNA was transfected into 
Plat-E cells and retroviral particles were harvested 48 h post-transfection. CD8 and CD4 
T cells were harvested from AAD transgenic mice using CD8 and CD4 mouse 
untouched T cells dynabead kit (ThermoFisher). T cells were activated with anti-CD28 
and anti-CD3 beads (ThermoFisher) and 30 U/mL of recombinant mouse IL-2 (Roche) 
for 24 h. 1 x 106 T cells were then added to 1 mL of filtered (.45 µm) retroviral 
supernatant with 50 µL of Lipofectamien 2000 (Life Technologies) per 6 mL of retroviral 
supernatant and an additional 30 U/mL of recombinant IL-2. The cells were spinfected 
by spinning cells at 2000 rpm for 1 h in the presence of IL-2. Cells were then incubated 
at 37°C for 72 h. After 48 h, T cells were split 1:2 in IMDM media. For activation assays, 
7.5 x 105 T cells were incubated with 7.5 x 105 T2 cells (HLA-A2+) and various 
concentrations of peptide in a final volume of 200 µL (96 well plate) for 24 h. 50 µL of 
supernatants were assayed for IFN-γ using Mouse IFN gamma ELISA Ready-SET-Go 
kit (eBioscience).  
Results 
Analysis of a panel of error-prone single-chain TCRs for stability 
 The Kranz lab received the sequence of a TCR  from our collaborators (Wolfgang 
Uckert and Dolores Schendel) that bound to survivin/HLA-A2 with low-affinity. This TCR 
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was isolated from a patient’s peripheral blood and it utilized the Vβ20 and Vα2 variable 
domains (202). Beth Marshall, a former graduate student in the Kranz lab, cloned this 
TCR into the yeast display pCT302 vector as a single-chain TCR (scTv) (Figure 5.1A). 
Since the wild-type TCR was not stable as a scTv (Figure 5.2), error-prone PCR was 
conducted to create a panel of mutants that enhanced expression as a scTv (Figure 
5.1B and 5.2). To compare stability of the different mutants, yeast were incubated on 
ice, 37°C, 42°C and 60°C for 30 minutes and then stained for Vβ and Vα expression 
(Figure 5.2). The Surv-EPL2 clone appeared to have the greatest stability as a scTv 
construct, so it was pursued for further affinity enhancement.  
Isolation of a high-affinity TCR for survivin/HLA-A2 
 To isolate a high-affinity TCR for survivin/HLA-A2, three combinatorial CDR3 
libraries were created consisting of 5 codons per library. Two libraries were within the 
CDR3β loop (residues 94-98 and 95-99) and one library was within the CDR3α loop 
(residues 92-96) (Figure 5.1). These libraries were pooled in equal ratios and 
subsequently sorted for binding to survivin/HLA-A2. After several rounds of sorting with 
survivin/HLA-A2 dimer there was no increase in survivin/HLA-A2 staining and 
significantly diminished staining for Vβ20 staining. A new search strategy was 
conceived where the first sort utilized the Vβ20 antibody and subsequent sorts were 
sorted for survivin/HLA-A2 binding. After the first sort with anti-Vβ20, the libraries 
displayed improved Vβ20 staining (Figure 5.3). Subsequent sorts were conducted with 
survivin/HLA-A2 dimer.  Sort #1, Sort #2 and Sort #3 were conducted with magnetic 
beads using either anti-Vβ20 or 100 nM survivin/HLA-A2 dimer. Sort #4 was conducted 
by fluorescence activated cell sorting (FACS) using 100 nM survivin/HLA-A2 dimer. The 
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top 1% of yeast cells were collected during the FACS sort. After the fourth sort, there 
was a positive staining population for survivin/HLA-A2.  
Six clones were sequenced after the fourth sort and two different sequences 
were represented (Figure 5.3). Five of the six clones had the K2.4.1 sequence and one 
had the K2.4.6 sequence (Figure 5.4). Both K2.4.1 and K2.4.6 clones had affinity 
enhancing mutations within the CDR3α loop. Neither the K2.4.1 nor the K2.4.6 clone 
maintained the wild-type sequence and the only shared mutation between the two 
clones was the R95Yα mutation.  
Analysis of K2.4.1 and K2.4.6 high-affinity clones 
 To characterize the properties of the two high-affinity survivin clones, titrations 
were conducted using survivin/HLA-A2 dimer ranging from 250 nM to 500 pM (Figure 
5.5A). These titrations suggested that the K2.4.1 clone bound with higher affinity than 
K2.4.6. Given that the wild-type survivin peptide bound with low-affinity to the HLA-A2 
complex, an anchor modified survivin peptide with a T2M substitution was used for 
sorting the yeast libraries and initial stains of the high-affinity clones. The T2M anchor 
modification of the survivin peptide was previously identified to enhanced binding to 
HLA-A2 without effecting TCR specificity (203). To ensure that the K2.4.1 clone bound 
to the endogenously processed peptide, a preliminary titration with HLA-A2 monomer 
containing the wild-type and anchor modified peptides was conducted (Figure 5.5B). 
K2.4.1 bound to both the wild-type and anchor modified peptides with low nanomolar 
affinity.  
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In vitro characterization of T cells expressing K2.4.1 TCR 
 To determine if the K2.4.1 TCR could confer survivin specific activity to T cells, a 
full-length TCR was synthesized containing the variable α and β domains of K2.4.1 
linked to the murine constant α and β domains respectively (Figure 5.6A). This construct 
was cloned into the pMP71 retroviral vector using NotI and EcoRI restriction sites. To 
ensure that the construct was expressed properly in T cells, the murine T cell hybridoma 
line 58-/- (co-receptor negative) was transduced with the K2.4.1 TCR and stained with 
survivin/HLA-A2 tetramer and Vβ20 antibody (Figure 5.6B). Given that the TCR 
expressed properly, primary CD8 and CD4 T cells were isolated from AAD transgenic 
mice and transduced with the K2.4.1 TCR. T cells were incubated with various 
concentrations of the SurvT2M peptide or null peptide (WT1) and T2 APCs (HLA-A2+). 
After 24 h incubation, supernatants were assayed for IFN-γ release. The K2.4.1 TCR 
conferred survivin specific activity to both CD4 and CD8 T cells expressing the TCR. 
Both CD8 and CD4 T cells appeared to have a similar EC50 value (approx. 5 x 10-9 M). 
The basal activity in CD4 K2.4.1 T cells appeared higher than basal activity with CD8 
K2.4.1 T cells and mock cells. 
Discussion 
 High-affinity human T cell receptors (TCRs) have been engineered by yeast 
display previously in the Kranz lab (110, 121, 132). Here I describe the work I did in 
engineering a high-affinity T cell receptor against the survivin/HLA-A2 cancer antigen. 
Survivin is a protein that has anti-apoptotic properties and is over-expressed in a variety 
of solid and hematological cancers (204). Recently, NCI compiled a list of potential 
targets for cancer immunotherapies based on a variety of factors (i.e. expression levels, 
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immunogenicity, specificity, etc.) (113). Survivin was ranked #21 as a potential 
immunotherapy target on a list with over 75 antigens.  HLA-A2 is one of the most 
common MHC genes and is expressed in nearly 40% of the global population (205). 
Therefore, a TCR that binds to survivin/HLA-A2 with high-affinity would be applicable to 
a broad spectrum of patients as adoptive or soluble TCR-based therapies.  
 A clone that bound to survivin/HLA-A2 with low-affinity was provided to us by our 
collaborators (202). This TCR was formatted into a single-chain TCR containing the 
variable domains linked by a flexible linker and cloned into the yeast-display vector 
(pCT302). As is the case with many single-chain TCRs, the wild-type TCR was not 
stable as a single-chain on the surface of yeast. A panel of mutants was created by 
error-prone PCR in an effort to stabilize the construct. It was from one of these 
stabilized clones that I created libraries in both the CDR3α and CDR3β domains.  
Upon combining the CDR3α and CDR3β libraries, there was a strong reduction 
in Vβ20 signal, presumably due to many of the mutations destabilizing the single-chain 
TCR. To enrich a population that was stable on the surface of yeast, I conducted my 
first sort of the pooled libraries with anti-Vβ20. This sort and the subsequent two sorts 
with survivin/HLA-A2 were conducted with magnetic beads. This was the first attempt of 
sorting large TCR yeast libraries with magnetic beads in our lab, although previous 
antibody engineering efforts have successfully utilized magnetic sorting to isolated high-
affinity clones (206). The magnetic sort with anti-Vβ20 greatly enriched a positive 
population for Vβ20. The following two sorts were conducted with magnetic beads for 
binding to survivin/HLA-A2 dimer. After the second sort with dimer, a third and final 
fluorescence activated cell sort (FACS) was conducted collecting the top 1% of clones 
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that bound to survivin/HLA-A2. This sort yielded a population of cells that were positive 
for staining with survivin/HLA-A2. From this population, I isolated two clones that bound 
to survivin/HLA-A2 with high-affinity: K2.4.1 and K2.4.6. Based on yeast binding 
titrations, we estimated these TCRs to bind to survivin/HLA-A2 in the range of 100 nM. 
FACS sorting can be both time-consuming and costly, the magnetic sorting approach 
allowed me to limit the number of FACS sorts while enriching my library for binding to 
survivin/HLA-A2. Based on these results, it may be more efficient to conduct initial sorts 
of large yeast libraries by magnetic sorting and only use FACS for the final sort.  
Both K2.4.1 and K2.4.6 TCRs had high-affinity mutations in the CDR3α domain. 
In an attempt to isolate an even higher affinity clone, I used the K2.4.1 TCR as a 
template to create libraries in the CDR3β domain. Similar to my first libraries, I sorted 
this library first for binding to anti-Vβ20 and subsequent sorts were conducted with 
survivin/HLA-A2. Unfortunately, this library did not yield clones that bound with higher 
affinity. The lack of higher affinity clones may have been due to the initial Vβ20 sort, 
which could have greatly diminished the library diversity in the Vβ domain. A potential 
method to sort for stability, while maintaining Vβ20 diversity would be to conduct an 
initial sort for c-myc and then conduct subsequent sorts with survivin/HLA-A2.  
Recently, in the lab we have created sequence fitness landscapes of TCRs, 
which produce a heat map displaying the fitness of various mutations in every CDR 
residue (148). Sequence fitness landscapes have allowed us to identify single-site 
mutations that enhance the affinity and stability of TCRs. A sequence fitness landscape 
of the K2.4.1 TCR was created by Scott Anderson under my guidance. The results from 
this analysis identified several enriched mutations that would presumably further 
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enhance the affinity of K2.4.1 for survivin/HLA-A2. This sequence fitness landscape is 
now guiding efforts by our collaborators to identify stabilizing mutations that would 
increase affinity and stability of the single-chain TCR when expressed in soluble form 
(112).  
One clinical application of high-affinity TCRs is use as an adoptive T cell therapy. 
For this type of therapy, T cells are transduced ex vivo with a TCR of interest, the T 
cells are then expanded and reintroduced into the patient. These therapies have had 
some early successes in the clinic (99, 100). Our lab and others have shown that using 
a high-affinity TCR to gain both CD8 and CD4 responses is advantageous for inhibiting 
tumor growth (83, 179). To determine if the K2.4.1 TCR is capable of activating both 
CD8 and CD4 T cells, I cloned K2.4.1 as a full-length TCR (human variable domains, 
murine constant domains) and transduced T cells isolated from AAD transgenic mice. 
These T cells were positive for survivin/HLA-A2 tetramer staining. Additionally, both 
CD8 and CD4 T cells were active when presented with HLA-A2+ APCs with survivin 
peptide loaded exogenously.  
 A recent study suggested that T cells may express a low level of survivin protein 
(202). The authors report that low levels of survivin expression mediated T cell fratricide 
by T cells expressing a survivin specific TCR. While this could limit the use of a survivin 
specific TCR in an adoptive T cell approach, a high-affinity TCR could still potentially be 
used as a soluble reagent, such as a bi-specific molecule. One of the most successful 
monoclonal antibodies for the treatment of lymphoma, rituximab, eliminates normal B 
cells when administered. Once the cancer is eliminated and infusions are completed, B 
cells return to normal levels (207). Therefore, even if a soluble TCR against survivin 
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would eliminate endogenous activated T cells, it could provide value as a potential 
therapeutic due to the ability of the T cell population to self-renew and that resting T 
cells may be spared. Additionally, more recent studies with a different survivin specific 
TCR, have shown that T cells expressing the TCR did not commit fratricide and were 
capable of targeting and controlling growth of a tumor expressing survivin (208).  
Unlike recent reports, I did not observe a significant dead population of T cells 
transduced with our high-affinity survivin TCR. Interestingly, CD4 T cells transduced 
with the K2.4.1 TCR appeared to have a higher basal activity of IFN-γ release than CD8 
and mock transduced cells. The higher basal activity could potentially be due a low-level 
of survivin expression only in CD4 T cells, and not CD8 T cells, within the AAD system. 
To validate the observation that CD4 K2.4.1 T cells have a higher basal level of activity, 
this experiment will need to be repeated. Additionally, further testing with human T cells 
transduced with K2.4.1 will also be needed to confirm that the TCR does not lead to 
fratricide.  
Since the K2.4.1 TCR was stabilized as a single-chain in yeast, the TCR 
presumably could also be expressed in our TCR-CAR system. This system links a 
single-chain TCR (containing only variable domains) to intracellular signaling domains 
of a chimeric antigen receptor (such as CD28 and CD3ζ). Our TCR-CAR system has 
been less sensitive than a traditional full-length TCR (87). If the high-affinity K2.4.1 TCR 
mediates some fratricide when expressed as a full-length TCR due to low levels of 
survivin expression in T cells, this undesirable effect could be bypassed through 
expressing the construct as a CAR. The K2.4.1 CAR potentially would not mediate 
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stimulation by the low levels of survivin in T cells, but perhaps it could still be activated 
by cancer cells that express higher levels of survivin.  
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Figures 
 
 
  
 
 
 
Figure 5.1 (A) Diagram of the survivin single-chain TCR in the pCT302 yeast display vector with HA and 
C-myc tags at N-terminus and C-terminus respectively. (B) Sequences of stabilized single-chain TCR 
clones isolated from error-prone library. The residues at which libraries were created are highlighted in 
yellow.  
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Figure 5.2 Clones isolated from error-prone library of the survivin TCR were incubated at various 
temperatures and then stained with either anti-Vβ20 (1:50) or anti-Vα2 (1:5) followed by Alexa fluor 
goat anti-mouse 647  (1:100). 
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Figure 5.3 Yeast were induced from the unsorted and sorted libraries and stained with anti-HA 
(1:50), anti-Vb20 (1:50), anti-Va2 (1:5) and survT2M/HLA-A2 dimer (100 nM), followed by Alexa fluor 
goat anti-mouse 647.  Sort #1 was a magnetic sort for anti-Vb20, sort #2 and #3 were magnetic 
sorts with 100 nM survT2M/HLA-A2 dimer (100 nM), sort #4 was by FACS with survT2M/HLA-A2 
dimer (100 nM). 
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Figure 5.4 Sequences of two high-affinity clones isolated from libraries after four rounds of sorting. 
Of six sequences clone, five of six had K2.4.1 sequence and one of six had K2.4.6 sequence. High-
affinity mutations are highlighted in yellow.  
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Figure 5.5 (A) High-affinity clones K2.4.1 and K2.4.6 were stained with various concentrations of 
survT2M/HLA-A2 dimer followed by goat anti-mouse 647. (B) K2.4.1 was stained with survivin/HLA-
A2 (top) and survT2M/HLA-A2 (bottom) monomer at various concentrations followed by SA-PE. The 
percentage of max binding (set at 1 µM) based on mean fluorescence intensity (MFI) was plotted 
against concentration of monomer.   
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Figure 5.6 (A) Diagram of full-length TCR that was constructed with the K2.4.1 TCR consisting of 
Vβ20 and Vα2 human domains fused to murine Cβ and Cα domains respectively. (B) The K2.4.1 TCR 
was transduced into the co-receptor negative 58
-/-
 T cell hybridoma cell line and stained with 
survT2M/HLA-A2 tetramer (left) and anti-Vβ20 (right). (C)  Primary CD8 (left) and CD4 (right) T cells 
isolated from AAD transgenic mice were transduced with the K2.4.1 TCR and incubated with T2 cells 
with various concentrations of survT2M peptide. Supernatants were then assayed for IFN-γ by ELISA.    
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